Natural products discovery and characterization via synthetic biology by Luo, Yunzi
  
 
 
NATURAL PRODUCTS DISCOVERY AND CHARACTERIZATION VIA 
SYNTHETIC BIOLOGY 
 
 
 
 
 
 
 
BY 
 
YUNZI LUO 
 
 
 
 
 
 
DISSERTATION 
 
Submitted in partial fulfillment of the requirements 
for the degree of Doctor of Philosophy in Chemical Engineering 
in the Graduate College of the  
University of Illinois at Urbana-Champaign, 2014 
 
 
 
 
 
Urbana, Illinois 
 
 
 Doctoral Committee: 
 
  Professor Huimin Zhao, Chair 
         Professor Yi Lu 
         Assistant Professor Mary L. Kraft 
         Assistant Professor Brendan A. Harley  
ii 
 
Abstract 
Microorganisms and plants have evolved to produce a myriad array of natural 
products that are of biomedical importance. Recent advances in synthetic biology 
have revolutionized our ability to discover and manipulate natural products 
biosynthetic pathways. This thesis describes in depth our efforts to enable natural 
products discovery and characterization via synthetic biology approaches.  
Type III polyketide synthases (PKSs) produce a wide array of aromatic structures 
in spite of their structural simplicity. An efficient strategy for cloning and 
characterizing Type III PKSs that are likely responsible for the synthesis of novel 
natural products from Eucalyptus species were developed. Five unique putative Type 
III PKSs genes were identified using this approach and two full-length genes were 
cloned and the biochemically characterized.   
With recent development in genome sequencing projects, cryptic pathways serve 
as a potential source for novel natural products discovery. A synthetic biology 
approach for cryptic pathway activation and characterization was developed. One 
cryptic pathway from Streptomyces griseus, containing a PKS/NRPS hybrid gene, 
was chosen as a model system. To decipher this cluster, we have developed a plug-
and-play platform based on the “DNA assembler” method. In this platform, one 
constitutive promoter was inserted in front of each gene involved in the pathway. 
qPCR data confirmed the increased transcription levels and HPLC data showed the 
formation of new polycyclic tetramate macrolactams (PTMs). However, for PTM 
biosynthesis, no clear mechanism has been reported. Therefore, Chapter 4 describes 
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the characterization of this PTM biosynthetic pathway by applying the same synthetic 
biology approach. We identified the boundary of this gene cluster by assembling a 
seven-gene construct and proposed a biosynthesis mechanism by studying a series of 
single-gene deletion and multiple-gene deletion constructs. Noticing that this one 
single gene cluster may have the potential to produce multiple products with closely 
related chemical structures, we biochemically characterized the modification enzymes 
in vitro and studied this phenomenon with a phylogenetically related pathway as well.  
Finally, after achieving the success in pathway activation and characterization 
with our newly developed synthetic biology platform, we decided to make it more 
generally applicable for natural products discovery in actinomycetes. Additional 
strong constitutive promoters were identified via RNA-seq technique. The selected 
strong promoters were characterized based on both qPCR data and XylE enzyme 
specific activity assay. In total, 10 relatively strong promoters were identified 
comparing with ermE*p, a widely used strong promoter reported in literature. These 
promoters will be used in our genomics-driven, synthetic biology platform for high 
throughput discovery of novel natural products in actinomycetes. 
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Chapter 1 Overview of Natural Products Discovery 
1.1 Importance of natural product biosynthesis 
1.1.1 Significant source for medicinal compounds 
 The human pharmaceutical development is significantly indebted to Nature, and 
especially to the natural products of bacteria, fungi, and plants (Figure 1.1). Natural 
products are the most significant source for modern medicine discovery (1). To date, 
77% of antibacterial drugs, 61% of anticancer compounds and 49% of anti-infectives 
approved in the past 30 years are natural products or their derivatives (2,3). The data 
shown in Annual Reports of Medicinal Chemistry highlight the invaluable role that 
natural products have played in the drug discovery process related to all disease types 
(4). Although many effective drugs have been discovered, the need for new 
therapeutic agents remains, due to the increasing antibiotic resistance to existing drugs 
and the recent threat of bioterrorism. However, major pharmaceutical companies have 
largely turned their efforts away from natural product discovery since the 1990s, 
because of the difficulties in supply, screening, and characterization of natural 
products, and in particular the increasing rediscovery rate of known compounds (5).  
With the advent of fast and inexpensive next generation genome sequencing 
technologies, the presence of multiple natural product biosynthetic gene clusters for 
which the cognate products have never been observed has revised our vision of the 
biosynthetic potential and metabolic capabilities of microorganisms, sparking a 
renaissance in natural product discovery. According to analysis of the genome 
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databases, only a small portion of the natural products has been discovered and 
characterized. For example, the Streptomyces species alone is predicted to produce as 
many as 150,000 natural products, while only 3% have been characterized (6). With 
the development of novel biotechnologies and expanding understanding of the 
biology world, the field of natural product discovery has been revisited.  
Many bioactive natural products are synthesized by non-ribosomal peptide 
synthetases (NRPSs) and polyketide synthases (PKSs) (7,8). 20 out of 7000 
polyketides known to exist have been commercialized as medicines, which has a “hit 
rate” that is already two orders of magnitude higher than other classes of chemicals 
(9). Therefore, investigations into the unknown compounds synthesized by these two 
classes of enzymes may lead to the discovery of a variety of novel chemotherapeutic 
agents. The genome sequence data reveals that these two classes of enzymes are 
widely distributed in all sources for natural product discovery, such as bacteria, fungi 
and plants. Coupling the sequence data with the highly-developed biotechnologies, 
such as metabolic engineering and synthetic biology, we could foresee the flourish of 
natural product discovery for future drug candidates.  
1.2 Common sources of natural products 
1.2.1 Plants as a source of natural products 
Medicinal plants have been used for thousands of years in the treatment of 
numerous ailments (10). Modern analytical techniques identified the bioactive 
compounds in plant extracts and approximately 25% of today’s medicines are derived 
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from plant natural products (11), including many highly successful drugs such as the 
best breast cancer therapy Taxol (paclitaxel) (12) and anti-Parkinson’s treatment L-
DOPA (13). Plant-derived polyketides such as curcuminoids (curcumin) and 
flavonoids (genistein, quercetin, resveratrol) are well-known complementary therapies, 
with a growing body of evidence vis-à-vis their usefulness as anti-inflammatory and 
anti-cancer agents (14,15).  
Particularly, Eucalypt polyketide natural products are known to be antiviral, 
antibacterial, anticancer, and cariostatic (inhibiting the growth of bacteria that cause 
tooth decay), and Eucalypts have been used by the Aboriginal people of Australia for 
the treatment of colds, influenza, toothache, snakebites, fevers, and other ailments 
(16).  
1.2.2 Fungi as a source of natural products 
Fungi have existed on earth for at least one thousand million years, and they have 
exploited and evolved secondary metabolism for the production of bioactive 
compounds (17). These compounds include toxins such as α-amanitin, the toxic 
principal component of Amanita phalloides (death cap), vomitoxin (deoxynivalenol) 
produced by the Fusaria family of plant pathogens and aflatoxin B1 produced by 
Aspergillus species. Fungi also produce potent psychoactive compounds such as 
muscimol, psilocybin and xenovulene A, pharmaceuticals such as the β-lactams and 
the statin lovastatin. These compounds illustrate the utility and diversity of chemical 
structures produced by fungi, and the diverse biosynthetic potential of these 
organisms. Among all the compounds produced by fungi, a wide variety of 
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polyketides with diverse structures, such as orsellinic acid, lovastatin, and aflatoxin 
can be found as well (17). Most of these compounds are bioactive and usually 
pharmacologically useful. For example, lovastatin produced by Aspergillus terreus, 
can lower the cholesterol level by inhibiting the rate-limiting enzyme in cholesterol 
biosynthesis. Fungi can inhabit almost all known environments on earth-from 
temperate soils and forests to deserts and from oceans to tropical rain forests. Thus, it 
is not surprising that they can produce numerous medicinal important natural products 
(18).  
1.2.3 Bacteria as a source of natural products 
Bacteria represent a rich source of natural products as well. Type II PKS are 
found in bacteria exclusively, which can synthesize a variety of polyketides, such as 
oxytetracycline from Streptomyces rimosus, and daunorubicin from Streptomyces 
peucetius (19). Bacteria produce many different tetracyclines, one of the most 
important classes of antibiotics, and anthracyclines, a potent class of anticancer 
compounds which includes daunorubicin. Actinomycetes are a group of bacteria 
capable of producing numerous natural products. The Streptomyces species alone is 
predicted to produce as many as 150,000 natural products. Most of them are 
secondary metabolites. For example, around 20 secondary metabolite biosynthesis 
pathways have been revealed from actinomycete Streptomyces coelicolor A3(2) (20) 
and the industrial actinomycete Streptomyces avermitilis (21), respectively. Another 
example is Streptomyces griseus, from which genomic sequence, 34 secondary 
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metabolite biosynthesis pathways have been found (22). These gene clusters reveal 
the high possibility of discovering new natural products. 
1.2.4 Cryptic pathways as a source of natural products 
The recent increase and availability of whole genome sequences have revised our 
view of the metabolic capabilities of microorganisms. A large number of cryptic 
biosynthesis pathways have been identified by bio-informatics study of these genome 
sequence data. Cryptic biosynthetic pathways are gene clusters for which the encoded 
natural products are unknown or the pathways are silent and the products cannot be 
detected under normal growth conditions. It is worthy to note that the number of 
cryptic pathways coding for putative natural products far outnumbers the number of 
currently known metabolites for a given organism. Thus, cryptic pathways serve as an 
enormous source for natural product discovery. 
Since the genome sequencing projects are mostly focused on the genomes of 
bacteria and fungi, the cryptic pathways related to valuable secondary metabolites are 
often revealed from the bacteria and fungi genome databases. For example, 
Streptomyces coelicolor was known to produce only 4 secondary metabolites (20), 
while genome analysis revealed 18 additional cryptic biosynthetic pathways. It is 
intriguing to note that this is not a particular case because analysis of other microbial 
genomes originating from Mycobacteria, Cyanobacteria and filamentous fungi 
showed the presence of a comparable or even larger number of cryptic pathways 
(23,24). The few natural products that have been correlated with their cryptic 
pathways are merely the tip of the iceberg, whilst plenty of metabolites await 
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discovery (25). The discovery of these numerous pathways represents a treasure trove, 
which is likely to grow exponentially in the future, uncovering many novel and 
possibly bio-active compounds. 
1.3 Technologies for natural product discovery and identification 
1.3.1 Genome mining 
Genome mining has been used in various fields to describe the exploitation of 
genomic information for the discovery of new processes, targets, and products. 
Genome sequencing projects have resulted in the deposition of a huge quantity of 
DNA sequence data from a wide variety of organisms in publicly accessible databases. 
This information can be exploited to generate new knowledge in several areas 
relevant to medicinal chemistry including the identification and validation of new 
drug targets in human pathogens, and the discovery of new chemical entities (23). The 
concept of exploiting genomic sequence data for the discovery of new natural 
products has emerged from the rapid expansion in knowledge of the genetic and 
biochemical basis for secondary metabolite biosynthesis, particularly in 
microorganisms, in the 1980s and 1990s (7).  
Large quantities of genomic sequence data have accumulated in public databases. 
Those of plants and microorganisms, containing numerous genes encoding proteins 
are likely to participate in the assembly of structurally complex bioactive natural 
products but not associated with the production of known metabolites. Therefore, they 
become invaluable as they shed light on the discovery of novel drugs.  
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Analysis of the complete genome sequence of the model actinomycete S. 
coelicolor A3(2) (20) and the industrial actinomycete S. avermitilis (21) have 
facilitated the prediction of unknown natural products. For example, the genome 
mining of these two bacteria revealed around 20 secondary metabolite biosynthetic 
gene clusters respectively, many of which have not been characterized yet. Another 
example is the genome sequence of S. griseus, which revealed 34 secondary 
metabolites pathways, but only six of them have been characterized (22).  
1.3.2 Metabolic engineering and pathway engineering 
The term metabolic engineering was first coined in the late 1980s and early 1990s 
with the goal to either increase the production of value-added molecules or degrade 
harmful compounds in a simple, effective and advantageous process via genetic 
manipulations (26). It is broadly defined as using recombinant DNA technology to 
improve cellular activities. Specifically, it involves the identification of metabolic 
pathways, modification and manipulation of biosynthetic pathways by blocking side 
reactions, over-production of desired products or introducing new reactions. This area 
is particularly important to natural product biosynthesis because it offers ways to 
improve current bioprocesses, such as optimization of the native biosynthetic pathway 
for increased production, enabling the heterologous expression of a pathway in 
industrial strains, and balancing metabolic flux for maximal production of desired 
compound, as well as providing access to novel chemicals and pharmaceuticals 
through the development of new bioprocesses. 
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Serious considerations are required when making the designs to direct carbon 
flow to a desired product at a high yield via metabolic engineering approaches. Four 
key elements are normally included: (i) identify and optimize the primary carbon flow 
to the target product, including addressing rate limiting steps, transcriptional and 
allosteric regulations; (ii) block competing pathways and side reactions; (iii) modify 
secondary metabolic pathways to enhance energy metabolism and availability of 
required substrates and enzymatic cofactors; and (iv) direct carbon flow to the target 
pathway from central metabolism (27). For example, hydrocortisone, an important 
starting material for steroidal drug synthesis, can be synthesized from glucose in yeast 
by engineering a recombinant Saccharomyces cerevisiae to express 13 assembled 
genes (28). Another example is to enhance the production of 6-deoxyerythronolide B 
(the polyketide precursor of erythromycin) in the heterologous host Escherichia coli 
to the level of the native producer through metabolic engineering (27). As for 
polyketides, the availability of acyl-CoA is a major obstacle in heterologous host such 
as E. coli or S. cerevisiae. Pathways that can use propionate and methylmalonate to 
produce these CoAs were introduced into the heterologous host, which resulted in an 
increase in the production of the final products (29,30).   
1.3.3 Heterologous expression 
Natural products show great promise as medicinal agents. Obviously, the most 
desirable approach for natural product discovery and production would be direct 
extraction and isolation of the target products from their native producers. However, 
only 1% of bacteria and 5% of fungi could be cultured under standard laboratory 
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conditions (31-34). Even if the native producer is cultivable in the laboratory, 
considerable amounts of time and efforts are required to optimize the growth 
condition for the production of a desired compound, not to mention the development 
of genetic manipulation tools in the native producer. As a result, over the past decade, 
the study of bioactive natural product biosynthesis has benefited significantly from 
the incorporation of heterologous expression tools.  
A heterologous host often refers to a well-characterized microorganism that can 
serve as a platform for natural product biosynthesis. Compared to native producers, 
heterologous hosts have several advantages such as ease to operate, simple growth 
conditions, excellent fermentation protocols, and abundant genetic manipulation tools 
(26).  
Polyketides are a major class of natural products that are synthesized by an 
evolutionarily related but architecturally diverse family of multifunctional enzymes 
called polyketide synthases. Heterologous expression of these megasynthases is 
particularly important as many of their products are produced in actinomycetes or 
plants that often suffer from slow growth rates. Another principal limitation for 
fundamental biochemical studies of these modular megasynthases and for their 
applications in biotechnology is the challenge associated with manipulating the native 
microorganism that produces a polyketide of interest. For example, they may have 
strict environmental requirements for growth or cannot be cultured readily (26). Host 
organisms may also have a complicated or multi-stage growth profile, which may 
result in little production of a target compound. To ameliorate this limitation, several 
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genetically tractable microorganisms such as E. coli, S. cerevisiae, and Streptomyces 
lividans have emerged as choice hosts due to their simplicity of use, excellent growth 
characteristics, and a plethora of readily accessible genetic tools (35).  
There are several requirements for reconstitution of polyketide biosynthesis in 
heterologous hosts: 1) the large multienzyme assemblies can be functionally 
expressed, 2) their posttranslational modification can be adequately met, 3) the 
availability of their potential substrates in vivo is in reasonable quantities, and 4) the 
producer cell is protected against the toxicity of the biosynthetic products. Already, 
heterologous expression of Type I and Type II PKSs has been achieved in E. coli to 
produce the antibiotic erythromycin (36) and plant flavonoids (37). In addition, 
unnatural substrates have been fed into a heterologous host for Type III PKS, which 
resulted in combinatorial biosynthesis of new medicinal natural products (38).  
1.3.4 Techniques used to activate cryptic pathways 
Analyses of more than 500 microbial genome sequences currently in the publicly-
accessible databases have revealed numerous examples of gene clusters encoding 
enzymes similar to those known to be involved in the biosynthesis of many important 
natural products (39). Examples of such enzymes include nonribosomal peptide 
synthetases (NRPSs), polyketide synthases (PKSs) and terpene synthases (TSs), as 
well as enzymes belonging to less thoroughly investigated families. Many of these 
gene clusters are hypothesized to assemble novel natural products. Numerous novel 
metabolites have been discovered as the products of so-called ‘‘cryptic’’ or ‘‘orphan’’ 
biosynthetic gene clusters and several recent reviews have described these discoveries 
11 
 
(23,25). The various approaches for discovery of the metabolic products of cryptic 
biosynthetic gene clusters are summarized in Figure 1.3. 
At the beginning of every discovery of an orphan pathway, in order to predict the 
chemical structure of the corresponding natural product, significant progress needs to 
be made in the understanding of biosynthetic pathways (25). With this accumulated 
knowledge, combined with advances in bioinformatics, it is nowadays possible to 
reasonably predict the product of an orphan biosynthetic pathway. Techniques usually 
used to activate the cryptic pathways include: i) prediction of physicochemical 
properties (40); ii) a genomisotopic approach (41); iii) an in vitro reconstitution 
approach (42); iv) a biosynthetic gene inactivation/comparative metabolic profiling 
approach (43); v) a heterologous gene expression/comparative metabolic profiling 
approach (44); vi) activation of silent clusters by manipulation of regulatory genes 
(24). 
1.3.5 Synthetic biology approaches 
The term synthetic biology was first introduced in the late 1970s to describe the 
application of recombinant DNA technology in engineered bacteria (45,46).  
However, it did not gain much attention until early 2000s, while the term of synthetic 
biology was again introduced, with emphasis on engineering principles and 
methodologies in designing, constructing and characterizing existing or novel 
biological systems from traditional genetic engineering research (47-50).  The field 
of synthetic biology lies at the interface of many different biological research areas, 
such as functional genomics, protein engineering, chemical biology, metabolic 
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engineering, systems biology, and bioinformatics. Not surprisingly, synthetic biology 
means different things to different people, even to leading practitioners in the field 
(51).  The fundamental idea behind synthetic biology is that any biological system 
can be broken down into individual functional building blocks (52). The key feature 
that distinguishes synthetic biology from traditional molecular biology and cellular 
biology is the focus on the design, construction and optimization of these building-
blocks in novel configurations, thus to modify existing properties or to create new 
ones (53).   
Synthetic biology has been applied in a variety of fields, from the incorporation 
of unnatural amino acids into proteins (54-58) to the integration of one genome into 
another (59-61), or even to the reconstruction of entirely new organisms with 
modified genomes (62-64). The successful applications of synthetic biology have 
made it an invaluable tool for natural product discovery via redesign and engineering 
of biosynthetic pathways and reconstruction of synthetic gene clusters.  
Nowadays, de novo synthesis of a biochemical pathway is possible using the 
DNA synthesis tools (65). Still, more efforts have been focused on construction and 
optimization of an existing biochemical pathway either in a native or a heterologous 
host. Pathway engineering can be designed rationally by mixing and matching well-
known, modular parts and modulating gene expression through various control 
mechanisms. However, the design at the pathway level is concerned with not only 
inclusion of the necessary biological parts such as promoters, genes, and proteins, but 
also optimization of the expressed functionality of those parts. Failure to balance the 
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flux in the synthetic pathway will result in a bottleneck and the accumulation of 
intermediates (66). One way to balance the flux is through transcription optimization 
of the various genes in the pathway. By fusing a library of promoters to the various 
enzymes in the isoprenoid production pathway, Pitera and coworkers have managed 
to engineer a flux-balanced pathway with improved yield and reduced metabolic 
burden (66). These well-characterized families of transcription regulators have 
emerged as powerful tools in metabolic engineering as they allow rational 
coordination and control of multi-gene expression, thereby decoupling pathway 
design from construction (67).  
The concept of synthetic biology is still in its infancy. With the enhancement in 
the availability and amount of well-characterized individual components, the field 
will increasingly provide valuable information for applications in drug discovery, 
biotechnology industry and basic biological research. In particular, with the 
availability of over 2000 whole genome sequences and advanced biotechnology tools, 
a rapid growth in the capabilities of synthetic biology for natural product discovery 
will be seen in the near future.   
1.4 Polyketides as natural products 
1.4.1 Polyketides 
Polyketides are a diverse group of natural products with important applications in 
medicine and industry. It can be found in a variety of organisms including plants, 
fungi, and bacteria, in which they are produced by polyketides synthases (PKSs). 
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Usually, they are not strictly required for the growth, development, or reproduction of 
their host organisms, but they perform an important role in both industrial chemical 
synthesis and drug discovery. Polyketides are structurally varied and in turn have a 
broad range of different biological activities. The diversity of natural polyketides 
comes both from the priming acyl-CoAs and elongating acyl-CoAs used, and the 
chemical transformations occurring after polyketide synthesis. Polyketide natural 
products are known to have antiviral (68), antibacterial (69), and anticancer (70) 
activities. Therefore, they are widely used in clinical trials and industry (9). For 
example, oxytetracycline serves as a broad-spectrum antibiotic, and it is active against 
a wide variety of bacteria. Another antibiotics erythromycin produced by 
Saccharopolyspora erythraea, has an antimicrobial spectrum similar to or slightly 
wider than that of penicillin, and thus is often prescribed for people who have an 
allergy to penicillins. The anticancer drug daunorubicin initially isolated from 
Streptomyces peucetius is synthesized by a PKS as well. 
1.4.2 Polyketide synthases 
Polyketides have diverse structures, which are introduced by different types of 
polyketide synthases. Generally, polyketides are derived from acetate and other short 
carboxylic acids by sequential decarboxylative condensations in a fashion similar to 
fatty acid biosynthesis. There are three types of PKSs known to date.  Type I and 
type II PKSs are microbial enzymes, whereas type III PKSs are mainly found in 
plants (71).  
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Type I PKSs, a group which is further sub-divided into iterative (Figure 1.4A) 
and modular type I PKSs (Figure 1.4B), are responsible for the biosynthesis of 
complex, largely reduced polyketides, such as macrolides (erythromycin and 
avermectin), polyethers (monensin and tetronasin), polyenes (candicidin and nystatin), 
and hybrid peptide-polyketide natural products, such as bleomycin, epothilone and 
rapamycin. Type I PKSs are made up of a single, very large multi-domain protein that 
is structurally organized into modules. Type II PKSs are multi-enzyme systems as 
well, but each domain contained in Type II PKSs acts as a free-standing enzyme 
(Figure 1.4C). Type III PKSs are small, homodimeric enzymes and represent a single 
domain (Figure 1.4D). One to six functional modules can be assembled into one 
individual PKS, each consisting of several distinct active sites, for each enzymatic 
step. A module is in charge of one cycle of polyketide elongation and the associated 
modifications. The order of modules in the PKS enzyme indicates the sequence of 
biosynthetic events. Variations of domains within the modules afford the structural 
diversity observed in the resultant polyketide products. The growing polyketide 
intermediates are tethered to the PKSs via a thioester linkage to the 4'-
phosphopantetheine prosthetic group of the acyl carrier protein (ACP) domain during 
the entire elongation process. Thus, the three core domains: β-ketoacyl synthase (KS), 
acyltransferase (AT), and ACP, catalyze the C-C elongation, and the accessory 
domains, such as ketoreductase, dehydratase, enoyl reductase and methyltransferase, 
control the modifications of the growing polyketide intermediates. Once the growing 
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polyketides chain reaches its full length, it is released from the PKS enzyme by a 
thioesterase (TE) domain or a discrete amidase to yield the final products (72). 
1.5 Project overview 
Microorganisms and plants have evolved to produce a myriad array of natural 
products that are of biomedical importance (3). This thesis focuses on discovery and 
characterization of novel natural products. Throughout my work, I have applied the 
above-mentioned tools to natural product biosynthesis and discovery, including: i) use 
of genome-mining to identify a target cryptic gene cluster, SGR810-815, from the 
sequenced genome of S. griseus; ii) use of synthetic biology to activate the cryptic 
SGR810-815 gene cluster from S. griseus in a heterologous host S. lividans, iii) 
discovery of novel Type III PKS enzymes by mining biodiversity of medicinal plants; 
iv) discovery and characterization of strong actinomycetes promoters. 
Chapter 2 describes the characterization of the Type III PKS enzyme EC2 from 
Eucalyptus camaldulensis. The overall goal is to identify new Type III PKS enzymes 
from bioactive plants. A PCR-based screening method for Type III PKS genes 
discovery was created and validated. Two Eucalyptus species were chosen as initial 
targets for Type III PKS discovery, including Eucalyptus robusta (16) and Eucalyptus 
camaldulensis. Nested degenerate primers were designed based on 14 different plant 
Type III PKS and were validated by amplifying PKSs from Hypericum perforatum.  
A total of 94 clones and 27 clones were isolated and sequenced from the cDNA 
libraries created from the leaves of E. camaldulensis and E. robusta, respectively.  
Five unique putative Type III PKSs genes were identified based on the screening 
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method. To further validate the cloned putative Type III PKS fragments, RACE-PCR 
(rapid amplification of cDNA ends-polymerase chain reaction) was used to clone the 
full-length gene.  One full-length gene was successfully cloned. The biochemical 
characterization of this enzyme led to the identification of one Type III PKS, which 
shares a high sequence identity (75%) with chaclone synthase (CHS) from Medicago 
sativa. The generation of naringenin from 4-coumaroyl-CoA and malonyl-CoA was 
confirmed. Also, different CoAs as start units were tested but no new reaction was 
detected.  
Chapter 3 reports the development of a synthetic biology approach for cryptic 
pathway activation. As many bioactive natural products are synthesized by non-
ribosomal peptide synthetases (NRPS) and polyketide synthases (PKS) (7,8), 
investigation into the unknown compounds synthesized by these two classes of 
enzymes may lead to the discovery of novel chemotherapeutic agents. Our motivation 
is to develop an efficient approach to decipher the cryptic natural product biosynthetic 
pathways. As proof of concept, one cryptic pathway from S. griseus (22), SGR810-
815, containing a PKS/NRPS hybrid gene, was chosen as a model system.  BLAST 
search indicates that the PKS/NRPS gene shares high sequence identity (63%) with 
the one from the heat-stable antifungal factor (HSAF) biosynthetic gene cluster (73) 
and 70-80% sequence homology with the recently characterized frontalamide gene 
cluster (74). However, the nature of the natural product encoded by the target pathway 
is still not clear. To decipher this cluster, we have developed a plug-and-play platform 
based on our recently developed “DNA assembler” method (75). In this platform, one 
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constitutive promoter was inserted in front of each gene involved in the pathway. 
Then all the resulting DNA products were co-transformed into S. cerevisiae for 
assembly into a single DNA molecule in one step based on the yeast homologous 
recombination mechanism. Verified constructs were integrated into the genome of S. 
lividans for heterologous expression. qPCR data confirmed the increased transcription 
levels and HPLC data showed the formation of new compounds. The new compounds 
were isolated and purified, and then identified to be polycyclic tetra macrolactams 
(PTMs) by mass spectrometric and NMR analysis. The successful activation of the 
cryptic pathway proved the power of the synthetic biology approach we developed. 
However, for PTM biosynthesis, no clear mechanism has been reported. With the 
pathway construction platform we developed, further investigation into the 
biosynthesis steps for PTMs was carried out.  
Chapter 4 describes the characterization of this PTM biosynthesis pathway by 
applying the same synthetic biology approach. In Chapter 3, we used a simple 
synthetic biology strategy to activate the cryptic PTM biosynthetic gene cluster 
SGR810-815 from S. griseus and identified two putative PTMs. To shed more light 
on the biosynthetic logic leading to PTMs, we sought to further exploit the plug-and-
play platform in our synthetic biology strategy to perform genetic manipulations on 
this gene cluster. We first identified the boundary of this gene cluster by assembling a 
seven-gene construct. Then, we created a series of single-gene deletion and multiple-
gene deletion constructs and characterized a number of intermediates. Noticing that 
this one single gene cluster may have the potential to produce multiple products with 
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closely related chemical structures, we biochemically characterized the modification 
enzymes in vitro. At the same time, a phylogenetically related pathway has also been 
reconstructed to confirm the function of the shared modification enzymes.  
Finally, after achieving the success in the applications of our newly developed 
natural product discovery platform, we decided to make it more generally applicable 
for natural product discovery in actinomycetes. However, because there are only a 
few characterized strong constitutive promoters in actinomycetes, we decided to 
identify additional strong constitutive promoters needed by our platform. Chapter 5 
provides the results on the screening and creation of a strong constitutive promoter 
library that could be used in actinomycetes via RNA-seq technique. The Streptomyces 
albus J1074 strain is one of the most widely used chassis for the heterologous 
production of bioactive natural products (76). S. albus J1074 carries the smallest 
genome among the completely sequenced species of the genus Streptomyces and the 
fast growth and an efficient genetic system make this strain an attractive model for 
expressing cryptic biosynthetic pathways to aid drug discovery (77). The whole 
transcriptome of this strain was sequenced at different time points to identify highly 
expressed genes in S. albus J1074 under two laboratory culture conditions. The 
potential promoter regions from these highly expressed genes were cloned and 
integrated to a XylE expression cassette. The strength of the promoters were 
characterized based on both the qPCR data and XylE enzyme specific activity assay. 
In total, 10 constitutive promoters were identified to be stronger than ermE*p, a 
widely used strong promoter reported in literature. These promoters will be used in 
20 
 
our genomics-driven, synthetic biology platform for high throughput discovery of 
novel natural products in actinomycetes. 
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1.7 Figures 
      
    Erythromycin                 Aflatoxin B1             Aloesone 
     S. erythrea                   A. flavus               R.palmatum 
   
  Taxol                      L-DOPA 
                 Taxus brevifolia                 Mucuna sp. 
Figure 1.1 Natural products discovered from bacteria, fungi and plants
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Figure 1.2 Polyketides and polyketide-terpene adducts from E. robusta. 
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Figure 1.3 Techniques used to activate cryptic pathways. 
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Figure 1.4 Representative structures of PKS enzymes. (a) Iterative Type I PKS, (b) Non-
iterative, modular Type I PKS, (c) minimal Type II PKS, and (d) Type III PKS. Domain 
abbreviations: KS, ketosynthase; AT, acyltransferase; ACP, acyl-carrier protein; KR, 
ketoreductase; DH, dehydratase; TE, termination
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Chapter 2 Discovery of New Type III PKS from Bioactive 
Plants 
2.1 Introduction 
Polyketides found in plants include chalcones and stilbenes. The enzymes responsible 
for the biosynthesis of these polyketides are classified as polyketide synthases (PKSs). In 
most cases, the production of polyketide metabolites in plant species has been traced to 
the activity of Type III PKSs. There are three types of PKSs. Type I PKSs are made up of 
a single, very large multi-domain protein that is structurally organized into modules. 
Type II PKSs are multi-enzyme systems as well, but each domain contained in Type II 
PKSs acts as a free-standing enzyme. Type III PKSs are the smallest PKSs and 
essentially represent a single domain of the multi-domain Type I or Type II PKS enzymes, 
mostly the KS domain. They usually form homodimers and the two independent active 
sites of the homodimer act iteratively, catalyzing the sequential condensation of two-
carbon acetate units derived from a malonate thioester into a growing polyketide chain 
(1). Although they are simple in structure, they can produce a variety of bioactive 
aromatic compounds with single or multi-ring structures.  
Medicinal plants have been used for thousands of years in the treatment of numerous 
diseases (2). Approximately 25% of today’s medicines are derived from plant natural 
products, such as the Taxol used in cancer therapy (3) (Figure 2.1). Overall, natural 
products from plants include terpenes, alkaloids, lignans, and polyketides. Many well-
known complementary therapies, such as curcuminoids (curcumin) and flavonoids 
(genistein, quercetin, resveratrol) occupied a large portion of the natural products 
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discovered from bioactive plants. They were usually extracted from plant extracts using 
newly developed analytical techniques (4,5). For example, the phloroglucinol 
components of bioactive plants were generally discovered by analyzing organic solvent 
fractions of plant materials (6). Phloroglucinol itself and its derivatives are smooth 
muscle relaxants and serve as antispasmodic in clinical use. It is sold in Europe under the 
names Spasfon and Spasfon Lyoc. The one used in industry and medicine is synthesized 
chemically; however, it has received little attention for bio-production. Searching 
databases of scientific literature uncovered a number of target plants across a wide range 
of species, we found phloroglucinol and its derivatives were isolated from Acacia 
arabica and Euclyptus kino and others (6). In nearly all cases, chemical characterization 
of the phloroglucinol natural products was not followed by subsequent characterization of 
the producing enzymes. So far, only two acylpholoroglucinol-producing enzymes from 
plants have been studied, isovalerophenone synthase from Humulus lupulus (7) and PKS1 
from Hypericum perforatum (8). Thus, the genetic materials of plants producing known 
phloroglucinol or its derivatives provide rich sources of uncharacterized phloroglucinol 
synthase enzymes. 
The well-studied plant Type III PKSs are the chalcone synthases (CHSs), which are 
involved in the synthesis of precursors of certain pigments. A large number of CHS 
family enzymes have been discovered and characterized (9). Based on these CHSs, it 
may be possible to isolate new Type III PKS from bioactive plants, such as enzymes that 
are capable of synthesizing phloroglucinol or acylphloroglucinol.  
The goal of this project is to create a PCR-based screening method using degenerate 
primers to identify new Type III PKSs, especially phloroglucinol synthases, from 
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bioactive plants. If no new enzymes are discovered, an enzyme with previously 
uncharacterized substrate specificity or new products will also be a valuable discovery. In 
this method, degenerate primers are used as probes to mine the plant genetic materials. 
Therefore, a validation of the degeneracy of the primers needs to be first carried out to 
confirm the efficiency of our degenerate primers. Once this method is validated, future 
discovery of new Type III PKSs can be processed and characterization of interesting 
enzymes can be performed to determine their substrate and product profiles.  
2.2 Results and discussion 
2.2.1 Design of the degenerate primers 
Detection of genes of interest by PCR is a commonly used strategies in molecular 
biology (10). Degenerate primers are used for amplifying a family of unknown genes by 
incorporating deoxyinosines in the primer sequence to create the genetic diversity. 
Inosine is a natural nucleoside commonly present in transfer RNAs and is able to base 
pair with thymidine, cytosine, and, to a less extent, adenine. This strategy has already 
been employed for discovery of Type III PKSs, such as the acridone synthase from 
Huperzia serrate (11), and the octaketide synthase from Aloe arborescens (12).  
Fourteen different enzymes from the plant Type III PKS family were chosen as the 
template for design of the degenerate primers. The phylogenetic relationship of these 
fourteen enzymes and their main polyketide products are shown in Figure 2.2. The 
mRNA sequences coding these enzymes were aligned using ClustalW. From the 
sequence alignment, regions sharing high homologies were found and six of them were 
chosen to create the degenerate primers. The locations of the three sets of conserved 
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regions, F1, F2, F3, R1, R2 and R3, mapped on the Medicago sativa chalcone synthase 2 
(CHS2) gene and protein sequences are shown in Figure 2.3. Three primer sets annealing 
at these regions (shown in yellow, green, and pink) amplify three gradually shorter 
fragments to perform a nest PCR, with fragment lengths of approximately 800 bp (yellow, 
region F1 and R3), 770 bp (green, region F2 and R2), and 400 bp (pink, region F3 and 
R1). Nest PCR would help to eliminate the false positives and also enrich the genetic 
materials of interest. The core fragments that were ~ 400 bp in length were specially 
designed in the region that contained the important residues, such as Thr-197 and Gly-
256. Those residues play an important role in substrate recognition and elongation of a 
Type III PKS. In this case, alignment of the resultant core fragments would give insights 
into the potential classification of the Type III PKSs. This would help avoiding cloning 
and characterizing less desirable enzymes. 
2.2.2 Validation of degenerate primers 
As the degenerate primers are the first key elements to insure successful 
amplification of the desired Type III PKS, Type III PKSs from Hypericum perforatum 
are used to validate the degenerate primers. Hypericum perforatum, known as St. John’s 
Worts, is a medical plant and its extracts are commonly used for the treatment of mild to 
moderate depression (13). Four polyketides, hyperforin, adhyperforin, hyperfricin, and 
pseudohypericin are found in this plant and believed to be bioactive (14). Thus, 
Hypericum perforatum is ideal to be used as the model system to test the degenerate 
primers as it is a medical plant and has a number of PKSs whose sequences are known. 
Four Type III PKSs have been cloned from H. perforatum: chalcone synthase, 
benzophenone synthase, PKS1, a hyperforin synthase and PKS2, which synthesizes the 
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octaketide precursor to hyperforin, emodin anthrone (15). The primary sequences of these 
four enzymes are divergent, so the ~400 bp fragment may be enough to differentiate the 
four genes. The validation experiment design is shown in Figure 2.4. 
In this study, the genetic materials were collected from the improved strain 
Hypericum perforatum var. Topas. Seeds were germinated on Murashige-Skoog media 
and grow for four weeks. Total RNA was extracted from immature tissue, purified and 
concentrated, and then used to create the cDNA library. One positive control gene, which 
synthesizes the RuBisCo (Ribulose-1,5-bisphosphate carboxylase oxygenase), was used 
to ensure the successful preparation of mRNA and cDNA library. RuBisco is the most 
abundant enzyme in green plants, so it was chosen as the positive control. Specific 
primers based on the published mRNA sequence of the four known PKSs (BPS, CHS, 
PKS1 and PKS2) were used to amplify the corresponding genes from the cDNA library 
(Figure 2.4). The amplified fragments were cloned into pET 26 vectors and confirmed by 
sequencing. The identities were greater than 90% versus the templates (BPS, 797/855 nt, 
93%; CHS, 1004/1067 nt, 94%; PKS1, 960/981 nt, 97%; PKS2, 1057/1078 nt, 98%). 
Then, degenerate primers were used to amplify the Type III PKSs based on a nest PCR 
protocol. Basically, PKS-F1/PKS-R3 were used to amplify the ~800 bp fragment and the 
resulting product was then used as template for the second round of amplification using 
PKS-F2/PKS-R2. The product of the second round of amplification served as the 
template for the last round of amplification by PKS-F3/PKS-R1. Product from the third 
round of nest PCR can be visible on agarose gel as shown on Figure 2.5.   
The fragments were cloned into a vector and 26 colonies were sequenced. The 
results showed that out of the 26, some belonged to the CHS and BPS from H. 
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perforatum, and an additional PKS was found. The sequence identity of various clones to 
CHS, BPS, PKS1 and PKS2 was shown in Table 2.1.  
A BLAST search based on the ~400 nt sequence of the unknown gene fragments 
(clones #5 and #8) indicates that it has significant homology to plant CHS and maybe 
root specific. Our inability to identify PKS1 and PKS2 may be due to the low expression 
level of these two genes, or may be due to the unavailability of these two genes in the 
immature plant tissue.  
Nonetheless, the validation data confirmed that the degenerate primers were able to 
amplify Type III PKS genes from a plant cDNA library. During the degenerate primer 
design process, no Type III PKS from H. perforatum was found, which proved that the 
degenerate primers designed were able to amplify Type III PKS from general plant 
tissues.  
2.2.3 Identification of target plants 
The target plants were selected based on two criteria: firstly, the plant needs to be 
bioactive, evidenced by use in traditional medicine and/or findings of high-valued 
compounds reported by scientific journals; secondly, the plant has been reported to 
produce phloroglucinol or its derivatives. By searching scientific database, several target 
plants have been selected over a wide range of species. Trees of Eucalyptus and ferns of 
Dryopteris are two groups of plants in which acylphloroglucinols are particularly 
abundant and no relevant genes have been cloned. 
Eucalypts produce a wide variety of acylphloroglucinol compounds which may be 
formylated or acylphloroglucinol-terpene adducts (e.g. euglobals and macrocarpals) (16). 
For example, the compound grandinol, produced by Eucalyptus grandis, is the most-
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studied acylphloroglucinols. Gradinol serves as a growth regulator in the plants and can 
inhibit germination (6). Eucalypt polyketide natural products are also known to be 
antiviral, antibacterial, anticancer, and cariostatic (inhibit the growth of bacteria that 
cause tooth decay), and Eucalypts have been used by the Aboriginal people of Australia 
for the treatment of colds, influenza, toothache, snakebites, fevers, and other ailments 
(16). The plant E. camaldulensis, from which the compound phloroglucinol has been 
isolated in the past, is an important species to study. 
2.2.4 Screening of PKS genes in target plants 
Based on the above-mentioned two criteria and literature search, two plants, 
Eucalyptus robusta and Eucalyptus camadulensis var. Silverton Province were chosen for 
study. E. robusta produces the dimeric and monomeric acylphloroglucinols Robustaol A 
and B, respectively, as well as the acylphloroglucinol-terpene adducts Robustadial A and 
B. The leaves of E. robusta are used to produce an anti-malarial medicine, “Da Ye An,” 
in China, and also to treat bacterial illnesses and dysentery. E. camaldulensis, or red gum, 
was chosen as the second target species. It is an abundant tree also known to produce 
acylphloroglucinol-terpene adducts. 
Specimens of the target plants E. camaldulensis var. Silverton Province and E. 
robusta were used for DNA cloning. Briefly, the collected leaf tissue was flash-frozen in 
liquid nitrogen and crushed, and total RNA was extracted from the plant tissue and used 
to create a cDNA library. This cDNA library was used as the template for nested PCR. At 
each stage, PCR products were analyzed by agarose gel electrophoresis, and in the initial 
step, an amplification of a fragment of the abundant mRNA for RuBisCo (Ribulose-1,5-
bisphosphate carboxylase oxygenase) was also used as a control. The first and second 
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amplifications did not result in bands of the expected size, with the exception of the 
RuBisCo control, but the final amplification gave a fragment of the appropriate size 
(~400 nt). The fragments were then digested and ligated into a vector for sequencing. The 
absence of product bands until the third nested PCR indicates the need for this strategy 
due to low abundance of the mRNAs of interest in Eucalyptus.  
A total of 94 clones and 27 clones were sequenced from the cDNA libraries 
created from the leaves of E. camaldulensis and E. robusta, respectively. Depending on 
the threshold (i.e. the number of different amino acids in the cloned DNA fragments), the 
number of different genes could range from 5 to 97. If the threshold in the validation 
experiment was used as a reference (i.e. genes with 80% sequence identity are considered 
the same), the identified DNA fragments could be classified into 11 groups, representing 
11 unique putative Type III PKSs genes. To make it more stringent, these 11 groups can 
be further consolidated into 5 groups (PKS1-5) according to the characteristic residues. 
Representation of each group ranged from 1 to approximately 50 clones and two of the 
three conserved catalytic triad residues in all known Type III PKSs (Cys and His) were 
present.  
Based on the translated sequence, specifically on the Gly-256 (M. sativa chalcone 
synthase numbering) equivalent and nearby residues, the activity of a new Type III PKS 
could be inferred. Enzymes utilizing coumaroyl-CoA as the priming acyl-CoA (chalcone 
synthase and stilbene synthase enzymes) typically possess a glycine at the equivalent of 
CHS Gly-256, and a DGH (Asp-255, Gly-256, His-257) pattern, indicating that PKS4 
likely represents CHS or STS enzymes. Benzophenone synthases possess a TAH pattern, 
which is shared by PKS2. Two enzymes possessed unusual residues at those locations: 
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AGH was seen in PKS1, and AAH for PKS5. The translated sequence of PKS3 shows 
that it possesses the residues EGQ at the CHS Asp-255, Gly-256, His-257 equivalent 
positions. ClustalW alignment of representative translated sequences from each group is 
shown in Figure 2.6, and highlights the diversity present among these five putative Type 
III PKS enzymes.  
2.2.5 Cloning of full length PKS genes using RACE-PCR 
To further investigate these putative Type III PKS fragments, RACE-PCR (rapid 
amplification of cDNA ends-polymerase chain reaction) was used to clone the full-length 
genes encoding the three Eucalyptus Type III PKSs. However, for Pks5, as the amount of 
this gene in the cDNA library was so low, the RACE-PCR failed to obtain the 3’- and 5’-
end of this gene. Thus we decided to focus on Pks1 and Pks3. The 3’- and 5’-ends of 
these two genes were obtained from RACE-PCR, and specific primers were designed to 
obtain the full-length gene. Full-length genes were successfully amplified from the cDNA 
library (Figure 2.7). The resulting full-length gene encoding Pks1 consists of 1170 
nucleotides, which corresponds to 389 amino acid residues, and the full-length gene 
encoding Pks 3 consists of 1182 nucleotides, which corresponds to 408 amino acid 
residues. The two full-length genes were sequenced. BLAST search indicates both Pks1 
and Pks3 share 75% sequence identity with M. sativa chalcone synthase. Bioinformatic 
analysis indicates that the catalytic triad residues (Cys, His, Asn) of Type III PKSs are all 
present in this protein. By comparing all the conserved residues in CHSs, including the 
catalytic triad: Cys164, His303, Asn336; the active sites: Thr197, Ile254, Gly256, Ser338; 
the catalytic site: Met137, Gly211, Gly216, Pro375, and the gate keepers: Phe215, 
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Phe265, it was found that all these residues are conserved in Pks3, while Pks1 has Ile265 
instead of Phe265. Therefore, we selected Pks1 for further characterization. 
2.2.6 Enzyme characterization and product identification 
In order to produce the large quantities of enzymes required for characterization 
studies, a heterologous host was needed for over-expression. Escherichia coli was chosen 
as the heterologous host. It is widely used for heterologous expression due to its fast 
growth, ease of transformation and mature and numerous availability of DNA cloning 
tools (17). The pks1 gene with C-terminal His6 was cloned into the IPTG-inducible 
pET26b(+) vector, which possesses a PT7 promoter, and expressed as a soluble protein in 
E. coli. A PKS1 protein band is clearly visible by SDS-PAGE analysis of purified soluble 
lysate from E. coli PKS1 expression. However, the purity was poor, so gel filtration was 
used to enhance the purity (Figure 2.8). 
At the same time, M. sativa chalcone synthase was cloned and purified to serve as 
the positive control. Enzymatic activity assay was carried out as described elsewhere (18). 
14 different CoAs were tested as the starter unit whereas malonyl CoA was used as the 
extension unit. Several HPLC programs were tested as listed in Table 2.3 and 2.4, and the 
highlighted one was chosen for CoA separation and product discovery.  
As for M. sativa chalcone synthase, 4-coumaroyl CoA was used as the starter unit 
and malonyl CoA as the extension unit. 4-coumaroyl-NAC was chemically synthesized 
and used as the starter unit.  The chemical structure of 4-coumaroyl-NAC was 
confirmed by both LC-MS and NMR (data not shown). Both CHS and Pks1 were 
incubated with these two substrates and the expected product peak for naringenin was 
detected (Figure 2.9), which indicated that the enzymes were active. However, after 
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testing all possible starter CoAs, no novel product was identified, which indicates that 
Pks1 is a member of the CHS family of Type III PKSs and shares the same function as M. 
sativa chalcone synthase. 
2.3 Conclusion 
In this study we developed a PCR-based screening method capable of identifying new 
Type III PKSs in medicinal plants. The screening system was successfully validated by 
identifying two known Type III PKSs and one unknown Type III PKS from Hypericum 
perforatum. Initial results from screening Eucalyptus species have been promising, and 
led to the identification of gene fragments from at least five putative Type III PKS 
enzymes between E. robusta and E. camaldulensis, including two enzymes which appear 
to be conserved in both species. Bioinformatic studies allowed us to identify one putative 
benzophenone synthase and three putative chalcone or stilbene synthases. RACE-PCR 
was used to obtain the full-length genes encoding two Eucalyptus Type III PKSs, 
however, further biochemical characterization showed that Pks1 belongs to the CHS 
family and has a same function as M. sativa chalcone synthase.  
2.4 Materials and methods  
2.4.1 Strains and reagents 
E. coli DH5α was obtained from the University of Illinois at Urbana-Champaign 
Biochemistry Department's Media Preparation Facility (Urbana, IL). Hypericum 
perforatum var. Topas seeds were purchased from Sand Mountain Herbs (Fyffe, AL). 
Eucalyptus robusta and Eucalyptus camaldulensis var. Silverton Province plants were 
obtained from Windmill Outback Nursery (Louisa, VA). Plasmid pET26b(+) and 
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pET28a(+) were obtained from Novagen (Madison, WI). All restriction endonucleases, as 
well as T4 DNA ligase and antarctic phosphatase, were purchased from New England 
Biolabs (Beverly, MA). The QIAprep Spin Plasmid Mini-prep Kit, QIAquick PCR 
Purification Kit, QIAquick Gel Extraction Kit, and RNeasy MinElute Cleanup Kit were 
purchased from Qiagen (Valencia, CA). The Total RNA Isolation Mini Kit was obtained 
from Agilent Technologies (Santa Clara, CA). All primers were synthesized by 
Integrated DNA Technologies (Coralville, IA). 5 PRIME MasterMix was purchased from 
5 PRIME Inc. (Gaithersburg, MD). Unless otherwise noted, all other reagents were 
purchased from Sigma-Aldrich (St. Louis, MO). 
2.4.2 Degenerate primer design 
The mRNA sequences of fourteen enzymes in the plant Type III PKS family were 
used as the templates to design degenerate primers: Hypericum androsoemum 
benzophenone synthase (BPS), Hordeum vulgare homoeriodictyol/eriodictyol synthase 
(HEDS), Medicago sativa chalcone synthase 2 (CHS2), Arachis hypogea stilbene 
synthase (STS), Pinus sylvestris stilbene synthase (STS), Gerbera hybrida 2-pyrone 
synthase (2-PS), Aloe arborescens octaketide synthase (OKS), Aloe arborescens 
pentaketide chromone synthase (PCS), Rheum palmatum aloesone synthase (ALS), 
Rheum palmatum benzalacetone synthase (BAS), Humulus lupulus isovalerophenone 
synthase (VPS), Hydrangea macrophylla stilbenecarboxylate synthase 1 (STCS1), 
Hydrangea macrophylla coumaroyl triacetic acid lactone synthase (CTAS), and Huperzia 
serrata acridone synthase (ACS).  
The mRNA sequences of the fourteen above enzymes were aligned using the 
ClustalW tool in the Biology Workbench suite (http://workbench.sdsc.edu) (19). Highly 
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similar regions were identified from the alignment, and the six regions chosen to create 
degenerate primers are mapped onto the M. sativa CHS2 mRNA and protein sequences in 
Figure 2.3. The conserved regions were denoted F1, F2, F3, R1, R2, and R3, and used to 
design primers of the same name. To keep degeneracy as low as possible, less conserved 
bases were replaced with deoxyinosine, with a maximum of three deoxyinosine 
nucleotides per primer. The primer sequences, their levels of degeneracy, and definitions 
of mixed bases are given in Table 2.5. Three sets of primers are designed to perform nest 
PCR, which is essential as repeating of F1-R3 cannot amplify desired fragments and 
using F3-R1 initially cannot generate enough amount of the desired fragment either. 
Restriction sites were added to primers PKS-F3 (NheI) and PKS-R1 (XhoI) to facilitate 
cloning the smallest fragments into a vector for sequencing; those primers are PKS-F3-F 
and PKS-R1-F. Primers both with and without flanking bases were generated because it 
was unclear whether non-hybridizing, flanking nucleotides would inhibit the 
amplification reaction. Based on the M. sativa CHS2 mRNA (Figure 2.3), the fragment 
amplified by PKS-F1 and PKS-R3 is 803 nt in length; the fragment amplified by PKS-F2 
and PKS-R2 is 776 nt; and the fragment amplified by PKS-F3(-F) and PKS-R1(-F) is 407 
nt. 
2.4.3 Seed sterilization and germination 
Before germinating, H. perforatum var. Topas seeds were sterilized by a four-step 
process: (1) seeds were washed in a solution of 70% ethanol and 0.1% Tween-20 with 
vigorous mixing for 1 minute; (2) seeds were washed in a solution of 5% NaOCl (bleach) 
with vigorous mixing for 10 minutes; (3) seeds were then rinsed with three washes of 
distilled, deionized water which was sterilized through a 0.22 µm syringe filter; (4) seeds 
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were soaked in a solution of Agribrom antifungal dissolved in sterile distilled, deionized 
water and incubated in the dark at 4 °C for 48 hours. Subsequently the sterilized seeds 
were rinsed in sterile distilled, deionized water, plated on Murashige-Skoog (no sucrose) 
plates (Murashige-Skoog basal salts, MES, 0.7% agar, pH 5.7) sealed with gas-permeable 
tape (3M, St. Paul, MN) and incubated in a lighted room to induce germination. After 
approximately four weeks, seedlings were removed from agar plates and plant tissue was 
collected and cDNA prepared as described below.  
2.4.4 Collection of plant tissue 
Plant tissue (leaf) was cut from live plants and immediately frozen on liquid nitrogen 
to prevent degradation of RNA. Frozen tissue was crushed to fine powder using a mortar 
and pestle cooled to freezing using liquid nitrogen. Crushed plant tissue was stored at -
80 °C until RNA extraction. 
2.4.5 Total RNA isolation and concentration and cDNA synthesis 
Total RNA was purified from crushed plant tissue using the Agilent Total RNA 
Isolation Mini Kit according to the manufacturer’s instructions. Approximately 100 mg 
of plant tissue was used in each RNA purification. To purify and concentrate RNA, the 
Qiagen RNeasy MinElute Cleanup Kit was used according to the manufacturer’s 
instructions. Total RNA was visualized by agarose gel electrophoresis and concentration 
and purity were determined using a NanoDrop (Thermo Fisher Scientific, Waltham, MA). 
Purified, concentrated total RNA was used as the template for cDNA synthesis using 
Transcriptor II reverse transcriptase enzyme (Invitrogen, Carlsbad, CA) and anchored 
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Oligo-dT20 primer (Invitrogen, Carlsbad, CA) according to the manufacturer’s 
instructions. 
2.4.6 Screen validation using Hypericum perforatum var. Topas 
To verify their expression, full-length genes for H. perforatum CHS, BPS, PKS1, and 
PKS2 were amplified from H. perforatum cDNA using the specific primers shown in 
Table 2.6 and 5 PRIME MasterMix according to the manufacturer’s instructions (PCR 
program: 95 °C, 3 min; [94 °C, 1 min; 50 °C 1 min; 68 °C 1 min 30 sec] x 50; 68 °C, 7 
min). PCR products were analyzed by agarose gel electrophoresis and then bands of the 
appropriate size were purified by gel purification and extraction. DNA sequencing 
reactions were performed using the same primers initially used to amplify the genes 
(Table 2.6) and the BigDye Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems, 
Foster City, CA) according to the manufacturer’s instructions. DNA was sequenced by 
the Biotechnology Core DNA Sequencing Laboratory at the University of Illinois at 
Urbana-Champaign (Urbana, IL). Comparing the sequencing results versus published 
sequences confirmed that all four PKSs were expressed in the H. perforatum seedlings. 
Amplifications with the degenerate primers were performed using the following 
PCR program: 95 °C, 3 min; [94 °C, 1 min; 50 °C 1 min; 68 °C 1 min 30 sec] x 50; 68 °C, 
7 min. DNA fragments were amplified from cDNA using the primers shown in Table 2.5 
and 5 PRIME MasterMix according to the manufacturer’s instructions. Amplification of 
the RuBisCo fragment was performed using specific primers for the RuBisCo gene in 
conjunction with the first amplification using PKS-F1 and PKS-R3 primers, to verify the 
amplification was successful and cDNA was present. For amplifications using cDNA as 
the template, 1 µl of cDNA was used; alternatively, 5 µl of PCR product was used as the 
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template for subsequent nested PCR amplifications using primers PKS-F2 and PKS-R2 
or PKS-F3-F and PKS-R1-F.  
PCR-amplified ~400 nt DNA fragments were cloned into the pET26b(+) vector to 
facilitate DNA sequencing. The ~400 nt fragment was digested with NheI and XhoI (10 
units enzyme per µg DNA), and the vector was digested with XbaI and XhoI (10 units 
enzyme per µg DNA). Note that NheI and XbaI have compatible cohesive ends. After 
ligation using T4 DNA ligase, the plasmid was transformed into E. coli DH5α and single 
colonies were picked. Presence of an insert of the correct size was verified by colony 
PCR. Briefly, cells were collected from 200 µl overnight culture and resuspended in 200 
µl sterile distilled, deionized water. The samples were boiled for ten minutes, cooled to 
room temperature, and then spun at max speed in a bench top microcentrifuge for three 
minutes to pellet cell debris. A PCR amplification using Taq DNA polymerase 
(Invitrogen, Carlsbad, CA) was set up according to the manufacturer’s instructions with 5 
µl of the soluble cell lysate as template and using primers specific to the T7 promoter and 
the T7 terminator. The PCR product was analyzed by agarose gel electrophoresis. A 
plasmid with resulting PCR product of size ~500 nt was purified and submitted for DNA 
sequencing. Sequencing reactions were performed using primers specific to the T7 
terminator and the BigDye Terminator v3.1 Cycle Sequencing Kit. DNA was sequenced 
by the Biotechnology Core DNA Sequencing Laboratory at the University of Illinois at 
Urbana-Champaign (Urbana, IL). 
DNA sequencing of 26 fragments in pET26b(+) identified the ~400 bp fragments as 
belonging to the genes for H. perforatum CHS, H. perforatum BPS, and an additional, 
previously unknown gene, based on sequence homology (Table 2.1). The other two 
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enzymes, PKS1 and PKS2, were not identified, probably due to lower relative expression 
(and thus abundance of mRNA) in the young plants. 
2.4.7 Screening Eucalyptus species 
Leaf tissue was taken from E. robusta and E. camaldulensis var. Silverton Province 
trees (~1.5 m height) for RNA isolation. Collection of plant tissue, RNA isolation, and 
cDNA synthesis were completed as described in the sections above. Degenerate primer 
nested PCR, cloning of ~400 nt fragments, and DNA sequencing were performed as 
described above for H. perforatum. A total of 27 individual clones were submitted for 
sequencing from E. robusta and 94 from E. camaldulensis. ClustalW and BLAST 
analysis using the Biology Workbench Suite (19) were used to analyze the resulting DNA 
and translated protein sequences. Depending on the cut-off (i.e. the number of different 
amino acids in the cloned DNA fragments), the number of different Type III PKS genes 
ranges from 5 to 97 (Table 2.2). Phylogenetic analysis of all the Type III PKS fragments 
is given in Figure 2.10. 
2.4.8 RACE PCR 
The core fragment of EC2 was subjected to RACE PCR using gene specific primers 
(Figure 2.7) and the protocol of 3’/5’ RACE system for Rapid Amplification of cDNA 
Ends Kits Version 2.0 (Invitrogen, Carlsbad, CA). The PCR program consists of 94 °C (2 
min), 35 cycles at 94 °C (1 min), 55 °C (30s) and 72 °C (2 min), and a final 10 min 
extension at 72 °C. A plasmid with resulting PCR product of size ~1000 nt was purified 
and submitted for DNA sequencing. Sequencing reactions were performed using primers 
specific to the T7 terminator and the BigDye® Terminator v3.1 Cycle Sequencing Kit. 
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2.4.9 Protein purification 
Plasmids pET26b(+)-EC2, pET26(+)-ER4 and pET26(+)-CHS were transformed into 
E.coli BL21 (DE3) and single colonies were picked and inoculated 5 mL LB containing 
50 μg kanamycin mL-1 . Following overnight growth at 37 °C, and this culture was used 
to inoculate 500 mL TB containing the appropriate antibiotic, and grown at 37 °C until 
the optical density at 600 nm reached 0.8. Protein expression was induced with the 
addition of 0.25mM isopropyl-β-D-thiogalactopyranoside (IPTG), and growth was 
continued for an additional 18 hours at 20 °C. The flasks were chilled for 30 minutes, and 
then the cells were harvested by centrifugation (6000 g, 4 °C, 10 minutes). The resulting 
pellet was resuspended in 2 mL lysis buffer (10 mM imidazole, 50 mM sodium 
phosphate buffer, 300 mM NaCl, 10 mM imidazole, 15% glycerol, pH 8.0, 1 mg/mL 
lysozyme) per gram cell weight and frozen at -80 °C. Subsequently, cells were lysed 
using sonication and cellular debris was removed by centrifugation (40,000 g, 4 °C, 10 
minutes). Recombinant proteins were purified by chromatography on Ni-NTA resin by 
amino-terminal hexahistidine affinity tag. Captured proteins was washed with wash 
buffer (20 and 50 mM imidazole, 50 mM sodium phosphate buffer, 300 mM NaCl, 20 or 
50 mM imidazole, 15% glycerol, pH 8.0) and finally eluted in elution buffer (200 mM 
imidazole, 50 mM sodium phosphate buffer, 300 mM NaCl, 200 mM imidazole, 15% 
glycerol, pH 8.0). The protein content of individual elution fractions was estimated using 
Quick Start Bradford Protein Assay (Bio-Rad, Hercules, CA) and the appropriate 
fractions were pooled and buffer exchanged into 10 mM phosphate buffer pH 7.5 
containing 15% glycerol at 4 °C. The protein was concentrated using an Amicon Ultra 
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centrifugal filter device (Millipore, Billerca, MA). Representative SDS-PAGE analysis of 
recombinant proteins was shown in Figure 2.8.  
2.4.10 SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
Protein standards, Powerpac 300 power supply, Mini-PROTEAN 3 assembly, and 
precast acrylamide gels were purchased from Bio-Rad (Hercules, CA). Varying amounts 
of sample, dependent upon protein concentration, were mixed with 2 μl SDS-PAGE 
loading buffer (30% glycerol, 1% SDS, 0.3% bromophenol blue, 0.5 M Tris-HCl, pH 6.8) 
and water to a final volume of 20 μl, Samples were denatured at 98 °C for 10 minutes, 
cooled to 4 °C, and then loaded onto a gel in a Bio-Rad Mini-PROTEAN 3 assembly. 
Voltage was supplied by a Powerpac 300 power supply at a voltage of 100 V for 100 
minutes. Gels were stained with SimplyBlueTM Safestain from Invitrogen (Carlsbad, CA) 
followed by destaining overnight in distilled water. Destained SDS-PAGE gels were 
scanned subsequently discarded. 
2.4.11 Determination of activity 
Experiments were conducted according to the method of Mckhann, et al. (18) with 
some modifications. The experiments were carried out in triplicates using a range of 
different starting CoAs. For each reaction, substrate was incubated with EC2 enzyme (0.5 
mg/ml) in PBS buffer (pH 7.5) at 37°C for 15 minutes. Usually， 0.5 μM enzyme is 
used and 100 μM malonyl CoA in a total reaction volume of 400 μl. The concentration of 
priming acyl-CoA was 10 μl. The reaction mixture was incubated at 37 °C for 5 minutes 
before addition of malonyl-CoA. The reaction was quenched by the addition of 20 μl 20% 
HCl and kept room temperature until HPLC analysis. The reactions were analyzed using 
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an Agilent 1100 Series HPLC and ZORBAX SB-C18 reverse-phase column (3.0 x 150 
mm, 3.5 μm) (Aglient Technologies, Palo Alto, CA) monitoring at 254 nm.  
2.4.12 Product HPLC analysis method 
Product analysis method was conducted by comparing a series of different HPLC 
programs. An Agilent 1100 Series HPLC and ZORBAX SB-C18 reverse-phase column 
(3.0 x 150 mm, 3.5 μm) (Aglient Technologies, Palo Alto, CA) were used to monitor at 
280 nm and at a flow rate of 0.5 mL/min at 25 °C. Solvent A is water with 1% acetic acid 
and solvent B is methanol.  
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2.6  Figures and tables 
 
 
 
 
Figure 2.1 Examples of natural products derived from plants. 
 
Artemisinin Quinine Taxol
Grandinol 13
Kosotoxin 14
Dryopteroside
Euglobal III
OHO
OH O
Aspidinol B
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Figure 2.2 Phylogenetic analysis of the fourteen Type III PKS enzymes used to create 
degenerate primers in this study. The primary products of the enzymes are shown. The 
enzymes are, in order: HEDS, homoeriodictyol/eriodictyol synthase; ALS, aloesone 
synthase; BPS, benzophenone synthase; OKS, octaketide synthase; PCS, pentaketide 
chromone synthaes; STS, stilbene synthase; ACS, acridone synthase; CTAS, coumaroyl 
triacetic acid synthase; STCS1, stilbenecarboxylate synthase 1; 2-PS, 2-pyrone synthase; 
VPS, isovalerophenone synthase; CHS2, chalcone synthase 2; BAS, benzalacetone 
synthase. 
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Figure 2.3 Locations of the three sets of conserved regions used to create degenerate 
primers, mapped onto the M. sativa CHS2 gene and protein, are shown in yellow, green, 
and pink, corresponding to F1, F2, F3, R1, R2, and R3, respectively. Active site residues 
Cys-152, His-305, and Asn-338 are shown in red and marked with asterisks. Residues 
which are known to affect substrate preference and elongation number, Thr-197, Gly-256, 
and Ser-338, are shown in blue and marked with a triangle. 
      M  V  S  V  S  E  I  R  K  A  Q  R  A  E  G  P  A  T  I  L   
1     atggtgagtgtgtctgaaattcgtaaagctcaaagggcagaaggccctgcaactatcttg  60 
 
      A  I  G  T  A  N  P  A  N  C  V  E  Q  S  T  Y  P  D  F  Y   
61    gccattggcactgcaaatccagcaaattgtgttgaacaaagcacttatcctgatttttac  120 
 
      F  K  I  T  N  S  E  H  K  T  E  L  K  E  K  F  Q  R  M  C   
121   tttaaaattacaaatagtgagcacaaaactgaacttaaagagaaatttcagcgcatgtgt  180 
 
      D  K  S  M  I  K  R  R  Y  M  Y  L  T  E  E  I  L  K  E  N   
181   gataaatctatgatcaagaggagatacatgtatctaacagaggagattttgaaagaaaat  240 
 
      P  N  V  C  E  Y  M  A  P  S  L  D  A  R  Q  D  M  V  V  V   
241   ccaaatgtttgtgaatacatggcaccttcattggatgcaaggcaagacatggtggtggta  300 
 
      E  V  P  R  L  G  K  E  A  A  V  K  A  I  K  E  W  G  Q  P   
301   gaggtacctagactagggaaggaggctgcagtgaaggctataaaagaatggggtcaacca  360 
 
      K  S  K  I  T  H  L  I  V  C  T  T  S  G  V  D  M  P  G  A   
361   aagtcaaagattactcacttaatcgtttgcaccacaagtggtgtcgacatgcctggagcc  420 
 
      D  Y  Q  L  T  K  L  L  G  L  R  P  Y  V  K  R  Y  M  M  Y   
421   gattatcaactcaccaaactcttaggtcttcgcccatatgtgaaaaggtacatgatgtac  480 
               * 
      Q  Q  G  C  F  A  G  G  T  V  L  R  L  A  K  D  L  A  E  N   
481   caacaagggtgttttgcaggtggcacggtgcttcgtttggctaaagatttggctgagaac  540 
                                                      ▼ 
      N  K  G  A  R  V  L  V  V  C  S  E  V  T  A  V  T  F  R  G   
541   aacaaaggtgctcgtgtgttggttgtttgttctgaggtcaccgctgtcacatttcgtggg  600 
 
      P  S  D  T  H  L  D  S  L  V  G  Q  A  L  F  G  D  G  A  A   
601   cctagtgatactcacttggacagccttgttggacaagcactatttggagatggagctgct  660 
 
      A  L  I  V  G  S  D  P  V  P  E  I  E  K  P  I  F  E  M  V   
661   gcactcattgttggttctgatccagtaccagaaattgagaaacctatatttgagatggtt  720 
                                                   ▼ 
      W  T  A  Q  T  I  A  P  D  S  E  G  A  I  D  G  H  L  R  E   
721   tggactgcacaaacaattgctcctgatagtgaaggagccattgatggtcaccttcgtgaa  780 
 
      A  G  L  T  F  H  L  L  K  D  V  P  G  I  V  S  K  N  I  T   
781   gctggactaacatttcaccttcttaaagatgttcctgggattgtttcaaagaacatcact  840 
 
      K  A  L  V  E  A  F  E  P  L  G  I  S  D  Y  N  S  I  F  W   
841   aaagcattggttgaggctttcgagccattgggaatttctgattacaactcaatcttttgg  900 
            * 
      I  A  H  P  G  G  P  A  I  L  D  Q  V  E  Q  K  L  A  L  K   
901   attgcacatcctggtggacctgcaattctagatcaagtagagcaaaagttagccttaaag  960 
                                                   *     ▼ 
      P  E  K  M  N  A  T  R  E  V  L  S  E  Y  G  N  M  S  S  A   
961   cctgaaaagatgaatgcaactagagaagtgctaagtgaatatggaaatatgtcaagtgca  1020 
 
      C  V  L  F  I  L  D  E  M  R  K  K  S  T  Q  N  G  L  K  T   
1021  tgtgttttgtttatcttagatgaaatgagaaagaagtcaactcaaaacggattgaagaca  1080 
 
      T  G  E  G  L  E  W  G  V  L  F  G  F  G  P  G  L  T  I  E   
1081  acgggagaaggacttgaatggggtgtattgtttggttttggaccaggacttaccattgaa  1140 
 
      T  V  V  L  R  S  V  A  I  * 
1141  acagttgttttgcgtagcgtggctatatga  1170 
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Figure 2.4 Overview of the PCR-based method for discovering new Type III PKS genes. 
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           a:   L  Rub  CHS PKS1 PKS2 BPS  b:   L    D 
   
Figure 2.5 (a) Gene fragments (~1000 nt) for H. perforatum RuBisCo (Rub), CHS, PKS1, 
PKS2 and Benzophenone synthase (BPS), amplified by specific primers and analyzed by 
agarose gel electrophoresis. (b) The nest PCR product from the third round of PCR (~400 
nt) from H. perforatum. 
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Figure 2.6 Alignment of Type III PKS fragments from five distinct enzymes discovered 
in this work. Catalytic histidine residue is marked in red. The CHS Thr-197 and CHS 
Gly-256 equivalent residues are marked in blue.  
  
 PKS1    AKDVAENNKGARVLVVCAEITVCTFRGPTETYLDNLVGQALFGDGASSVIVGSDPVPGV-ERPLYEIVS 
PKS2    AKDVAENNANARVLVVCAENTAMTFHAPNESHLDVIVGQAMFSDGAAALIIGANPDTAAGERAVFNILS 
PKS3    AKDVAENNAGARVLVVCSEITVTTFRGPSAENLANLVGQAIFGDGAAALIIGSDPEIPA-ERPIFQLVW 
PKS4    -KDVAENNKGARVLVVCSEITAVTFRGPSDTHLDSLVGQALFGDGAAALIVGSDPIPEI-ERPLFEMVW 
PKS5    ----AENNKGARVLVVCSEITAVTFRGPSDTRLDNLVGQALFGDGAAALIVGSDPIPEI-EKPSFEMVW 
 
PKS1    TSQTLLP-NSEGAIAGHVREIGLTIHLLKDVPGLISKNVEKNMTEAFHPLGITDWNSLFFIVHPGGTGI 
PKS2    ASQTIVP-GSDGAITAHFYGMGMSYFLKEDVIPLFRDNIADVMKEAFSPLDVSDWNSLFYSIHPGGPAI 
PKS3    TAETVLP-NSEGAIEGQLRDVGLTFGLSDGVPHLIANHIEKRLKEAFDSLGISDWNSIFWVPHPGGPAI 
PKS4    TAQTILP-DSEGAIDGHLREVGLTFHLLKDVPGLISKNIEKALVEAFQPLGISDYNSIFWIAHPGGTAI 
PKS5    TAQTIFPHDGEDIIAAHFREIGLTIHLHRDIPRLVSKNIEKAMIEAFQPLGISDYNSIFWIAHPGGRGI 
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Figure 2.7 Amplification of the full length gene. The first two lanes used Taq for PCR, 
and the first one had the stop codon while the second one contained the His-tag. The third 
and fourth lane used phusion for PCR and same order as the first two. 
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           L  Pks3  Pks3 after gel filtration 
 
Figure 2.8 Pks3 protein before and after gel filtration. 
  
50kD 
30kD 
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Figure 2.9 Detection of naringenin. The peak appeared at 29.786 min showed the 
production of naringenin. 
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Figure 2.10 Phylogenetic analysis of all the cloned Type III PKS fragments. 
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Table 2.1 Sequence identity (%) of ~400 nt fragments to known H. perforatum PKSs. 
# BPS CHS PKS1 PKS2 # BPS CHS PKS1 PKS2 
1 94 50 41 38 14 95 48 37 38 
2 93 50 43 34 15 54 87 45 43 
3 95 52 42 39 16 54 88 46 44 
4 55 88 47 43 17 55 87 45 43 
5* 55 54 35 30 18 58 80 46 46 
6 53 84 44 41 19 70 48 34 43 
7 55 81 46 45 20 53 84 45 42 
8* 58 49 36 43 21 54 88 46 44 
9 54 88 45 44 22 93 52 42 40 
10 90 49 35 40 23 94 48 36 38 
11 94 51 40 42 24 93 48 32 33 
12** - - - - 25 93 49 38 40 
13 90 47 32 37 26** 69 45 37 41 
*Previously uncharacterized Type III PKS 
**Low quality sequencing data. 
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Table 2.2 The number of expected different Type III PKS genes. 
 
Number of different amino 
acids (out of ~136) 
Number of expected 
different genes 
1 97 
5 31 
10 16 
15 12 
20 11 
30 9 
50 5 
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Table 2.3 HPLC programs tested for CoA separation. 
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Table 2.4 HPLC programs for product discovery. 
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Table 2.5 DNA sequence and degeneracy of primers used in this study. 
 
Primer Sequence, 5’  3’ Degeneracy 
PKS-F1 GCIATIVMDSARTGGGGNC 288 
PKS-F2 TCIVRRATIACICAYBTNRT 576 
PKS-F3 GYIAARGAYITNGGNGARAACAA 256 
PKS-F3-F* GCGTTCGCTAGCGYIAARGAYITNGGNGARAACA 256 
PKS-R1 ATNSCISKICCICCRGGRTG 128 
PKS-R1- GCGTTCCTCGAGATNSCISKICCICCRGGRTG 128 
PKS-R2 CCSMWITCIWDNCCITCNCC 768 
PKS-R3 TCIAYNGTNADICCIGGNCC 384 
±Mixed bases B: C, G, T; D: A, G, T; H: A, C, T; K: G, T; M: A, C; N: A, C, G, T; 
 S: C, G; V: A, C, G; W: A, T ; Y: C, T. 
*Additional flanking bases are in italics; the NheI restriction site is underlined. 
**Additional flanking bases are in italics; the XhoI restriction site is underlined. 
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Table 2.6 Gene-specific primers for H. perforatum Type III PKSs. 
 
Primer Sequence, 5’  3’ 
CHS-F ATGGTGACCGTGGAAGAAGTCAG 
CHS-R TTAATATGCGACACTGTGAAGGACCAC 
BPS-F ATGGCCCCGGCGATG 
BPS-R CTGGAGAATTGGGACACTCTGGAG 
PKS1-F ATGTCTAACTTGGAGACCAATGGCTC 
PKS1-R TCATAGGCATAGGCTTCGAAGAAGG 
PKS2-F ATGGGTTCCCTTGACAATGGTTC 
PKS2-R TTAGAGAGGCACACTTCGGAGC 
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Table 2.7 Gene-specific primers for RACE PCR. 
 
Primer Sequence, 5’  3’ 
EC2-F1 CGACACCGAGACCTACCTGGACAACC 
EC2-F2 CGAGTGGGCCAGGCTCTGTTCG 
EC2-F3 CGATTCGCTAGCGATGGCGCCTCCTCCACC 
EC2-R1 TTCGCTAGCTGTCCAGGTAGGTCTCG 
EC2-R2 ACAGAGCCTGGCCCAC 
EC2-R3 GGTGGAGGAGGCGCCATC 
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Chapter 3 Activation of a Cryptic Biosynthetic Pathway 
from Streptomyces griseus via a Synthetic Biology Approach 
3.1 Introduction 
Microorganisms have evolved to produce a myriad array of natural products of 
medical importance. For example, Actinobacteria, especially Streptomycetes, are 
prolific sources of bioactive natural products, many of which exhibit important 
medical properties (1). It has been estimated that 77% of antibacterial drugs and 78% 
of anticancer drugs are natural products or have been derived from natural products 
(2). However, since the 1990s the number of newly discovered natural products has 
been decreasing. Known compounds are constantly rediscovered, and the discovery of 
novel products is hampered due to the lack of screening methods or efficient genetic 
manipulation tools. Recent advances in genome sequencing have uncovered numerous 
novel natural product gene clusters, the number of which far exceeds the 
characterized ones. Such discoveries sparked a renaissance in the field of natural 
product discovery, which highlights the untapped biosynthetic potential and metabolic 
capabilities of microorganisms.  
Genomics-based bottom-up approaches have been developed to unveil new 
natural products that were undetected under standard fermentation conditions. 
Computational analysis of sequenced genomes and metagenomes has revealed 
numerous gene clusters that are potentially involved in the biosynthesis of natural 
products. Until now, the genome sequences of ~3000 organisms have been fully 
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determined with many more soon to be completed 
(http://www.genomesonline.org/cgi-bin/GOLD/bin/gold.cgi). However, only a small 
fraction of this rich genome sequencing data has been exploited. Recently revealed 
genome sequencing data clearly showed that the number of pathways coding for 
putative valuable natural products largely outnumbers the number of currently known 
secondary metabolites for a given organism (3-6).  A total of 18 additional gene 
clusters involved in secondary metabolite production were discovered from the 
complete genome sequence of Streptomyces coelicolor, while the strain was 
previously known to produce only four compounds before the S. coelicolor genome 
sequencing project (7).  In addition, even a larger number of such pathways were 
present in the genome mining results of myxobacteria (8,9) and filamentous fungi 
(10-12).  These gene clusters, for which the corresponding natural metabolites are 
unknown, are named as “cryptic pathways” or “orphan pathways” (3,4).  Among the 
cryptic pathways, non-ribosomal peptide synthetases (NRPS) and polyketide 
synthases (PKS) occurred frequently, which were found in the biosynthesis of 
numerous bioactive natural products (13,14). Investigation into the unknown 
compounds synthesized by these two classes of enzymes may lead to the discovery of 
novel chemotherapeutic agents. However, since the widely used DNA cloning 
methods for studying biosynthetic pathways are time-consuming and labor-intensive, 
our motivation is to develop an efficient approach to decipher the cryptic natural 
product biosynthetic pathways. 
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Up to date, two major approaches have been applied to biochemical pathway 
characterization and analysis. The first approach mainly focuses on activating native 
host genes while the second one takes the advantages of heterologous gene expression 
in a well-characterized host (15). The first approach involves screening of different 
culture conditions, which somehow helps to activate the cryptic pathway by 
introducing activators, environmental factors or remove repressors (4). However, this 
approach is usually time-consuming and labor-intensive. Another main drawback is 
that even if a pathway is turned on, sometimes, it is still unclear which factor triggers 
the activation. Also, most of native producers grow slowly and are not commonly 
cultivable in the laboratory. It has been reported that only 1% of bacteria and 5% of 
fungi have been cultivated in the laboratory (16-18). On the other hand, the second 
approach can avoid these drawbacks since a well-characterized organism typically 
grows fast in the laboratory and has abundant genetic tools for engineering. This 
approach offers the possibility for metabolic engineering that could enhance the 
production of target compounds and for combinatorial biosynthesis that may generate 
new derivatives of a target compound. Most important of all, when using a well-
characterized heterologous host with a clear background profile, it will be much easier 
for product identification. There are many examples of heterologous expression of 
natural products, such as polyketides (19,20), methylenomycin furans (21), and 
phosphonic acids (22,23). However, there are limitations for this method as well. It is 
diﬃcult to transfer large biosynthetic pathways and it is also not easy to introduce 
single/multiple mutations or perform gene deletions. Other problems exist as well, 
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such as low efficiency of promoter recognition, poor gene expression, or low yield (4). 
Therefore, the need for novel methods that are suitable for eﬃcient transfer, 
expression and modification of target biosynthetic pathways is obvious.  
Synthetic biology has emerged as a versatile tool for manipulating genes, 
pathways, networks, and whole cells (24). The fundamental idea behind synthetic 
biology is that any biological system can be regarded as a combination of individual 
functional elements, a limited number of which can be recombined in novel 
configurations to modify existing properties or to create new ones (25).  As a broad 
field, the successful applications of synthetic biology such as synthesis of proteins 
that do not exist in nature, design and engineering of signaling and metabolic 
pathways, and rebuilding of new organisms make it an invaluable tool for natural 
product discovery.  
Previously, our laboratory developed a highly efficient method, “DNA assembler” 
to rapidly assemble a multiple-gene biochemical pathway in a single-step fashion by 
use of the in vivo homologous recombination mechanism in Saccharomyces 
cerevisiae (26-32). In this chapter, we further exploited the DNA assembler method to 
activate the cryptic PTM biosynthetic gene cluster SGR810-815 from Streptomyces 
griseus (33) via a simple synthetic biology strategy and identified four putative PTMs. 
We demonstrated that a plug-and-play platform can be very useful for rapid cloning 
of a gene cluster and its heterologous expression in a desired organism. This would 
solve the problem of introducing large gene clusters into a heterologous host. On the 
other hand, as it is easy to perform genetic manipulations by using this method, we 
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can add different strong constitutive promoters in front of each gene in the gene 
cluster to control the gene expression. This would eliminate the problem of promoter 
recognitions and gene expression compared to heterologous expression alone. Future 
work will be focused on study of the biosynthetic mechanisms by performing targeted 
gene deletions. 
3.2 Results and discussion 
3.2.1 Selection of a target gene cluster 
As we have mentioned above, the recent increasing availability of whole genome 
sequences have revised our view of the metabolic capabilities of microorganisms. A 
few cryptic biosynthesis pathways have been identified by bioinformatics study 
(4,6,14). These numerous pathways represent a treasure trove, which is likely to grow 
exponentially in the future. This will lead to the uncovering of many novel and 
possibly bioactive compounds. The few natural products that have been correlated 
with their orphan pathways are merely the tip of the iceberg, whilst plenty of natural 
products await discovery (4). 
The complete genome sequence of Streptomyces griseus IFO 13350 was 
determined in 2008 (33). Streptomyces griseus is a soil bacterium producing an 
antituberculosis agent, streptomycin, which was discovered more than 60 years ago 
and was the first aminoglycoside antibiotic. There are 8,545,929 base pairs (bp) in the 
linear chromosome and the average G+C content is 72.2%. It was predicted that there 
are 7,138 open reading frames, six rRNA operons (16S-23S-5S), and 66 tRNA genes. 
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It contains extremely long terminal inverted repeats (TIRs) of 132,910 bp each. After 
comparisons with the genomes of two related species, Streptomyces coelicolor A3(2) 
and Streptomyces avermitilis, not only the characteristics of the S. griseus genome but 
also the existence of 24 Streptomyces-specific proteins was clarified. 34 gene clusters 
or genes for the biosynthesis of known or unknown secondary metabolites were found 
in the S. griseus genome.  
As proof of concept, one cryptic biosynthetic pathway from S. griseus, SGR810-
815, containing a PKS/NRPS hybrid gene, was chosen as a model system. BLAST 
search indicates that the PKS/NRPS gene shares high homology (63%) with the one 
from the heat-stable antifungal factor (HSAF) biosynthetic gene cluster (34,35) and 
70-80% sequence homology with the one from the recently characterized 
frontalamide gene cluster (36), respectively. Those clusters with high sequence 
homology seem to produce structurally similar compounds, called polycyclic 
tetramate macrolactams (PTMs) (Figure 3.1).  
PTMs contain one tetramic acid and a polycyclic system (usually two to three 
rings) fused to macrolactams and exhibit diverse biological activities such as 
antifungal, antibiotic and antioxidant properties (34-40). PTMs were previously 
isolated from symbionts of marine sponges, such as discodermide, alteramide A and 
cylindramide (40). Recently, PTMs have been found in bacteria, such as maltophilin 
from Stenotrophomonas maltophilia (41), heat-stable antifungal factor (HSAF) from 
Lysobacter enzymogenes (34), as well as ikarugamycin (42), dihydromaltophilin (37) 
and frontalamides (36), all from medicinally important Streptomyces species. Most 
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interestingly, Clardy and coworkers found that the PTM biosynthetic gene cluster 
from streptomycetes was a common origin for PTM biosynthesis in phylogenetically 
diverse bacteria and was conserved in more than 50% of the sequenced Streptomyces 
species (43).  
One reason why the discovery and characterization of PTM biosynthetic gene 
clusters are challenging is because most of the PTM gene clusters remain silent under 
typical fermentation conditions either in the native or heterologous host. For example, 
after many trials, the frontalamide biosynthetic gene cluster was shown to become 
functional only under one specific culture condition (36). Another obstacle is that 
most of the native producers are genetically intractable. As a matter of fact, these 
challenges are not unique to the PTM biosynthetic gene clusters. Numerous natural 
product biosynthetic gene clusters are considered as silent or cryptic. A number of 
approaches has been developed to activate silent or cryptic biosynthetic gene clusters, 
such as manipulating cell culture parameters (44), expressing the putative pathway-
specific regulator under a well-characterized promoter (45), testing a variety of 
heterologous hosts (46) or silencing other major secondary metabolite biosynthetic 
gene clusters (47). However, these approaches can only be applied on a case-by-case 
basis. To discover and characterize novel PTM biosynthetic gene clusters, a generally 
applicable approach capable of activating cryptic gene clusters without specific 
tailoring to the gene cluster of interest is highly desirable.  
Therefore, we sought to study the uncharacterized PTM gene cluster SGR810-
815 from the sequenced S. griseus (48). This gene cluster contains an evolutionarily 
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conserved hybrid PKS-NRPS gene (SGR814) with a size of approximately 9.5-
kilobases (kb). This PKS-NRPS gene contains DNA sequences encoding nine 
domains (KS-AT-DH-KR-ACP-C-A-PCP-TE) and is flanked upstream by a gene 
encoding a putative sterol desaturase and downstream by several putative 
oxidoreductase genes. We chose this cryptic biosynthesis pathway as a model system 
to develop a generally applicable approach for cryptic pathway activation.   
3.2.2 Construction of the original pathway via DNA assembler 
In principle, DNA assembler can be used to assemble custom-designed DNA 
fragments in any desired order by designing PCR primers to generate appropriate 
overlaps between the adjacent ones. Usually, a S. cerevisiae helper fragment carrying 
a centromere sequence (CEN), an automatic replication sequence (ARS) and a Ura+ 
selection marker, an E. coli helper fragment carrying a pBR322 ori and a Apr+ 
selection marker, and a helper fragment carrying an ori and a selection marker 
required by the desired organism, are individually prepared. These helper fragments 
are mixed with the pathway fragments, and subsequently co-transformed into S. 
cerevisiae to be assembled into a single molecule. The transformants are selected on 
SC-Ura plates and the assembled circular DNAs are subsequently purified from S. 
cerevisiae. The isolated yeast plasmids need to be transformed to E. coli for 
enrichment and further verification. Finally, the verified plasmids can be transformed 
to the desired heterologous host for expression of the target pathway.  
First, we sought to reconstruct the original SGR810-815 biosynthetic pathway 
from S. griseus in Streptomyces lividans. To construct a shuttle system carrying the 
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complete SGR810-815 gene cluster and particularly in order to minimize the possible 
mutations introduced by PCR, the biosynthetic gene cluster was split into seven 
segments with the size of ~4-5 kb each (Table 3.1). 7 pairs of primers were designed 
to cover the whole cluster according to the reported genomic sequence of S griseus 
and three pairs of primers were designed for amplification of the three helper 
fragments and generating overlap regions with the beginning and ending of the target 
cluster. The S. cerevisiae helper fragment carrying CEN6, ARS H4 and Ura3 
sequences was amplified from a yeast vector. The E. coli helper fragment carrying 
oriR6K and accIV sequences was amplified from an E. coli vector, and accIV encodes 
for an AprR gene. The S. lividans helper fragment carrying oriT, int, ϕ31 attP and tL3 
sequences was amplified from the vector used for recombination with the possible 
cluster-containing fosmids in the traditional top-down approach as reported in 
literature (22). OriT is the origin of conjugal transfer; int encodes for an integrase; tL3 
encodes for a terminator and ϕC31 attP is the junction site for integration into the 
ϕC31 site of the chromosome. The construct is shown in Figure 3.2a. 
Each of the fragments was individually amplified, gel purified and mixed with 
others at the end. After precipitation in ethanol, the mixture was re-dissolved in 
ddH2O and co-transformed into S. cerevisiae through electroporation and spread onto 
SC-Ura plates. Typically, 30-50 colonies appeared after 2-3 days of incubation at 
30 °C, which were then randomly picked for plasmid isolation. 20 colonies were 
inoculated in SC-Ura liquid culture and the purified yeast plasmids were individually 
transformed to E. coli WM1788 and selected on LB-Apr+ plates. E. coli plasmids 
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were subsequently purified and checked by gel electrophoresis. As a result, 18 out of 
the 20 plasmids have a relatively large size (the size of the correctly assembled 
plasmid is approximately 36 kb) while the other two are too small to be the desired 
plasmid. The 18 plasmids were subjected to restriction digestion by NcoI, ApaLI and 
XmnI. 13 of them exhibited an expected digestion pattern, indicating an assembly 
efficiency of 65% (Figure 3.3).   
The first three verified clones were named as pYL-#1, pYL-#7, and pYL-#18, 
respectively, and subsequently introduced into S. lividans via conjugal transfer and 
integrated into the ϕC31 site of the genome. The exconjugant integrants were verified 
by PCR and checked for potential production of novel natural products.   
3.2.3 Product detection for the original cluster in a heterologous host 
Traditional extraction methods were applied for product detection according to 
the workflow shown in Figure 3.4. However, no product was detected from HPLC. 
Later, ammonium sulfate precipitation was performed based on the previously 
reported HSAF extraction method (34), as well as the SPE process and YMS plates 
extraction from the frontalamide extraction method (36), but still no product was 
identified. 
3.2.4 Quantitative real-time PCR (qPCR)  
As we have confirmed that the whole cluster was correctly reconstituted in the 
heterologous host, the first concern was the gene expression issue. Thus, revers-
Transcription PCR was performed to track the gene expression levels. Total RNA was 
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isolated based on the protocol of Total RNA Isolation Mini Kit and cDNA was 
synthesized afterwards. In parallel, to eliminate genomic DNA contamination, cDNA 
synthesis reaction without reverse transcriptase was carried out to serve as the 
negative control. Primers were designed to amplify a ~300 bp fragment for each gene 
from the cDNA library. As shown in Figure 3.5, all genes are expressed under the 
growth condition. 
In order to quantify the gene expression level, quantitative real-time PCR (qPCR) 
was employed to track the gene expression level. The hrdB gene (49), an essential 
gene of Streptomyces coelicolor A3(2), which indicates the presence of an open 
reading frame encoding a putative polypeptide of 442 amino acid (aa) residues with a 
molecular weight (Mr) of 48,412, was chosen as the internal control for all following 
qPCR experiments and its transcription signal remained comparable in all samples. 
The principal sigma-like transcriptional factor of S. coelicolor (HrdB) protein showed 
an extensive aa sequence homology with the known principal sigma factors of 
Escherichia coli, Bacillus subtilis, Pseudomonas aeruginosa and Myxococcus xanthus 
(49). The HrdB protein is the house-keeping protein in Streptomyces strains. The hrdB 
gene in S. griseus shows high sequence similarity to the hrdB gene of Streptomyces 
coelicolor A3(2) (89.9%) and Streptomyces aureofaciens (88.1%) (50). Due to its 
stable and consistent expression level in Streptomyces strains, we chose this gene to 
serve as the internal control. Primers for genes in the target cluster were designed by 
Real-Time PCR tools on the website of Integrated DNA Technologies (Coralville, IA) 
(https://www.idtdna.com/scitools/Applications/RealTimePCR/). Samples were run on 
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the ABI Prism 7900 HT Real-Time Quantitative PCR machine and the results were 
analyzed by SDS software. A standard curve was made first for all pair of primers 
using genomic DNA of pYL-#18 as the template. One representative example was 
shown in Figure 3.6. Real-Time PCR was performed according to a protocol 
described elsewhere (51).  
In order to obtain stable and consistent data, cells were grown for 4 days and 
samples for RNA isolation were collected at different time points, 48 h, 72 h, 96 h and 
120 h. The gene expression levels from different time points were compared (Figure 
3.7). Overall, all genes were expressed after 72 h and the expression level reaches its 
plateau. Therefore, 72 h was chosen as the best time point for collecting cells for total 
RNA isolation. However, we found that in the pYL-#18 construct, the expression 
levels for all genes were low and not comparable to those of the native producer- S 
griseus (SG) (Figure 3.8).  
3.2.5 Construction of the ermE*p-construct 
After observing the poor gene expression levels from the qPCR results, several 
additional constructs were assembled in a similar fashion as mentioned above to 
facilitate the natural product discovery. Five different constructs were made for 
different purposes. The first one was called ermE-1 (E1 or Ep), which contains an 
ermE* promoter in front of the whole gene cluster (Figure 3.2B). 
While in the ermE* promoter construct (Ep), all genes were confirmed to be 
expressed and the first gene immediately downstream of the ermE* promoter showed 
a great increase in the gene expression level, which demonstrated that by adding 
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constitutive promoters, gene expression level can be enhanced (Figure 3.8). It is 
obvious to see that after adding constitutive promoter, the expression levels of all 
genes have been improved by different extent.  
3.2.6 Promoter identification and characterization 
Based on the above results, we decided to add different constitutive promoters in 
front of each gene in the target cluster. Because the DNA assembler method used for 
natural product gene cluster refactor relies on homologous recombination (52,53), 
different promoters with low sequence similarity are needed for different genes in 
order to increase the gene cluster assembly efficiency. However, few constitutive or 
inducible promoters have been characterized in Streptomycetes despite decades of 
research, and the reported commonly used promoter is ermE*p (54-56). Therefore, 
promoter candidates upstream of 23 housekeeping genes originating from species in 
the Actinobacteria class were cloned and analyzed, such as RNA polymerase subunit 
α and β, DNA gyrase, elongation factors, RNA polymerase sigma factors, amino-acyl 
tRNA synthetase and enzymes in the essential metabolic pathways. From EGFP 
confocal microscope analysis, two promoters showed strong activities, gapdhp and 
rpsLp (Figure 3.9). Based on this observation, we started to search similar promoters 
from other Actinobacteria species. As shown on Figure 3.10, 10 promoters were 
highly active in Streptomyces lividans, and six of them were used in the following 
work. The sequences of the 6 promoters used in the following work are listed in Table 
3.3. 
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3.2.7 Development of a plug-and-play platform 
As we have already confirmed that by adding constitutive promoters in front of 
a target gene would highly increase the gene expression level, we decided to develop 
a simple synthetic biology strategy in which a plug-and-play scaffold is used to 
decouple gene cluster expression from native sophisticated regulation cascades 
(Scheme 3.1). The key step in this strategy is to use a set of well-characterized 
promoters and the DNA assembler method (52,53) to refactor the target cryptic 
biosynthetic gene cluster in a genetically tractable heterologous host. The product(s) 
will be detected and characterized using analytical chemistry methods such as LC-MS 
and NMR or biological activity assays.  
We sought to reconstruct the entire gene cluster SGR810-815 by inserting six 
constitutive promoters upstream of the SGR genes (reconstructed cluster: RC, Figure 
3.2C and D). Two controls, one carrying the intact regulatory elements (original 
cluster: OC) and the other containing the ermE*p promoter added upstream of the 
whole cluster (Ep), were constructed previously. The gene fragments and the 
promoter fragments were PCR amplified and assembled using the DNA assembler 
method (53) and the correct constructs were verified by restriction digestions. All 
these constructs were integrated into S. lividans for heterologous expression. As 
shown in Figure 3.8, all the genes in the reconstructed gene cluster were substantially 
transcribed, and the first gene under the rpsLp (Cellulomonas flavigena) promoter 
showed an approximately 150-fold higher expression level compared to the internal 
control hrdB (57-59). In contrast, the expression levels for most SGR genes in either 
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the native producer (SG) or two control strains were very low. These data confirmed 
the silencing of the gene cluster under the typical cultivation conditions, and 
suggested that via gene cluster reconstruction, the transcription of each gene in a 
cryptic gene cluster could be significantly increased. 
3.2.8 Identification of final products 
We followed the product extraction method described in literature (36) to isolate 
the potential product from the target cluster. By comparing the HPLC profiles of the 
negative control (S. lividans without the target gene cluster) and the sample, a 
potential product was observed at around 24.1 min and the corresponding mass was 
(M+H): 511 (Figure 3.11 and 3.12).   
3.2.9 Isolation and characterization of novel PTMs 
To determine the chemical structures of these compounds, large-scale cultivation 
(equivalent to ~4L liquid culture) of the heterologous host harboring the target 
reconstructed gene cluster was carried out to obtain sufficient amounts of these 
compounds. High-resolution electrospray ionization mass spectrometry in positive 
mode showed an m/z of 511.2807 for compound a [M(C29H38O6N2)+H]+ 
(calculated: 511.2808) and 511.2781 for compound b [M(C29H38O6N2)+H]+ 
(calculated: 511.2808). Their corresponding chemical structures (Figure 3.13) were 
elucidated by extensive one- and two-dimensional NMR spectroscopy (1H, 13C, 
DQCOSY, TOCSY, gHSQC, gHMBC, and NOESY) and MS experiments (Figure 
3.14, 3.15, 3.12 and Table 3.4). Key COSY and HMBC correlations were summarized 
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in Figure 3.16. For compound a, the Double-Quantum Filtered COSY (Phase-
sensitive) (DQCOSY) spectrum revealed the spin system, and the heteronuclear 
multiple bond correlation (HMBC) supported the coupling of H2 and H3 to C1, as 
well as H23 to C19. For compound b, the characteristic C-H coupling constants (C14, 
JC-H = 172 Hz and C15, JC-H = 181 Hz, measured using a high resolution coupled 
gHSQC) suggested the presence of an epoxide ring (60). All compounds belong to the 
group of tetramic acid-containing macrolactam natural products, compound a shares 
the same structure as previously reported alteramide A (61) while compound b has 
never been reported in literature. The NOESY correlations to confirm the 
stereochemistry of compound b were summarized in Figure 3.17. The production of 
these novel tetramic acid-containing macrolactams in a heterologous host clearly 
confirms the iterative use of the single PKS-NRPS module, which is rare in bacteria. 
Moreover, we have cultivated the above-mentioned control strains and the native 
producer S. griseus under several different cultivation conditions (MYG liquid or 
solid media and YMS liquid or solid media), and the fermentation broths were 
extracted and analyzed by HPLC. For the control strains, no distinct difference was 
observed compared with the wild type S. lividans. For the native producer, neither 
compound a nor compound b could be detected.  
3.3 Conclusions 
We have successfully activated a silent PTM gene cluster and discovered novel 
PTM compounds by fully reconstructing the target gene cluster in a heterologous host. 
The production of these novel tetramic acid-containing macrolactams in a 
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heterologous host directly confirms the iterative use of the single PKS-NRPS module, 
which is an intriguing feature of this type of enzymes in bacteria. Although this 
cluster shares sequence homology with other characterized PTM gene clusters and the 
PTMs characterized from these gene clusters all share similar backbones, there are 
notable differences in their chemical structures.  
It should be noted that the strategy we employed in this study is simple, generally 
applicable, and potentially scalable in studying other cryptic natural product gene 
clusters. The key innovative aspect of this strategy is the use of the DNA assembler 
method to achieve full gene cluster reconstruction for cryptic gene clusters in a single-
step manner. This strategy is distinct from other related strategies such as (1) using 
promoter replacement to activate cryptic single genes which focused on single genes 
rather than the entire gene cluster, (2) gene-by-gene reassembly in a heterologous host 
which used multiple plasmids to reconstruct known gene clusters or performed the 
assembly in multiple steps, or (3) use of recombination based systems for gene cluster 
activation which directly cloned an entire gene cluster without any reconstruction. 
Using the same experimental set-up, this strategy can in principle enable the 
activation of many cryptic PTM biosynthetic gene clusters of interest in 
Streptomycetes and other Actinomycetes. Moreover, this strategy may be further 
modified for activation of cryptic gene clusters from other organisms such as 
myxobacteria, cyanobacteria, and fungi as long as appropriate heterologous hosts and 
functional promoters can be obtained. For the promoters, strong constitutive 
promoters used to drive the expression of each gene in a target gene cluster can be 
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readily identified from the heterologous host by real-time PCR or RNA-seq. It is 
noteworthy that due to the plug-and-play nature of the system, a cryptic gene cluster 
of interest can be readily reconstructed and the entire process may be fully automated. 
With the continually decreasing cost of DNA synthesis, the entire gene cluster may be 
reconstructed by using synthetic genes and/or promoters. Finally, this strategy is 
much more flexible and versatile for generating gene deletions or additions for 
mechanistic studies or creation of novel compounds than traditional combinatorial 
biosynthesis approaches. Overall, the synthetic biology approach we developed 
represents a new technology platform for discovery and characterization of novel 
natural products from sequenced genomes and metagenomes for pharmaceutical and 
biotechnological applications. 
In order to further demonstrate the versatility of this approach and address the 
remaining questions, we plan to carry out the following experiments for mechanistic 
studies. New constructs with deletion of genes encoding tailoring enzymes will be 
constructed to illustrate the cluster biosynthetic mechanism. If the predictions 
regarding the SGR814 activity are correct, then this enzyme would have a unique 
ability to catalyze a second round of iterative polyketide synthesis before 
condensation with the δ-amino group originating from ornithine. A Dieckmann 
cyclization would render the backbone complete, with concomitant product release.  
However it remains unclear how the 5,5,6 polycycle of the final compound is formed. 
This biosynthetic feature will be solved once we obtain the polyketide intermediates 
formed by SGR814. Therefore, we sought to assemble constructs without the tailoring 
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enzymes in order to elucidate the biosynthetic mechanisms more clearly, which will 
be the focus of Chapter 4. 
3.4  Materials and methods  
3.4.1  Strains and reagents 
S. cerevisiae YSG50 (MATα, ade2-1, ade3Δ22, ura3-1, his3-11, 15, trp1-1, leu2-
3, 112 and can1-100) was used as the host for DNA assembly and integration.  S. 
lividans 66 and S. griseus were obtained from the Agricultural Research Service 
Culture Collection (Peoria, IL) and E. coli BL21 (DE3) was obtained from Novagen 
(Madison, WI). Plasmids pAE4, E. coli strains WM6026 and WM1788 were 
developed by the Metcalf group (University of Illinois, Urbana-Champaign).  The 
pRS426 and pRS416 plasmid (New England Biolabs, Beverly, MA) were modified by 
incorporating the hisG and partial δ sequence (δ2) that flank the multiple cloning site 
and serve as the vectors for assembly of various pathways. Nalidixic acid and IPTG 
were obtained from Sigma-Aldrich (St. Louis, MO). ISP2, agar, beef extract, yeast 
extract, malt extract, and other reagents required for cell culture were obtained from 
Difco (Franklin Lakes, NJ). All restriction endonucleases, as well as T4 DNA ligase 
and antarctic phosphatase, were purchased from New England Biolabs (Beverly, MA).   
Phusion DNA polymerase was from Finnzymes (Espoo, Finland). FailsafeTM 2x 
premix buffer G was purchased from EPICENTRE Biotechnologies (Madison, WI). 
SYBR Green PCR master mix was purchased from Applied Biosystems (San 
Francisco, CA). The QIAprep Spin Plasmid Mini-prep Kit, QIAquick PCR 
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Purification Kit, QIAquick Gel Extraction Kit, and RNeasy MinElute Cleanup Kit 
were purchased from Qiagen (Valencia, CA). The total RNA was extracted using the 
RNeasy Mini Kit (QIAGEN, Valencia, CA). All primers were synthesized by the 
Integrated DNA Technologies (Coralville, IA). Yeast YPAD medium-containing 1% 
yeast extract, 2% peptone and 2% dextrose supplied with 0.01% adenine 
hemisulphate was used to grow S. cerevisiae YSG50 strain. Synthetic complete drop-
out medium lacking uracil (SC-Ura) was used to select transformants containing the 
assembled biochemical pathways of interest. 
3.4.2 DNA manipulation 
S. griseus was grown in liquid MYG medium (4 g/L yeast extract, 10 g/L malt 
extract and 4 g/L glucose) at 30 °C with constant shaking (250 rpm) for 2 days. The 
genomic DNA was isolated from S. griseus using the Wizard Genomic DNA isolation 
kit from Promega (Madison, WI). Pairs of primers were designed with the sequences 
shown in Table 3.2. Pathway fragments 1-SG, 2-SG, 3-SG, 4-SG, 5-SG, 6-SG, and 7-
SG were amplified from the genomic DNA of S. griseus. Generally, the PCRs were 
carried out in 100 µL reaction mixture consisting of 50 µL FailSafeTM PCR 2xPreMix 
G from Epicentre Biotechnologies (Madison, WI), 2.5 pmol of each primer, 1 µL 
yeast plasmid or genomic DNA and 2.0 unit Phusion DNA polymerase for 35 cycles 
on a PTC-200 Thermal Cycler (MJ Research, Watertown, MA). Each cycle consisted 
of 10 s at 98 °C, 30 s at 58 °C and 3 min at 72 °C, with a final extension of 10 min. 
The S. cerevisaie helper fragment was amplified from the commercial vector pRS416, 
while the E. coli helper fragment and the S. lividans helper fragment were amplified 
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from the Streptomyces-E. coli shuttle vector pAE4. In order to obtain good assembly 
efficiency, the overlaps between the pathway fragments were designed to be 400 bp. 
We encountered some difficulties in amplifying the S. cerevisaie helper fragment, and 
in the end, a sufficient amount of amplification product was only obtained by using a 
short pair of primers (Table 3.2). As a result, the S. cerevisaie helper fragment only 
overlaps with 7-SG and the E. coli helper fragment with 40 bp. The S. lividans helper 
fragment has overlaps of 80 bp with the adjacent E. coli helper fragment and 1-SG.  
Following electrophoresis, the PCR products were individually gel-purified from 1.0% 
agarose gels using Qiagen Gel Purification kit. For gapdhp(SG) and rpsLp(SG), the 
genomic DNA of S. griseus was isolated using the Wizard® Genomic DNA 
Purification Kit (Promega, Madison, WI) and then used as the template for PCR 
amplification of the two target promoters. Promoters from other hosts were obtained 
through primer splicing in which 6-10 overlapping oligonucleotides designed based 
on the sequence of each promoter are joined together by overlap extension PCR. 
Genes with corresponding promoters were also ligated together by overlap extension 
PCR. To ensure high efficiency of yeast homologous recombination, the “promoter 
upstream-gene-promoter downstream” cassette was built to generate a ~200 bp 
overlap region with adjacent fragments. 100 ng of each individual fragments was 
mixed and precipitated with ethanol. The resulting DNA pellet was air-dried and 
resuspended in 4 µL Milli-Q double deionized water and subsequently electroporated 
into S. cerevisiae using the protocol reported elsewhere (26).   
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3.4.3 Yeast transformation 
Yeast transformation was performed by electroporation. YPAD medium (50 mL) 
was inoculated with a 0.5 mL overnight S. cerevisiae YSG50 culture and shaken at 
30 °C and 250 rpm for 4-5 h until OD600 reached 0.8-1.0. Yeast cells were harvested 
by centrifugation at 4 °C and 4000 rpm for 5 min.  The supernatant was discarded 
and the cell pellet was washed with 50 mL ice-cold Milli-Q double-deionized water, 
followed by another wash with cold 1 M sorbitol and finally resuspended in 250 µL 
cold sorbitol. An aliquot of 50 µL of yeast cells together with 4 µL DNA mixture was 
electroporated in a 0.2 cm cuvette at 1.5 kV. The transformed cells were immediately 
mixed with 1 mL room temperature YPAD medium and shaken at 30 °C for 1 h.  
Following that, the cells were harvested by centrifugation, washed with room 
temperature 1 M sorbitol several times to remove the remaining medium and finally 
resuspended in 1 mL sorbitol. Aliquots of 30-50 mL were spread on SC-Ura plates for 
the selection of the transformants, and the plates were incubated at 30 °C for 2-4 days 
until colonies appeared. Colonies were randomly picked to SC-Ura liquid medium 
and grown for 1 day, after which yeast plasmid was isolated using Zymoprep II Yeast 
plasmid Miniprep kit (Zymo Research, CA), and genomic DNA was prepared using 
Wizard Genomic DNA isolation kit from Promega (Madison, WI). 
3.4.4 Verification of the assembled gene clusters 
Colonies were randomly picked to SC-Ura liquid media and grown for 2 days, 
after which yeast plasmid was isolated using Zymoprep II Yeast plasmid Miniprep kit 
(Zymo Research, CA). Yeast plasmids were transformed to E. coli strain WM1788 
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and selected on Luria Broth (LB) agar plates supplemented with 50 µg/ml apramycin.  
Colonies were inoculated into 5 mL of LB media supplemented with 50 µg/mL 
apramycin, and plasmids were isolated from the liquid culture using the plasmid 
miniprep kit from Qiagen. Plasmids isolated from E. coli were then subjected to 
restriction digestion by different enzymes, after which the reaction mixtures were 
loaded to 0.7% agarose gels to check for the correct restriction digestion pattern by 
DNA electrophoresis. 
3.4.5 Streptomycete cultivation, RNA extraction and qPCR analysis 
A seed culture was grown in MYG medium (10 g/L malt extract, 4 g/L yeast 
extract, and 4 g/L glucose) at 30 °C with constant shaking (250 rpm) until saturation, 
and inoculated into fresh MYG with a ratio of 1:100. The total RNA was extracted 
using the RNeasy Mini Kit (QIAGEN, Valencia, CA). Reverse transcription was 
carried out using the First-strand cDNA Synthesis Kit (Roche Applied Science, 
Indianapolis, IN). Real-time PCR was performed with SYBR® Green PCR Master 
Mix on the 7900HT Fast Real-Time PCR System (Applied Biosystems, Carlsbad, 
CA). Primers were designed by the online tool provided by Integrated DNA 
Technologies (https://www.idtdna.com/scitools/Applications/RealTimePCR/). 10 μL 
of 2× SYBR Green Mix, 1 μL of cDNA, 1 μL of each primer at a concentration of 10 
pmol/μL and 7 μl of ddH2O were mixed gently in each well of the Applied 
Biosystems® MicroAmp® Optical 96-Well Reaction Plate. Reactions were performed 
using the following program: 2 min at 50 °C, 10 min at 95 °C for one cycle followed 
by 15 s at 95 °C, 30 s at 60 °C and 30 s at 72 °C for 40 cycles with a final cycle of 10 
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min at 72 °C. The endogenous gene hrdB, encoding the RNA polymerase sigma 
factor, was used as the internal control for promoter screening. The expression levels 
of other candidate genes were normalized by the expression of the control. Data was 
analyzed using SDS2.4 software (Applied Biosystems).   
3.4.6 Heterologous expression in S. lividans 
The verified clones were transformed to E. coli WM6026 (22) and selected on LB 
agar plates supplemented with 19 µg/mL 2,6-diaminopimelic acid and 50 µg/mL 
apramycin. These transformants were then used as the donors for conjugative transfer 
of the assembled plasmids to S. lividans 66 following the protocol described 
elsewhere (22). S. lividans exconjugants were picked and re-streaked on ISP2 plates 
supplemented with 50 µg/mL apramycin and grown for 2 days. For the reconstructed 
gene cluster SGR810-815, a single colony was inoculated into 20 mL of ATCC172 
liquid medium (5 g/L yeast extract, 20 g/L soluble starch, 5 g/L N-Z Amine Type A, 1 
g/L CaCO3, and 10 g/L glucose) supplemented with 50 µg/mL apramycin in a 125 mL 
shake-flask (3 mm glass beads added to improve liquid mixing and aeration). Aliquots 
of this seed culture with a volume of 250 μL were spread for confluence over Petri 
dish plates containing approximately 25-30 mL of YMS solid agar medium (4 g/L 
yeast extract, 10 g/L malt extract, 4 g/L soluble starch, and 20 g/L Bacto agar) and the 
plates were incubated for 7 days at 30 °C.  
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3.4.7 HPLC-MS analysis 
To isolate potential compounds, agar and the adherent cells were stored at -80 °C 
for 24 h, after which the frozen cultures were thawed completely and the released 
liquids were collected. The liquids were extracted by ethyl acetate with a ratio of 1:1 
twice, concentrated 1000-fold, and subjected to HPLC analysis. HPLC was performed 
on the Agilent 1100 series LC/MSD XCT plus ion trap mass spectrometer with a 
Phenomenex Luna C18 reverse-phase column (3.0 x 150 mm, 3.5 μm). HPLC 
parameters were as follows: solvent A, 0.1% formic acid in water; solvent B, 0.1% 
formic acid in acetonitrile; gradient, 10% B for 5 min, to 100% B in 25 min, maintain 
at 100% B for 10 min, return to 10% B in 1 min and finally maintain at 10% B for 9 
min; flow rate 0.3 mL/min; detection by UV spectroscopy at 260 nm. Under such 
conditions, products are eluted at 26.8 min (compound a), 27.8 min (compound b). 
The MS system was operated using a drying temperature of 350 ○C, a nebulizer 
pressure of 35 psi, a drying gas flow of 8.5 L/min, and a capillary voltage of 4500 V. 
3.4.8 Structure elucidation of compounds a-b  
Compounds a and b were isolated by reverse-phase HPLC using a Phenomenex 
Luna 10u C18 column (10 mm × 250 mm) on the Agilent 1100 series LC/MSD XCT 
with an isocratic solvent of 60% acetonitrile in water with 0.1% formic acid (with a 
flow rate of 3 mL/min and a wavelength of 260 nm). The high resolution MS was 
performed on a Waters Q-Tof Ultima system (Walters, Milford, MA). All NMR 
experiments were carried out on a Varian UNITY INOVA 600 MHz spectrometer, 
except for the 13C NMR spectra, which were recorded on a Bruker Avance III 500i 
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with a 5 mm 13C(1H) cryogenic probe at the National Magnetic Resonance Facility at 
the University of Wisconsin at Madison. The structures were determined based on 1-
D and 2-D NMR data. The relative configurations were determined by using 2-D 
NOESY experiments.  
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3.6 Figures and tables 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1 Chemical structures of known PTMs.  
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Figure 3.2 Different constructs assembled by DNA assembler. (a) The cryptic 
biosynthetic cluster from S. griseus including the upstream and downstream genes and 
the vector map of the original construct (OC: the native gene cluster with native 
promoters). The predicted function of each gene is listed in the table. (b) Vector maps of 
the ermE* construct (Ep: the native gene cluster with an ermE* promoter in front of the 
whole gene cluster). (c) Gene cluster contains six different promoters in front of each 
gene. (d) The reconstructed cryptic SGR810-815 gene cluster from S. griseus. P1: 
gapdh(Kocuria rhizophila), P2: gapdh(Streptomyces griseus), P3: ermE*, P4: 
rpsL(Tsukamurella paurometabola), P5: rpsL(Streptomyces griseus), P6: 
rpsL(Cellulomonas flavigena). 
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Figure 3.3 Physical characterization of the recombinant clones through restriction 
digestion.  Plasmids were digested by NcoI, XmnI, and ApaLI. The correct clones were 
marked as the red stars. 
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Figure 3.4 Sample preparation workflow. 
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#18 Construct 
  L     810     811     812    813     815          L              814(-)              814(+) 
  
Figure 3.5 Reverse-Transcription PCR results. The left figure: on the top of the figure, 
the results showed that the genes in #18 constructs were all expressed except 814. The 
bottom part is the negative controls. The right figure showed the gene 814 was expressed 
when compared with the negative control. 
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Figure 3.6 One example of the standard curve made for Real-Time-PCR. pYL-#18 
genomic DNA was used as the PCR template, which was diluted to 100,1000, 10000 and 
100000 times.  
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Figure 3.7 Real-time PCR data at different time points. 1: #18 120h, 2: #18 72h, 3:#18 
96h, 4:E1 120h, 5: E1 72h, 6: E1 96h, 7: SG: 120h, 8:SG 48h, 9:SG 72h, 10: SG 96h. 
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Figure 3.8 Comparison of the gene expression level of different constructs. HrdB was 
used as internal control, whose expression level was set as 1. OC: original construct; SG: 
S. griseus (native producer); Ep: ErmE promoter added in front of the whole gene cluster; 
FC: Expression cassette (different promoters in front of each gene in the cluster). 
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Figure 3.9 EGFP confocal microscope results identified two strong promoters: gapDHp 
and rpsLp from S. griseus. 
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Figure 3.10 EGFP confocal microscope results for promoters: gapDHp and rpsLp from 
other species. 
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Figure 3.11 HPLC analysis of the extract from the S. lividans strain carrying the 
reconstructed gene cluster SGR810-815. *: major products, #: minor products. UV 
chromatographs were recorded at 280 nm. 
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Figure 3.12 MS1 and MS2 data of the identified new potential product peak. (a) MS1 
and MS2 data of compound a. (b) MS1 and MS2 data of compound b.  
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Figure 3.13 Chemical structures of the products of the SGR810-815 gene cluster from S. 
griseus. 
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Figure 3.14 NMR analysis of compound a from the reconstructed cryptic gene cluster 
SGR810-815. (a) 1H NMR spectrum. (b) DQ-COSY NMR spectrum. (c) gHSQC NMR 
spectrum. (d) gHMBC NMR spectrum. 
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Figure 3.14 (Cont.) 
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Figure 3.15 NMR analysis of compound b from the reconstructed cryptic gene cluster 
SGR810-815. (a) 1H NMR spectrum. (b) DQ-COSY NMR spectrum. (c) gHSQC NMR 
spectrum. (d) gHMBC NMR spectrum.  
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Figure 3.15 (Cont.) 
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Figure 3.16 Key COSY and HMBC correlations for compounds a and b. 
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Figure 3.17 Key NOESY correlations for compound b. 
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Scheme 3.1. The workflow of the synthetic biology strategy used to activate a cryptic 
biosynthetic gene cluster. Key steps include: (a) analyzing a sequenced genome or 
metagenome to identify target biosynthetic gene clusters; (b) PCR-amplifying or 
chemically synthesizing the corresponding DNA fragments; (c) selecting a set of suitable 
promoters (well-characterized or newly identified according to the target heterologous 
host) for gene cluster reconstruction; (d) assembling the reconstructed biosynthetic gene 
cluster in yeast; (e) isolating the assembled constructs from yeast and re-transforming 
them into E. coli for plasmid enrichment and verification; (f) verifying the assembled 
constructs by restriction digestion; (g) transferring the reconstructed biosynthetic gene 
cluster into the target heterologous host; (h) growing the strains in either liquid or solid 
media; (i) analyzing samples on HPLC for product detection; (j) characterizing the 
potential products by LC-MS and NMR.  
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Table 3.1 Fragments size and region located on the genomic DNA of S griseus. 
 
Fragments Primers Size Region 
1 1-for 5635 2501-8135 
 1-rev   
2 2-for 4479 7716-12194 
 2-rev   
3 3-for 5226 11775-17000 
 3-rev   
4 4-for 5220 16581-21800 
 4-rev   
5 5-for 4810 21381-26190 
 5-rev   
6 6-for 3048 25771-28818 
 6-rev   
7 7-for 4141 28381-32521 
 7-rev   
Yeast fragment Yeast-for 1859 32522-34380 
 Yeast-rev   
E. coli fragment E.coli-for 1430 34381-35810 
 E. coli-rev   
Streptomyces fragment Strep-for 3353 35811-2500 
 Strep-rev   
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Table 3.2 Primers designed to amplify each gene from the genomic DNA of S griseus. 
Construct Primer name Primer sequence (5’-3’) 
pYL-805-822 1-for gtagaaacagacgaagaagctagctttgcactggattgcggtgggtcctttcgggtcgac 
1-rev tcaccagtcgtggacggttc 
2-for ttcaacacggtgtacgacta 
2-rev gtgagcggcgacaggacagg 
3-for cttccgtacgaggcgggcgt 
3-rev gcgtactacctcctgctgca 
4-for gaagcggccctcggcctcgt 
4a-rev gcaaactcatcgacctcgac 
4b-for cgtcctcgtcggtgatgtcg 
4-rev gtcgcctacacctcgcgcgc 
5-for gatctcaccggtgctgtggc 
5-rev tcacccctgtcgcagccagt 
6-for gggacccgcgccgcggtgga 
6a-rev cgatcgtcatgttcagcgtg 
6b-for gatccatcacgggatccatc 
6-rev gaacagcacagcgatggagg 
7-for ggactgctggtccgacgatc 
7-rev ttatagcacgtgatgaaaaggacccaggtggcacttttcgcttcgtcatctgggccctgg 
yeast-for cgaaaagtgccacctgggtc 
yeast-rev gtgagtttagtatacatgca 
E.coli-for aaaactgtattataagtaaatgcatgtatactaaactcatgtcatcacgatactgtgat 
E.coli-rev aatattgtgagtttagtatacatgca 
Streptomyces-for acccattcaaaggccggcattttcagcgtgacatcattctgtgggccgtacgctggtact 
Streptomyces-rev ccgcgatactgcgacgagccgtcgacccgaaaggacccaccgcaatccagtgcaaagcta 
pYL-805-822-ermE*p 1-for acgcccgtctcctccccggggcggacgcgaatcgggcccagtgggtcctttcgggtcgac 
1-rev tcaccagtcgtggacggttc 
2-for ttcaacacggtgtacgacta 
2-rev gtgagcggcgacaggacagg 
3-for cttccgtacgaggcgggcgt 
3-rev gcgtactacctcctgctgca 
4-for gaagcggccctcggcctcgt 
4a-rev gcaaactcatcgacctcgac 
4b-for cgtcctcgtcggtgatgtcg 
4-rev gtcgcctacacctcgcgcgc 
5-for gatctcaccggtgctgtggc 
5-rev atgctgttggctggacaatcgtgccggttggtaggatcccctccccctcatcgccacttg 
ermEp-for cgtccatccgtgaccctccacaagtggcgatgagggggagggatcctaccaaccggcacg 
ermEp-rev tatgtcctgacctgccctgacgtgatgcggcggtctctctggtaccagcccgacccgagc 
6b-for gaccaggcgtgccggcgcgtgctcgggtcgggctggtaccagagagaccgccgcatcacg 
6-rev gaacagcacagcgatggagg 
7-for ggactgctggtccgacgatc 
7-rev ttatagcacgtgatgaaaaggacccaggtggcacttttcgcttcgtcatctgggccctgg 
yeast-for cgaaaagtgccacctgggtc 
yeast-rev gtgagtttagtatacatgca 
Streptomyces-for aaaactgtattataagtaaatgcatgtatactaaactcacaattcttgaagacgaaaggg   
S1-rev cagcccgagggagtacaggg 
S2-for gggcgcatgctcttgacctg 
S2-rev cgtgcgaaggcccccggcgg 
S3-for cctggctccggaggagatcg 
Streptomyces-rev ccgcgatactgcgacgagccgtcgacccgaaacgacccactgggcccgattcgcgtccgc 
pYL-FC-SGR810-815 810-for ccggtgcggggcccggtgagcgccgggccccgcaccggtcctaccacctgacgccgagcc 
810-rev gccggagtgcaccgcacacccactcgcagaggagattgcaatgcaccggctgttcttcga 
gapdhp(KR)-for gacggggcggccccggttcctcgaagaacagccggtgcattgcaatctcctctgcgagtg 
gapdhp(KR)-rev Gttgaccacgaccgaccccacgcgtccggccccggtgccgcacgggccggtgaaccccgc 
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Table 3.2 (Cont.) 
Construct Primer name Primer sequence 
pYL-FC-SGR810-815 811-for ccacatgaaccaacattcatgcggggttcaccggcccgtgcggcaccggggccggacgcg 
 811-rev ggcgtcgaaaaccggcgtacctaacgaggagatcggttcatgaagatcgcgaaatgggtg 
gapdhp(SG)-for cttcgacgtgttcgcggaccacccatttcgcgatcttcatgaaccgatctcctcgttagg 
gapdhp(SG)-rev gcccgttcgtcccgccgcaccgacggagaggaagtcatgactcggcggcgagcgggggac 
812-for gctggaccacgcgggcgcgccgacgacgggcgccccggtgtcatgacttcctctccgtcg 
812-rev tgccggttggtaggacaccactcgcgagagaggcgtatccgtgagcggcgacaggacagg 
ermEp-for gggcgcccccgggccgggtccctgtcctgtcgccgctcacggatacgcctctctcgcgag 
ermEp-rev gctcgaccggtggtccgcacgggagagcgaggaagcgtgaggtaccagcccgacccgagc 
813-for gaccaggcgtgccggcgcgtgctcgggtcgggctggtacctcacgcttcctcgctctccc 
813-rev gccgatggcagccgaaacgaagtaaggaacctgcgcttctatggcggatgacgatgacgaccccac 
rpsLp(TP)-for gttccctgctggtccagtcggtggggtcgtcatccgccatagaagcgcaggttccttact 
rpsLp(TP)-rev gcgctccgtcctggggggagacgcggcccatggcggatgaaccgggtccgcgatcggcgg 
814-for gtggtcaaaagtgttcgcctccgccgatcgcggacccggttcatccgccatgggccgcgt 
814-1-rev ggcaaactcatcgacctcga 
814-2-for ctcgtcggtgatgtcgaggg 
814-rev aggttagtttcacgaacggcacacagaaaccggagaagtaatggccgacgcgaacaaccg 
rpsLp(SG)-for ccaccttgttccgtaacgcccggttgttcgcgtcggccattacttctccggtttctgtgt 
rpsLp(SG)-rev tgcaccacggcttgctccaccacgacttgaggagttcggcaggggcgcgcggccccggcc 
815-for ccccggacgggacggccggcggccggggccgcgcgcccctgccgaactcctcaagtcgtg 
815-rev gtgccggtcagaccagagaacaccgacagacggagacgtaatggacgagcgcgagcactc 
rpsLp(CF)-for aatatattccgccatcggcggagtgctcgcgctcgtccattacgtctccgtctgtcggtg 
rpsLp(CF)-rev tctctctctccccctcatcgccacttgtggagggtcacggcccgccgcgggcgctggagg 
8-for cggcccggggcccgcccgagcctccagcgcccgcggcgggcgtgaccctccacaagtggc 
8-rev ttatagcacgtgatgaaaaggacccaggtggcacttttcggggggctcctcgattcgtt 
yeast-for cgaaaagtgccacctgggtc 
yeast-rev gtgagtttagtatacatgca 
E.coli-for aaaactgtattataagtaaatgcatgtatactaaactcatgtcatcacgatactgtgat 
E.coli-rev aatattgtgagtttagtatacatgca 
Streptomyces-for acccattcaaaggccggcattttcagcgtgacatcattctgtgggccgtacgctggtact 
Streptomyces-rev gtgcggggcccggcgctcaccgggccccgcaccgggggttcgcaatccagtgcaaagcta 
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Table 3.3 The sequences of the heterologous promoters which are active in S. lividans 
used in this study. 
 
Promoter Origin Length (nt) Sequence 
ermE*p Saccharopolyspora 
erythraea 
282 ggtaccagcccgacccgagcacgcgccggcacgcctggtcgatgtcggac
cggagttcgaggtacgcggcttgcaggtccaggaaggggacgtccatgcga
gtgtccgttcgagtggcggcttgcgcccgatgctagtcgcggttgatcggcgat
cgcaggtgcacgcggtcgatcttgacggctggcgagaggtgcggggaggat
ctgaccgacgcggtccacacgtggcaccgcgatgctgttgtgggctggacaa
tcgtgccggttggtaggacaccac 
gadphp(Streptomyces 
griseus) 
Streptomyces 
griseus 
239 ctcggcggcgagcgggggacgttggtcccgcacccgccgggacccgggtc
ccggcgggcgaaacggaggtccgtgctcctactggcgagtacggatctccg
gccgtatccggtggcgtgcggtggccctctcgatgtcacccccggggcctcgg
agaggtagggtcggaagcggtcggggacatccctatacaactcgccggcgt
cgaaaaccggcgtacctaacgaggagatcggttc 
rpsLp(Streptomyces 
griseus) 
Streptomyces 
griseus 
311  aggggcgcgcggccccggccgccggccgtcccgtccgggggcccgtggcc
ggggcggtcccggcgtgtcgcggcggacagcatttgttttgacccagctccgt
gaggtaggtacgctcaagccttgtgcctggggtgtgcctgggctcgggtgcgtg
tcctcaaccgcatcgcgagtccgtcagtagccaccgcaatctgcgcccttcctg
ccttcggggcgggagtccgcagtattcgacacacccgaccgcgtgggtcggc
gatgttccaggttagtttcacgaacggcacacagaaaccggagaagta 
rpsLp(Tsukamurella 
paurometabola) 
Tsukamurella 
paurometabola 
363  accgggtccgcgatcggcggaggcgaacacttttgaccactatgagttcatcc
aggtaagcttggtcgccgtgcctggtgaatgccaggacgatcgctcgtgccca
tactgcaggccggacctccgggaccacgtacggacacgcgacacgcccga
cctcggggtacgtgcgaggcgggtagctacttcccggaaacgggactgacc
agcagagacggcgaaagccggaactgccggtggggccgcgctgcggaag
tcgcaccctcgatgagggacggcttgcccggagctacaaccgcagcagtag
agccaccggccggacggccgatggcagccgaaacgaagtaaggaacctg
cgcttct 
gapdhp(Kocuria  
rhizophila) 
Kocuria  
rhizophila 
235  cacgggccggtgaaccccgcatgaatgttggttcatgtggggtttgcgccagct
gtgtcgcagttgccccccgccactgttcccggggcatgaatcccgctagaatg
aacacggaagagcaggtggaccccgggtcgtcaccgcacttcgggtgtggg
atttatgccgattggttttgatcccacatccggacgggccggagtgcaccgcac
acccactcgcagaggagattgca 
rpsLp(Xylanimonas 
cellulosilytica) 
Xylanimonas 
cellulosilytica 
302  gccctgcaggcggaagtcaggtagacacgacttccgctagtccttgcaaggt
ctgctgacgtgaggcggggcggtcgtttttgaccgccccgccttcgtcatgtag
gctcgctcgctgtgcctggcgtgtcttcagacgcccaggtcccggtgccgtgag
gcccgggccatcgagccggtggtacgtggctgcggtccccttgtgagggctgc
gcgccgtgtgctgtccggcgcgcacagccttgaatccacccgcgggggccg
gccggtctccgtgagctcgagaagacgacggagacgta 
rpsLp(Cellulomonas 
flavigena) 
Cellulomonas 
flavigena 
419  cccgccgcgggcgctggaggctcgggcgggccccgggccggaggcggcc
gcgaccacgacgcccgcgggacgtgacgagcggcacgactcgacgactc
cgggctcctttgacgctgtccgtcgcgccgggtagcgtaggacaccgtgcccg
cgccgtcgggccctcgcgcgtgcactcggtcgaccgctccctgccggagtgg
gtgcgggtgcacggggtggctccccacctcctctcggatcggtcctcgcggac
tgccgccgtgcggaggaccggggcgacacgcccgggcgcgggggtcggt
gcgggactccagacctccggggtagtcgtgcgacgggcgacgatccgggcc
gagccggccgtcctgggtgacgggtgccggtcagaccagagaacaccgac
agacggagacgta 
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Table 3.4 1Ha and 13Cb NMR data (in CD3OD) of compounds a and b. 
Number Compound a Compound b 
 1H (ppm) 13C (ppm) 1H (ppm) 13C (ppm) 
1  167.5  167.2 
2 5.74 (m) 136.7 5.80 (m) 123.0 
3 6.92 (dd, 15.1,10.9) 140.7 6.90 (dd, 15.0, 11.2) 140.1 
4 6.04 (dd, 15.1,11.1) 128.4 6.21 (dd, 15.0, 11.0) 129.1 
5 5.65 (m) 124.7 5.78 (m) 144.8 
6 2.51 (m) 52.7 2.65 (m) 51.4 
7a 1.22 (m) 42.9 
 
1.20 (m) 41.8 
7b 1.91 (m) 2.00 (m) 
8 2.43 (m) 41.4 2.52 (m) 42.2 
9a 0.92 (m) 35.0 
 
0.91 (m) 39.2 
9b 1.94 (m) 2.12 (m) 
10 1.58 (m) 56.3 1.40 (m) 53.3 
11 1.34 (m) 53.4 1.20 (m) 47.2 
12 2.10 (m) 57.4 2.05 (m) 59.4 
13 1.58 (m) 56.3 1.13 (m) 55.9 
14 3.88 (m) 77.2 2.79 (dd, 8.6,2.3) 59.0 
15 5.92 (dd, 15.4,18.4) 130.3 2.55 (dd, 7.1,2.2) 60.7 
16 6.17 (dd, 15.5,10.8) 131.2 3.84 (m) 74.1 
17 7.29 (dd, 15.2,10.6) 140.5 7.01 (dd, 15.7,3.5) 144.9 
18 7.02 (d, 15.4) 121.7 7.54 (d, 15.6) 121.9 
19  179.3  179.4 
20  101.1  103.4 
21  173.4  167.5 
22     
23 3.94 (m) 68.5 3.88 (dd, 8.2, 2.9) 59.2 
24  194.5  193.6 
25a 3.99 (m) 71.1 
 
2.00 (m) 28.8 
25b  1.91 (m) 
26a 1.38 (m) 31.6 
 
1.58 (m) 21.4 
26b 1.25 (m) 1.66 (m) 
27a 3.66 (m) 36.8 
 
3.72 (m) 39.8 
27b 2.79 (m) 2.69 (m) 
28     
29a 1.61 (m) 25.9 
 
1.61 (m) 25.8 
29b 1.08 (m) 1.07 (m) 
30 0.89 (m) 11.5 0.88 (m) 11.4 
31 1.03 (m) 16.7 1.04 (m) 16.3 
aδ (ppm) 600 MHz; multiplicities; J values (Hz) in parentheses. bδ (ppm) 145MHz, acquired with gHSQC, gHMBC and 
13C 
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Chapter 4 Further Characterization of the Cryptic PTM 
Biosynthetic Pathway from Streptomyces griseus  
4.1 Introduction 
PTMs contain one tetramic acid and a polycyclic system (usually 2-3 rings) fused 
to macrolactams and exhibit diverse biological activities such as antifungal, antibiotic, 
and antioxidant properties (1-7). They are a family of biomedically promising natural 
products with challenging molecular frameworks. In 1985, two isomers, isolated from 
Lysobacter gummosus ATCC 39472, named catacandins A and B, had good activity 
against Candida species (MIC 3–12 µg/ml), but no activity against Gram-negative or 
Gram-positive bacteria (8) were reported as the first potential PTM compounds. 
However, full elucidated structures of PTMs did not come out until the early 1990s 
from the compounds isolated from marine sponges and/or their associated microbiota 
(9,10). Recently, PTMs have been found in bacteria, such as maltophilin from 
Stenotrophomonas maltophilia (3), heat-stable antifungal factor (HSAF) from 
Lysobacter enzymogenes (4,7), as well as ikarugamycin (11), dihydromaltophilin (2), 
and frontalamides (1), all from medicinally important Streptomyces specie.  
Catacandins A and B, maltophilin and dihydromaltophilin were found to exhibit 
potent antifungal activity, but no investigations were done on their biosynthetic gene 
clusters or mechanisms. The molecular weight of maltophilin is identical to those of 
the catacandins, and it contains the same acyltetramic moieties which were reported in 
the catacandins’ partial structures. It seems likely that they all belong to the PTM 
family, which indicates that the origin of PTM biosynthetic pathways are widespread 
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in phylogenetically diverse bacteria. Later, the chemical structures of HSAF (4), 
frontalamides (12) and ikarugamycin (13) have been linked to their biosynthetic 
origins, and the structural determination showed that HSAF is identical to 
dihydromaltophilin. Most interestingly, Clardy and co-workers found that the PTM 
biosynthetic gene cluster from Streptomycetes was a common origin for PTM 
biosynthesis in phylogenetically diverse bacteria and was conserved in more than 50% 
of the sequenced Streptomyces species (1). Taken together, these PTM biosynthesis 
gene clusters are likewise highly similar, consisting of a hybrid polyketide 
synthase/nonribosomal peptide synthetase (PKS/NRPS) equipped with a series of 
red/ox-tailoring enzymes.  
The mode of action of HSAF was studied using Aspergillus nidulans as the test 
organism (14). The results indicated that HSAF disrupts polarized growth by the 
depletion of a group of sphingolipids and leads to loss of membrane organization and 
formin localization at hyphal tips. Further studies revealed that HSAF could induce 
the accumulation of sphingolipid intermediates, which causes thickening of the cell 
wall and thus leads to increased chitin deposition and irreversibly blocking elongation 
of the hyphal tips (15). Because fungal sphingolipids are structurally distinct from 
mammalian sphingolipids, they have become an attractive new target for the 
development of novel antifungal drugs (16). This novel mode of action of HSAF, 
together with the unusual chemical structure that is distinct from any existing 
antifungal drug on the market, makes PTMs potentially promising drug leads. 
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Despite the emerging significance of PTMs in basic and applied biology, the 
mechanisms for the key steps in PTM biosynthesis, such as installation of two 
polyketide chains and subsequent formation of the polycyclic ring system, remain 
elusive (1,4,17). Most intriguingly, the PKS only consists of a single module. 
Considering the structures of the products that have been characterized, it was 
believed that the sole PKS involved in these clusters acts as an iterative PKS (4,12,13). 
Although this is a common situation in fungal PKSs, it is very rare in bacterial 
polyketide synthases. HSAF biosynthesis was the first biosynthetic gene cluster 
reported for PTM biosynthesis. To understand the mechanism, Lou et al. 
heterologously expressed the NRPS domains of the HSAF biosynthesis pathway (4). 
The formation of the tetramic acid moiety demonstrated that this NRPS is responsible 
for forming both α- and δ- amide bonds as well as the carbon–carbon bond between 
ornithine’s carbonyl carbon and one hexaketide’s α-carbon. These results support the 
hypothesis that HSAF biosynthesis involves an iterative PKS-NRPS. In my previous 
chapter, the heterologous expression of the entire gene cluster and the detection of the 
potential PTM products once again confirm the presence of the unrecognized 
mechanism for bacterial polyketide-peptides.  
Except for the formation of the tetramic acid moiety catalyzed by the NRPS-
derived thioesterase domain, the only PTM biosynthetic steps that have so far been 
investigated in more detail is the origin of the hydroxyl moiety attached to the 
ornithine building blocks, which is introduced by a post-PKS/NRPS-hydroxylation 
(18). Therefore, many questions in the formation of PTMs still need to be answered. 
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For example, for the most intriguing aspect, how the single PKS module determines 
the chain length and structure of the two separate polyketide chains is not very clear. 
Another very interesting aspect is how the cascade of redox enzymes lead the two 
polyketide chains to form the polycyclic system. Further biochemical characterization 
of each of these enzymes should eventually unveil the secrets of PTM biosynthesis. 
One of the possible reasons why the discovery and characterization of PTM 
biosynthetic gene clusters are challenging is because most of the PTM gene clusters 
remain silent under typical fermentation conditions either in the native or 
heterologous host. Previously, we used a simple synthetic biology strategy to activate 
the cryptic PTM biosynthetic gene cluster SGR810-815 from Streptomyces griseus 
and identified two putative PTMs. To shed more light on the biosynthetic logic 
leading to PTMs, in this chapter, we further exploited the plug-and-play platform to 
perform genetic manipulations on this gene cluster and biochemically characterized 
the oxidoreductases involved. We elucidated their biosynthetic steps by creating and 
characterizing a series of gene deletion constructs and the in vitro activity assay of the 
key enzymes. We not only provide new insights to the subsequent formation of the 
polycyclic system, but also reveal a new paradigm of clustered biosynthetic genes. 
Instead of following a sequential order for the genes involved in one pathway, we 
found that they may diverge into parallel branches, as a result, generate homologous 
products. To confirm this, gene deletion constructs of the HSAF pathway are also 
assembled and characterized. 
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4.2 Results and discussion 
4.2.1 Determination of the boundary of the cluster 
As we have characterized two PTM products from the cryptic pathway by 
applying the plug-and-play scaffold, we attempted to elucidate the biosynthetic steps 
of this new gene cluster using the same synthetic biology strategy. We first 
determined the exact boundary of the gene cluster by extensive bioinformatics 
analysis of upstream and downstream regions of this gene cluster and then constructed 
another seven-gene gene cluster with an upstream putative aminotransferase gene 
(Figure 4.1 and Table 4.1). The expression of this putative aminotransferase gene was 
confirmed by qPCR and the products were identified to be the same as the ones from 
the six-gene gene cluster (Figure 4.1), indicating that the putative aminotransferase 
gene was not essential.  
4.2.2 Construction of single-gene deletion constructs  
In principle, DNA assembler can be used to assemble custom-designed DNA 
fragments in any desired order by designing PCR primers to generate appropriate 
overlaps between the adjacent ones. Usually, a S. cerevisiae helper fragment carrying 
a centromere sequence (CEN), an automatic replication sequence (ARS) and a Ura+ 
selection marker, an E. coli helper fragment carrying a pBR322 ori and a Apr+ 
selection marker, and a helper fragment carrying an ori and a selection marker 
required by the desired organism, are individually prepared. These helper fragments 
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are mixed with the pathway fragments, and subsequently co-transformed into S. 
cerevisaie to be assembled into a single molecule.  
Next, to decipher the biosynthetic steps, a series of mutant gene clusters 
consisting of single gene deletions were constructed via the DNA assembly method 
(Figure 4.2 and Table 4.2). Each of the gene and promoter fragments was individually 
PCR amplified, gel purified. Genes with corresponding promoters were also ligated 
together by overlap extension PCR. To ensure high efficiency of yeast homologous 
recombination, the “promoter upstream-gene-promoter downstream” cassette was 
built to generate a ~200 bp overlap region with adjacent fragments. The fragments 
were co-transformed into S. cerevisiae through electroporation and spread onto SC-
Ura plates. Typically, 30-50 colonies appeared after 2-3 days of incubation at 30 °C, 
which were then randomly picked for plasmid isolation. 10 colonies were inoculated 
in SC-Ura liquid culture and the purified yeast plasmids were individually 
transformed to E. coli WM1788 and selected on LB-Apr+ plates. E. coli plasmids 
were subsequently purified and checked by gel electrophoresis. The plasmids with 
relatively large size were subjected to restriction digestion by three different 
restriction enzymes. As a result, for all the single deletion constructs, usually 6-10 of 
them exhibited an expected digestion pattern, indicating an assembly efficiency of 60-
100%.   
4.2.3 Analysis of the single-gene deletion constructs  
The verified clones were transformed to E. coli WM6026 (19) and these 
transformants were then used as the donors for conjugative transfer of the assembled 
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plasmids to S. lividans 66 following the protocol described elsewhere (19). For the 
single deletion constructs, a single colony of each construct was inoculated into 20 
mL of ATCC172 liquid medium. Aliquots of this seed culture with a volume of 250 
μL were spread for confluence over Petri plates containing approximately 25-30 mL 
of YMS solid agar medium and the plates were incubated for 7 days at 30 °C. 
We followed the product extraction method described in literature (12) to isolate 
the potential product from these single deletion clusters. As expected, the SGR814 
single deletion construct lost the ability to produce any target compounds, indicating 
the essential role of the PKS-NRPS hybrid gene (Figure 4.3). The SGR815 single 
deletion construct (Figure 4.3) abolished the production of compound a and instead 
produced compound c [M(C29H38O5N2)+H]+ with an m/z of 495.2864 (Figure 4.4) 
(calculated: 495.2859) as a major product. Compound c was characterized via LC/MS 
and NMR (Figure 4.5, Figure 4.6 and Table 4.3). By comparing the structures of 
compound a and compound c, we noticed that the difference is the lack of a hydroxyl 
group proximal to the tetramic-acid moiety of the compounds. Therefore, it was clear 
that SGR815 serves as a hydroxylase, similar to its homologous enzyme characterized 
in the HSAF (18) and frontalamides (1) gene clusters. This 3-hydroxyl group on the 
ornithine residue seems to be a feature common to nearly all PTM natural products 
found in phylogenetically diverse organisms. 
Both the SGR812 single deletion construct and the SGR814 single gene construct 
(the construct only contains the SGR814 gene and a strong constitutive promoter) 
failed to produce any related compounds, indicating that SGR812 may be involved in 
130 
 
the first step of the formation of the polycyclic system (Figure 4.3). The SGR813 
single deletion construct (Figure 4.3) revealed one major peak at ~34 min with a 
corresponding m/z of 477.2757 for compound d [M(C29H36O4N2)+H]+ (calculated: 
477.2753) and the chemical structure of compound d was subsequently determined 
(Figure 4.4, Figure 4.5, Figure 4.7 and Table 4.3). The interesting 4-membered ring in 
compound d is the first observation of such structure in known PTMs. The structure 
of compound d suggests that it may be a shunt product after SGR813 deletion. These 
results suggest that both SGR812 and SGR813 are involved in the formation of the 
polycyclic system.   
4.2.4 Construction of the multiple-gene deletion constructs 
To further confirm the results obtained from single-deletion constructs, multiple-
deletion gene constructs were constructed via the same approach (Figure 4.8 and 
Table 4.4). Each of the gene and promoter fragments was individually PCR amplified, 
gel purified. Then genes with corresponding promoters were ligated together by 
overlap extension PCR. To ensure high efficiency of yeast homologous recombination, 
the “promoter upstream-gene-promoter downstream” cassette was built to generate a 
~200 bp overlap region with adjacent fragments. All the fragments were co-
transformed into S. cerevisiae through electroporation and spread onto SC-Ura plates. 
Typically, 30-50 colonies appeared after 2-3 days of incubation at 30 °C, which were 
then randomly picked for plasmid isolation. 10 colonies were inoculated in SC-Ura 
liquid culture and the purified yeast plasmids were individually transformed to E. coli 
WM1788 and selected on LB-Apr+ plates. E. coli plasmids were subsequently 
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purified and checked by gel electrophoresis. The plasmids with relatively large size 
were subjected to restriction digestion by at least three different restriction enzymes. 
As a result, for all the multiple-deletion constructs, usually 8-10 of them exhibited an 
expected digestion pattern, indicating an assembly efficiency of 80-100%.   
4.2.5 Analysis of the multiple-gene deletion constructs 
We followed the methods we described in section 4.2.3 to heterologously express 
the assembled constructs and isolate the potential products from these multiple-
deletion clusters. First, the 3-gene gene cluster consisting of SGR812, SGR813, and 
SGR814 was evaluated (Figure 4.8 and Table 4.4). Compound c was found to be the 
major product (Figure 4.9), indicating that this compound is a key biosynthetic 
intermediate.  
To further elucidate the function of the other redox enzymes, several 4-gene gene 
clusters were built. First, a 4-gene gene cluster consisting of SGR812, SGR813, 
SGR814, and SGR815 was constructed (Figure 4.8 and Table 4.4) and its main 
product was compound a (Figure 4.9), which again confirmed the functional role of 
SGR815 as a hydroxylase. Although the SGR810 and SGR811 single gene deletion 
constructs both maintained the production of compound a and compound b, the loss 
of compound b in these 3-gene and 4-gene constructs indicates that SGR810 and 
SGR811 are involved in the formation of the epoxide ring and their functions might 
be redundant (Figure 4.3). To further exploit the functions of these two genes, two 
additional 4-gene gene clusters were made consisting of SGR812, SGR813, SGR814, 
and SGR810 or SGR811 respectively (Figure 4.8 and Table 4.4). The 4-gene gene 
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cluster consisting of SGR810, SGR812, SGR813, and SGR814 produced compound b 
as a major product, which indicated that SGR810 might be involved in the formation 
of the epoxide ring. While the 4-gene gene cluster consisting of SGR811, SGR812, 
SGR813, and SGR814 revealed one new peak at ~28 min with a corresponding m/z of 
495.3 for compound e [M(C29H38O5N2)+H]+ (calculated: 495.2859) (Figure 4.9) 
and the chemical structure of compound e was subsequently determined (Figure 4.10, 
Figure 4.11, Figure 4.12 and Table 4.5). Based on the structures of these newly 
characterized intermediates, we proposed a biosynthetic route for this group of PTMs 
(Figure 4.13).  
4.2.6 Reconstitution of the oxidoreductases in vitro 
To confirm the functional roles of SGR810, SGR811 and SGR815, we decided to 
biochemically characterize them in vitro. In order to produce the large quantities of 
enzymes required for in vitro assay, we chose E. coli as a heterologous expression 
host. The full-length genes were cloned from the genomic DNA of S. griseus into 
pET28a(+), creating both N-terminal and C-terminal His6-tags. E. coli BL21 (DE3) 
cells were transformed with this constructs and lysates of IPTG-induced (0.1 mM) 
cultures were analyzed by SDS-PAGE to check for presence of soluble proteins (20). 
Clear overexpression bands for SGR810 and SGR815 were detected and confirmed 
by Western blot analysis (Figure 4.14). While for SGR811, most of the target protein 
was detected in the insoluble fraction. To maximize soluble expression of SGR811, 
different IPTG induction concentrations and culturing temperatures were tested. 
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Finally, with a 0.01mM IPTG-induced culture growing at 16 Ԩ for 18 hrs, we would 
be able to obtain the soluble SGR811 protein.	 	
A two-step purification of these three enzymes were developed. First, an ion 
exchange column was used to remove some of the protein impurities. Then, the His6-
tag allowed the purification of the enzymes using immobilized affinity 
chromatography with Ni2+-NTA resin coupled with fast performance liquid 
chromatography (FPLC). The purities of all these three enzymes were analyzed by the 
SDS-PAGE (Figure 4.14) and were greater than 80%. The concentrations of final 
enzyme stocks were determined by the Bradford method (21).  
4.2.7 Investigation of the HSAF pathway  
The proposed biosynthetic route for this group of PTMs (Figure 4.12) showed 
that the formation of the PTM compounds may follow several parallel pathways 
instead of a sequential order of all the genes involved. To discover whether this is true 
or not in other PTM biosynthetic pathways, we refactored the HSAF pathway and 
designed four intermediate constructs with multiple-gene deletions of this pathway 
(Figure 4.15).  
Those multiple-gene deletion constructs were constructed using the same 
approach as described before. Each of the gene fragments was individually PCR 
amplified from the genomic DNA of Lysobacter enzymogenes, and then gel purified. 
The genes fragments with the corresponding promoters were ligated together by 
overlap extension PCR. To ensure high efficiency of yeast homologous recombination, 
the “promoter upstream-gene-promoter downstream” cassette was built to generate a 
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~200 bp overlap region with adjacent fragments. All the fragments were co-
transformed into S. cerevisiae through electroporation and spread onto SC-Ura plates. 
Typically, 30-50 colonies appeared after 2-3 days of incubation at 30 °C, which were 
then randomly picked for plasmid isolation. 10 colonies were inoculated in SC-Ura 
liquid culture and the purified yeast plasmids were individually transformed to E. coli 
WM1788 and selected on LB-Apr+ plates. E. coli plasmids were subsequently 
purified and checked by gel electrophoresis. The plasmids with relatively large size 
were subjected to restriction digestion by at least three different restriction enzymes. 
As a result, for all the multiple-gene deletion constructs, usually 8-10 of them 
exhibited an expected digestion pattern, indicating an assembly efficiency of 80-100%.   
We followed the methods we described in section 4.2.3 to heterologously express 
the assembled constructs and isolate the potential products from these multiple-gene 
deletion clusters.  Initial HPLC-MS analysis indicated that the 3-gene cluster of the 
HSAF pathway produced an intermediate with a molecular weight of [M+H]+ 477.3 
(Figure 4.16). Comparing the MS2 data with previously characterized compounds, 
this one shares an identical MS2 pattern with compound c except for the loss of one 
additional –OH group. This supports our hypothesis that compound c serves as the 
scaffold for further parallel modifications by other oxidoreductases involved in these 
pathways.  
4.3 Conclusions 
We have successfully used a synthetic biology strategy to investigate the 
biosynthetic route for PTMs, especially for the formation of the polycyclic system. 
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SGR815 was confirmed to be a hydroxylase, which is conserved in all known PTM 
gene clusters. SGR812 and SGR813 were annotated as oxidoreductases and can be 
found in most of the known PTM gene clusters. Based on phylogenetic analysis, these 
two enzymes are distinct and may catalyze different reactions even though they 
belong to the same family of oxidoreductases. Indeed, our results from the gene 
deletion constructs suggest that SGR812 is involved in the formation of the first 
cyclic ring while the SGR813 is responsible for the closure of the second ring. 
Interestingly, we noticed that two related PTM gene clusters from Saccharophagus 
degradans and Salinospora arenicola only contain homologs of SGR812, which 
supports the proposed role of SGR812 in ring formation. That is because the reaction 
catalyzed by SGR812 takes place before the ones catalyzed by other oxidoreductases. 
The last two enzymes, SGR811 and SGR810, are also conserved in most of the 
related PTM gene clusters, but with greater sequence diversity. Our results suggest 
that they are likely to perform oxidative reactions on the backbone. For SGR810, it is 
most likely involved in the formation of the epoxide ring, while for SGR811, with the 
structure of compound e in hand, we would argue that it catalyzes the formation of the 
third ring in the polycyclic system and may spontaneously activate the closure of 
additional rings with the rearrangement of the double bonds.  
It should be noted that based on our results, the three different oxidoreductases 
lead to three different PTM products respectively, which indicates that the 
biosynthetic steps may not follow a sequential linear order, but act in parallel 
reactions.  To confirm this, we will further carry out the in vitro assay with the 
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purified oxidoreductases individually and tests the different HSAF deletion constructs 
we designed.  
4.4 Materials and methods  
4.4.1  Strains and reagents 
 S. cerevisiae YSG50 (MATα, ade2-1, ade3Δ22, ura3-1, his3-11, 15, trp1-1, 
leu2-3, 112 and can1-100) was used as the host for DNA assembly and integration.  
S. lividans 66 and S. griseus were obtained from the Agricultural Research Service 
Culture Collection (Peoria, IL) and E. coli BL21 (DE3) was obtained from Novagen 
(Madison, WI). Plasmids pAE4, E. coli strains WM6026 and WM1788 were 
developed by the Metcalf group (University of Illinois, Urbana-Champaign). The 
pRS426 and pRS416 plasmid (New England Biolabs, Beverly, MA) were modified by 
incorporating the hisG and partial δ sequence (δ2) that flank the multiple cloning site 
and serve as the vectors for assembly of various pathways. Nalidixic acid and IPTG 
were obtained from Sigma-Aldrich (St. Louis, MO). ISP2, agar, beef extract, yeast 
extract, malt extract, and other reagents required for cell culture were obtained from 
Difco (Franklin Lakes, NJ). All restriction endonucleases, as well as T4 DNA ligase 
and antarctic phosphatase, were purchased from New England Biolabs (Beverly, MA).   
Phusion DNA polymerase was from Finnzymes (Espoo, Finland). FailsafeTM 2x 
premix buffer G was purchased from EPICENTRE Biotechnologies (Madison, WI). 
SYBR Green PCR master mix was purchased from Applied Biosystems (San 
Francisco, CA). The QIAprep Spin Plasmid Mini-prep Kit, QIAquick PCR 
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Purification Kit, QIAquick Gel Extraction Kit, and RNeasy MinElute Cleanup Kit 
were purchased from Qiagen (Valencia, CA). The total RNA was extracted using the 
RNeasy Mini Kit (QIAGEN, Valencia, CA). All primers were synthesized by the 
Integrated DNA Technologies (Coralville, IA). Yeast YPAD medium-containing 1% 
yeast extract, 2% peptone and 2% dextrose supplied with 0.01% adenine 
hemisulphate was used to grow S. cerevisiae YSG50 strain. Synthetic complete drop-
out medium lacking uracil (SC-Ura) was used to select transformants containing the 
assembled biochemical pathways of interest. 
4.4.2 DNA manipulation 
S. griseus was grown in liquid MYG medium (4 g/L yeast extract, 10 g/L malt 
extract and 4 g/L glucose) at 30 °C with constant shaking (250 rpm) for 2 days. The 
genomic DNA was isolated from S. griseus using the Wizard Genomic DNA isolation 
kit from Promega (Madison, WI). Pairs of primers were designed with the sequences 
shown in Table 4.1, 4.2 and 4.4. Pathway fragments were amplified from the genomic 
DNA of S. griseus. Generally, the PCRs were carried out in 100 µL reaction mixture 
consisting of 50 µL FailSafeTM PCR 2xPreMix G from Epicentre Biotechnologies 
(Madison, WI), 2.5 pmol of each primer, 1 µL yeast plasmid or genomic DNA and 
2.0 unit Phusion DNA polymerase for 35 cycles on a PTC-200 Thermal Cycler (MJ 
Research, Watertown, MA). Each cycle consisted of 10 s at 98 °C, 30 s at 58 °C and 3 
min at 72 °C, with a final extension of 10 min. The S. cerevisaie helper fragment was 
amplified from the commercial vector pRS416, while the E. coli helper fragment and 
the S. lividans helper fragment were amplified from the Streptomyces-E. coli shuttle 
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vector pAE4. Following electrophoresis, the PCR products were individually gel-
purified from 1.0% agarose gels using Qiagen Gel Purification kit. For gapdhp(SG) 
and rpsLp(SG), the genomic DNA of S. griseus was isolated using the Wizard® 
Genomic DNA Purification Kit (Promega, Madison, WI) and then used as the 
template for PCR amplification of the two target promoters. Promoters from other 
hosts were obtained through primer splicing in which 6-10 overlapping 
oligonucleotides designed based on the sequence of each promoter are joined together 
by overlap extension PCR. Genes with corresponding promoters were also ligated 
together by overlap extension PCR. To ensure high efficiency of yeast homologous 
recombination, the “promoter upstream-gene-promoter downstream” cassette was 
built to generate a ~200 bp overlap region with adjacent fragments. 100 ng of each 
individual fragments was mixed and precipitated with ethanol. The resulting DNA 
pellet was air-dried and resuspended in 4 µL Milli-Q double deionized water and 
subsequently electroporated into S. cerevisiae using the protocol reported elsewhere 
(22).   
4.4.3 Yeast transformation 
Yeast transformation was performed by electroporation. YPAD medium (50 mL) 
was inoculated with a 0.5 mL overnight S. cerevisiae YSG50 culture and shaken at 
30 °C and 250 rpm for 4-5 h until OD600 reached 0.8-1.0. Yeast cells were harvested 
by centrifugation at 4 °C and 4000 rpm for 5 min. The supernatant was discarded and 
the cell pellet was washed with 50 mL ice-cold Milli-Q double-deionized water, 
followed by another wash with cold 1 M sorbitol and finally resuspended in 250 µL 
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cold sorbitol. An aliquot of 50 µL of yeast cells together with 4 µL DNA mixture was 
electroporated in a 0.2 cm cuvette at 1.5 kV. The transformed cells were immediately 
mixed with 1 mL room temperature YPAD medium and shaken at 30 °C for 1 h.  
Following that, the cells were harvested by centrifugation, washed with room 
temperature 1 M sorbitol several times to remove the remaining medium and finally 
resuspended in 1 mL sorbitol. Aliquots of 30-50 mL were spread on SC-Ura plates for 
the selection of the transformants, and the plates were incubated at 30 °C for 2-4 days 
until colonies appeared. Colonies were randomly picked to SC-Ura liquid medium 
and grown for 1 day, after which yeast plasmid was isolated using Zymoprep II Yeast 
plasmid Miniprep kit (Zymo Research, CA), and genomic DNA was prepared using 
Wizard Genomic DNA isolation kit from Promega (Madison, WI). 
4.4.4 Verification of the assembled gene clusters 
Colonies were randomly picked to SC-Ura liquid media and grown for 2 days, 
after which yeast plasmid was isolated using Zymoprep II Yeast plasmid Miniprep kit 
(Zymo Research, CA). Yeast plasmids were transformed to E. coli strain WM1788 
and selected on Luria Broth (LB) agar plates supplemented with 50 µg/ml apramycin.  
Colonies were inoculated into 5 mL of LB media supplemented with 50 µg/mL 
apramycin, and plasmids were isolated from the liquid culture using the plasmid 
miniprep kit from Qiagen. Plasmids isolated from E. coli were then subjected to 
restriction digestion by different enzymes, after which the reaction mixtures were 
loaded to 0.7% agarose gels to check for the correct restriction digestion pattern by 
DNA electrophoresis. 
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4.4.5 Streptomycete cultivation, RNA extraction and qPCR analysis 
A seed culture was grown in MYG medium (10 g/L malt extract, 4 g/L yeast 
extract, and 4 g/L glucose) at 30 °C with constant shaking (250 rpm) until saturation, 
and inoculated into fresh MYG with a ratio of 1:100. The total RNA was extracted 
using the RNeasy Mini Kit (QIAGEN, Valencia, CA). Reverse transcription was 
carried out using the First-strand cDNA Synthesis Kit (Roche Applied Science, 
Indianapolis, IN). Real-time PCR was performed with SYBR® Green PCR Master 
Mix on the 7900HT Fast Real-Time PCR System (Applied Biosystems, Carlsbad, 
CA). Primers were designed by the online tool provided by Integrated DNA 
Technologies (https://www.idtdna.com/scitools/Applications/RealTimePCR/). 10 μL 
of 2× SYBR Green Mix, 1 μL of cDNA, 1 μL of each primer at a concentration of 10 
pmol/μL and 7 μl of ddH2O were mixed gently in each well of the Applied 
Biosystems® MicroAmp® Optical 96-Well Reaction Plate. Reactions were performed 
using the following program: 2 min at 50 °C, 10 min at 95 °C for one cycle followed 
by 15 s at 95 °C, 30 s at 60 °C and 30 s at 72 °C for 40 cycles with a final cycle of 10 
min at 72 °C. The endogenous gene hrdB, encoding the RNA polymerase sigma 
factor, was used as the internal control for promoter screening. The expression levels 
of other candidate genes were normalized by the expression of the control. Data was 
analyzed using SDS2.4 software (Applied Biosystems).   
4.4.6 Heterologous expression in S. lividans 
The verified clones were transformed to E. coli WM6026 (19) and selected on LB 
agar plates supplemented with 19 µg/mL 2,6-diaminopimelic acid and 50 µg/mL 
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apramycin. These transformants were then used as the donors for conjugative transfer 
of the assembled plasmids to S. lividans 66 following the protocol described 
elsewhere (19). S. lividans exconjugants were picked and re-streaked on ISP2 plates 
supplemented with 50 µg/mL apramycin and grown for 2 days. For the reconstructed 
gene cluster SGR810-815, a single colony was inoculated into 20 mL of ATCC172 
liquid medium (5 g/L yeast extract, 20 g/L soluble starch, 5 g/L N-Z Amine Type A, 1 
g/L CaCO3, and 10 g/L glucose) supplemented with 50 µg/mL apramycin in a 125 mL 
shake-flask (3 mm glass beads added to improve liquid mixing and aeration). Aliquots 
of this seed culture with a volume of 250 μL were spread for confluence over Petri 
dish plates containing approximately 25-30 mL of YMS solid agar medium (4 g/L 
yeast extract, 10 g/L malt extract, 4 g/L soluble starch, and 20 g/L Bacto agar) and the 
plates were incubated for 7 days at 30 °C.  
4.4.7 HPLC-MS analysis 
To isolate potential compounds, agar and the adherent cells were stored at -80 °C 
for 24 h, after which the frozen cultures were thawed completely and the released 
liquids were collected. The liquids were extracted by ethyl acetate with a ratio of 1:1 
twice, concentrated 1000-fold, and subjected to HPLC analysis. HPLC was performed 
on the Agilent 1100 series LC/MSD XCT plus ion trap mass spectrometer with a 
Phenomenex Luna C18 reverse-phase column (3.0 x 150 mm, 3.5 μm). HPLC 
parameters were as follows: solvent A, 0.1% formic acid in water; solvent B, 0.1% 
formic acid in acetonitrile; gradient, 10% B for 5 min, to 100% B in 25 min, maintain 
at 100% B for 10 min, return to 10% B in 1 min and finally maintain at 10% B for 9 
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min; flow rate 0.3 mL/min; detection by UV spectroscopy at 260 nm. Under such 
conditions, products are eluted at 28.5 min (compound c), 34.6 min (compound d) and 
28.6 min (compound e). The MS system was operated using a drying temperature of 
350 ○C, a nebulizer pressure of 35 psi, a drying gas flow of 8.5 L/min, and a capillary 
voltage of 4500 V. 
4.4.8 Structure elucidation of compounds c-e  
Compounds c, d and e were isolated by reverse-phase HPLC using a Phenomenex 
Luna 10u C18 column (10 mm × 250 mm) on the Agilent 1100 series LC/MSD XCT 
with an isocratic solvent of 60% acetonitrile in water with 0.1% formic acid (with a 
flow rate of 3 mL/min and a wavelength of 260 nm). The high resolution MS was 
performed on a Waters Q-Tof Ultima system (Walters, Milford, MA). All NMR 
experiments were carried out on a Varian UNITY INOVA 600 MHz spectrometer, 
except for the 13C NMR spectra, which were recorded on a Bruker Avance III 500i 
with a 5 mm 13C(1H) cryogenic probe at the National Magnetic Resonance Facility at 
the University of Wisconsin at Madison. The structures were determined based on 1-
D and 2-D NMR data. The relative configurations were determined by using 2-D 
NOESY experiments.  
4.4.9 Cloning, expression and purification of the oxidoreductases 
The genes were PCR amplified from the genomic DNA of S. griseus using 
primers containing NdeI and XhoI restriction sites and cloned into the corresponding 
sites of pET28a(+), creating both N- and C-terminal His6-tag.  
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E. coli BL21 (DE3) cells overexpressing these genes were grown in Luria-Bertani 
(LB) medium supplemented with kanamycin (50µg/mL). Cells were grown at 37 Ԩ	to 
OD600 ~0.6-0.8 and then induced at 16 Ԩ	 by the addition of IPTG to a final 
concentration of 0.1 mM (SGR810 and SGR815) and 0.01 mM (SGR811). The 
cultures were incubated at 16 Ԩ	for an additional 18 hours, after which the cells were 
harvested by centrifugation (10 minutes at 8,000 x g) and resuspended in 2 mL lysis 
buffer (10 mM imidazole, 50 mM sodium phosphate buffer, 300 mM NaCl, 10 mM 
imidazole, 15% glycerol, pH 8.0, 1 mg/mL lysozyme) per gram cell weight and 
frozen at -80 °C. Subsequently, cells were lysed using sonication and cellular debris 
was removed by centrifugation (40,000 x g, 4 °C, 10 minutes). Recombinant proteins 
were purified by chromatography on Ni-NTA resins by the amino-terminal 
hexahistidine affinity tag. Captured proteins were cleaned up with a wash buffer (20 
and 50 mM imidazole, 50 mM sodium phosphate buffer, 300 mM NaCl, 20 or 50 mM 
imidazole, 15% glycerol, pH 8.0) and finally eluted in an elution buffer (200 mM 
imidazole, 50 mM sodium phosphate buffer, 300 mM NaCl, 200 mM imidazole, 15% 
glycerol, pH 8.0). The protein content of individual elution fractions was estimated 
using Quick Start Bradford Protein Assay (Bio-Rad, Hercules, CA) and the 
appropriate fractions were pooled and buffer exchanged into 10 mM phosphate buffer 
pH 7.5 containing 15% glycerol at 4 °C. The protein was concentrated using an 
Amicon Ultra centrifugal filter device (Millipore, Billerca, MA).  
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4.4.10 Polyacrylamide gel electrophoresis (SDS-PAGE) 
Protein standards, Powerpac 300 power supply, Mini-PROTEAN 3 assembly, and 
precast acrylamide gels were purchased from Bio-Rad (Hercules, CA). Varying 
amounts of samples, dependent upon protein concentrations, were mixed with 2 μl 
SDS-PAGE loading buffer (30% glycerol, 1% SDS, 0.3% bromophenol blue, 0.5 M 
Tris-HCl, pH 6.8) and water to a final volume of 20 μl. Samples were denatured at 
98 °C for 10 minutes, cooled to 4 °C, and then loaded onto a gel in a Bio-Rad Mini-
PROTEAN 3 assembly. Voltage was supplied by a Powerpac 300 supply at a voltage 
of 100 V for 100 minutes. Gels were stained with SimplyBlueTM Safestain from 
Invitrogen (Carlsbad, CA) followed by destaining overnight in distilled water. 
Destained SDS-PAGE gels were scanned subsequently discarded. 
4.4.11 Western blot analysis of proteins 
Proteins were subjected to SDS-PAGE as described above. The proteins were 
then transferred to a polyvinylidene fluoride (PVDF) membrane using a Mini Trans-
Blot Cell from Bio-Rad (Hercules, CA). The PVDF membrane was blocked in 3% 
non-fat milk in a phosphate buffered saline (PBS) buffer. The primary antibody, His-
tag mouse monoclonal antibody from Novagen (Madison WI) was added to the 
blocking solution 1:1000 dilution and the membrane was incubated for 2 hours at 
room temperature. The membrane was incubated with a secondary antibody, goat 
anti-mouse antibody from Sigma (St. Louis, MO) for another 2 hrs at room 
temperature, and then washed three times with PBS buffer. The membrane was then 
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incubated with Western blot substrate for 10 minutes to let the reaction reveal the 
potential band.  
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4.6 Figures and tables  
 
 
 
 
 
 
 
 
 
Figure 4.1 Characterization of the 7-gene cluster. (a) Vector map of the 7-gene cluster 
construct. (b) HPLC analysis of the 7-gene cluster construct compared with the 6-
gene cluster construct. 
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Figure 4.2 Vector maps of the single-gene deletion constructs. For each single gene 
deletion construct, both the gene and its corresponding promoter were deleted. 
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Figure 4.3 HPLC analysis of single gene deletion constructs. 
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Figure 4.4 Chemical structures of the products of the SGR810-815 gene-gene 
deletion clusters from S. griseus. 
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Figure 4.5 LC/MS analysis of the S. lividans strain carrying the refactored deletion 
constructs. (a) MS data for compound c. (b) MS data for compound d. 
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Figure 4.6 NMR analysis of compound c from the refactored cryptic gene cluster 
SGR810-815. (a) 1H NMR spectrum. (b) Double-Quantum Filtered Correlation 
Spectroscopy (Phase-Sensitive) (DQ-COSY) NMR spectrum. (c) Heteronuclear 
Multiple Quantum Coherence (gHSQC) NMR spectrum. (d) Heteronuclear Multiple-
Bond Correlation Spectroscopy (gHMBC) NMR spectrum. 
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Figure 4.6 (Cont.) 
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Figure 4.7 NMR analysis of compound d from the refactored cryptic gene cluster 
SGR810-815. (a) 1H NMR spectrum. (b) Double-Quantum Filtered Correlation 
Spectroscopy (Phase-Sensitive) (DQ-COSY) NMR spectrum. (c) Heteronuclear 
Multiple Quantum Coherence (gHSQC) NMR spectrum. (d) Heteronuclear Multiple-
Bond Correlation Spectroscopy (gHMBC) NMR spectrum. 
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Figure 4.7 (Cont.)  
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Figure 4.8 Vector maps of the multiple-gene deletion constructs. pYL-RC-SGR814 
only contains the gene SGR814 with gapdhp(EL) promoter; pYL-RC-SGR812-814 
contains genes SGR812, SGR813, and SGR814 with corresponding promoters; pYL-
RC-SGR812-815 contains genes SGR812, SGR813, SGR814 and SGR815 with 
corresponding promoters. pYL-RC-SGR810+812-814 contains genes SGR810, 
SGR812, SGR813 and SGR814 with corresponding promoters. pYL-RC-SGR811-
814 contains genes SGR811, SGR812, SGR813 and SGR814 with corresponding 
promoters. 
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Figure 4.9 HPLC analysis of 3-gene and 4-gene constructs. 
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Figure 4.10 Chemical structures of the products of the SGR811-814 gene cluster 
from S. griseus. 
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Figure 4.11 LC-MS analysis of compound e from the refactored cryptic gene cluster 
SGR810-815 after fraction collection.  
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Figure 4.12 NMR analysis of compound e from the refactored cryptic gene cluster 
SGR810-815. (a) 1H NMR spectrum. (b) Double-Quantum Filtered Correlation 
Spectroscopy (Phase-Sensitive) (DQ-COSY) NMR spectrum. (c) Heteronuclear 
Multiple Quantum Coherence (gHSQC) NMR spectrum. (d) Heteronuclear Multiple-
Bond Correlation Spectroscopy (gHMBC) NMR spectrum. 
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Figure 4.12 (Cont.) 
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Figure 4.13 Proposed biosynthetic mechanism for formation of the five tetramic acid-
containing macrolactams. The PKS is responsible for the hexaketide chain synthesis 
and works together with the NRPS to condense the two polyketide chains with 
ornithine. The formation of the first polycyclic ring is catalyzed by SGR812 and the 
second ring is closed by SGR813. Compound c is the key intermediate that can be 
converted into compound a by SGR815 or compound b by SGR810 or compound e 
by SGR811. A shunt product compound d will be formed if SGR813 is absent in the 
cluster. SEnz is the carrier protein within the PKS or NRPS. The red structures are the 
ones with full-set of NMR data. 
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Figure 4.14 SDS-PAGE analysis of proten overexpression. (a) SGR810. (b) SGR811. 
(c) SGR815. (d) Purification of SGR810 and SGR815.  
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Figure 4.15 Vector maps of the multiple-gene deletion constructs of the HSAF 
pathway. pYL-FC-HSAF-3-genes contains homologs of genes SGR812, SGR813, and 
SGR814 with corresponding promoters; pYL-FC-HSAF-3+1-genes contains 
homologs of genes SGR812, SGR813, SGR814 and SGR811 with corresponding 
promoters. pYL-FC-HSAF-4-genes contains homologs of genes SGR812, SGR813 
SGR814 and OX1 from HSAF with corresponding promoters. pYL-FC-HSAF-4+1-
genes contains homologs of genes SGR811, SGR812, SGR813, SGR814 and OX1 
from HSAF with corresponding promoters. 
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Figure 4.16 LC/MS analysis of the S. lividans strain carrying the refactored deletion 
HSAF constructs. MS data for key intermediate from the HSAF 3-gene pathway.  
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Table 4.1 The primers used for refactoring the cryptic S. griseus gene cluster SGR 
810-816. 
Construct Primer name Primer sequence (5’-3’) 
pYL-FC-SGR810-
816 
810-for ccggtgcggggcccggtgagcgccgggccccgcaccggtcctaccacctgacgccgagcc 
810-rev gccggagtgcaccgcacacccactcgcagaggagattgcaatgcaccggctgttcttcga 
gapdhp(KR)-for gacggggcggccccggttcctcgaagaacagccggtgcattgcaatctcctctgcgagtg 
gapdhp(KR)-rev gttgaccacgaccgaccccacgcgtccggccccggtgccgcacgggccggtgaaccccgc 
811-for ccacatgaaccaacattcatgcggggttcaccggcccgtgcggcaccggggccggacgcg 
811-rev ggcgtcgaaaaccggcgtacctaacgaggagatcggttcatgaagatcgcgaaatgggtg 
gapdhp(SG)-for cttcgacgtgttcgcggaccacccatttcgcgatcttcatgaaccgatctcctcgttagg 
gapdhp(SG)-rev gcccgttcgtcccgccgcaccgacggagaggaagtcatgactcggcggcgagcgggggac 
812-for gctggaccacgcgggcgcgccgacgacgggcgccccggtgtcatgacttcctctccgtcg 
812-rev tgccggttggtaggacaccactcgcgagagaggcgtatccgtgagcggcgacaggacagg 
rpsLp(XC)-for gggcgcccccgggccgggtccctgtcctgtcgccgctcacggatacgcctctctcgcgag 
rpsLp(XC)-rev gctcgaccggtggtccgcacgggagagcgaggaagcgtgaggtaccagcccgacccgagc 
813-for gaccaggcgtgccggcgcgtgctcgggtcgggctggtacctcacgcttcctcgctctccc 
813-rev gccgatggcagccgaaacgaagtaaggaacctgcgcttctatggcggatgacgatgacgaccccac 
rpsLp(TP)-for gttccctgctggtccagtcggtggggtcgtcatccgccatagaagcgcaggttccttact 
rpsLp(TP)-rev gcgctccgtcctggggggagacgcggcccatggcggatgaaccgggtccgcgatcggcgg 
814-for gtggtcaaaagtgttcgcctccgccgatcgcggacccggttcatccgccatgggccgcgt 
814-1-rev ggcaaactcatcgacctcga 
814-2-for ctcgtcggtgatgtcgaggg 
814-rev aggttagtttcacgaacggcacacagaaaccggagaagtaatggccgacgcgaacaaccg 
rpsLp(SG)-for ccaccttgttccgtaacgcccggttgttcgcgtcggccattacttctccggtttctgtgt 
rpsLp(SG)-rev tgcaccacggcttgctccaccacgacttgaggagttcggcaggggcgcgcggccccggcc 
815-for ccccggacgggacggccggcggccggggccgcgcgcccctgccgaactcctcaagtcgtg 
815-rev gtgccggtcagaccagagaacaccgacagacggagacgtaatggacgagcgcgagcactc 
rpsLp(CF)-for aatatattccgccatcggcggagtgctcgcgctcgtccattacgtctccgtctgtcggtg 
rpsLp(CF)-rev tctctctctccccctcatcgccacttgtggagggtcacggcccgccgcgggcgctggagg 
8-for cggcccggggcccgcccgagcctccagcgcccgcggcgggcgtgaccctccacaagtggc 
8-rev gtaaggtgcccgtagacgcacgtccgaccgaaggagcagcggggggctcctcgattcgtt 
gapdhp(EL)-for cgtccggcagcacatcagcgaacgaatcgaggagccccccgctgctccttcggtcggacg 
gapdhp(EL)-rev cggggaactgggcgcgcaccgcgccgatgtcgtacgacaagcgtatcccctttcagatac 
816-for tcctgcaattcttagtgcgagtatctgaaaggggatacgcttgtcgtacgacatcggcgc 
816-rev caggtggcacttttcgcttcgtcatctgggccctggccgctcacccctgtcgcagccagt 
yeast-for cgaaaagtgccacctgggtc 
yeast-rev gtgagtttagtatacatgca 
E.coli-for aaaactgtattataagtaaatgcatgtatactaaactcatgtcatcacgatactgtgat 
E.coli-rev aatattgtgagtttagtatacatgca 
Streptomyces-
for 
acccattcaaaggccggcattttcagcgtgacatcattctgtgggccgtacgctggtact 
Streptomyces-
rev 
gtgcggggcccggcgctcaccgggccccgcaccgggggttcgcaatccagtgcaaagcta 
  
167 
 
Table 4.2 The primers used for the single-gene deletion constructs of S. griseus gene 
cluster. 
Construct Primer name Primer sequence (5’-3’) 
pYL-RC-SG-6-
gene-d810 
1-for gtagaaacagacgaagaagctagctttgcactggattgcggtgggtcctttcgggtcgac 
1-1-rev gatggttggcgatgccgttg 
1-1-for gaccttcgagcaggccaacc 
1-rev ccgggcggccaaccggggcaaggtactcgtcgaactctgagaccggtgcggggcccggcg 
811-for ccggtgcggggcccggtgagcgccgggccccgcaccggtctcagagttcgacgagtacct 
811-rev ggcgtcgaaaaccggcgtacctaacgaggagatcggttcatgaagatcgcgaaatgggtg 
gapdhp(SG)-for cttcgacgtgttcgcggaccacccatttcgcgatcttcatgaaccgatctcctcgttagg 
gapdhp(SG)-rev gcccgttcgtcccgccgcaccgacggagaggaagtcatgactcggcggcgagcgggggac 
812-for gctggaccacgcgggcgcgccgacgacgggcgccccggtgtcatgacttcctctccgtcg 
812-rev tgccggttggtaggacaccactcgcgagagaggcgtatccgtgagcggcgacaggacagg 
ermEp-for gggcgcccccgggccgggtccctgtcctgtcgccgctcacggatacgcctctctcgcgag 
ermEp-rev gctcgaccggtggtccgcacgggagagcgaggaagcgtgaggtaccagcccgacccgagc 
813-for gaccaggcgtgccggcgcgtgctcgggtcgggctggtacctcacgcttcctcgctctccc 
813-rev gccgatggcagccgaaacgaagtaaggaacctgcgcttctatggcggatgacgatgacgaccccac 
rpsLp(TP)-for gttccctgctggtccagtcggtggggtcgtcatccgccatagaagcgcaggttccttact 
rpsLp(TP)-rev gcgctccgtcctggggggagacgcggcccatggcggatgaaccgggtccgcgatcggcgg 
814-for gtggtcaaaagtgttcgcctccgccgatcgcggacccggttcatccgccatgggccgcgt 
814-1-rev ggcaaactcatcgacctcga 
814-2-for ctcgtcggtgatgtcgaggg 
814-rev aggttagtttcacgaacggcacacagaaaccggagaagtaatggccgacgcgaacaaccg 
rpsLp(SG)-for ccaccttgttccgtaacgcccggttgttcgcgtcggccattacttctccggtttctgtgt 
rpsLp(SG)-rev tgcaccacggcttgctccaccacgacttgaggagttcggcaggggcgcgcggccccggcc 
815-for ccccggacgggacggccggcggccggggccgcgcgcccctgccgaactcctcaagtcgtg 
815-rev gtgccggtcagaccagagaacaccgacagacggagacgtaatggacgagcgcgagcactc 
rpsLp(CF)-for aatatattccgccatcggcggagtgctcgcgctcgtccattacgtctccgtctgtcggtg 
rpsLp(CF)-rev tctctctctccccctcatcgccacttgtggagggtcacggcccgccgcgggcgctggagg 
8-for cggcccggggcccgcccgagcctccagcgcccgcggcgggcgtgaccctccacaagtggc 
8-rev ttatagcacgtgatgaaaaggacccaggtggcacttttcggggggctcctcgattcgtt 
9-for cggcacccttccctacgagt 
9-rev ttgaggagtgcctccaggtc 
10-for ggttcggacgaagacgcgtc 
10-rev ttatagcacgtgatgaaaaggacccaggtggcacttttcgcttcgtcatctgggccctgg 
yeast-for cgaaaagtgccacctgggtc 
yeast-rev gtgagtttagtatacatgca 
E.coli-for aaaactgtattataagtaaatgcatgtatactaaactcatgtcatcacgatactgtgat 
E.coli-rev aatattgtgagtttagtatacatgca 
Streptomyces-
for 
acccattcaaaggccggcattttcagcgtgacatcattctgtgggccgtacgctggtact 
Streptomyces-
rev 
ccgcgatactgcgacgagccgtcgacccgaaaggacccaccgcaatccagtgcaaagcta 
pYL-RC-SG-6-
gene-d811 
1-for gtagaaacagacgaagaagctagctttgcactggattgcggtgggtcctttcgggtcgac 
1-1-rev gatggttggcgatgccgttg 
1-1-for gaccttcgagcaggccaacc 
1-rev gacctcccgcagcccgcggcggctcggcgtcaggtggtaggaccggtgcggggcccggcg 
810-for ccggtgcggggcccggtgagcgccgggccccgcaccggtcctaccacctgacgccgagcc 
810-rev gccggagtgcaccgcacacccactcgcagaggagattgcaatgcaccggctgttcttcga 
gapdhp(KR)-for gacggggcggccccggttcctcgaagaacagccggtgcattgcaatctcctctgcgagtg 
gapdhp(KR)-rev gttgaccacgaccgaccccacgcgtccggccccggtgccgcacgggccggtgaaccccgc 
Gap-for ccacatgaaccaacattcatgcggggttcaccggcccgtgcggcaccggggccggacgcg 
Gap-rev gcccgttcgtcccgccgcaccgacggagaggaagtcatgaacgcgacccgccctccgttc 
812-for ctgggcagcaccgtcggatcgaacggagggcgggtcgcgttcatgacttcctctccgtcg 
812-rev tgccggttggtaggacaccactcgcgagagaggcgtatccgtgagcggcgacaggacagg 
ermEp-for gggcgcccccgggccgggtccctgtcctgtcgccgctcacggatacgcctctctcgcgag 
ermEp-rev gctcgaccggtggtccgcacgggagagcgaggaagcgtgaggtaccagcccgacccgagc 
813-for gaccaggcgtgccggcgcgtgctcgggtcgggctggtacctcacgcttcctcgctctccc 
813-rev gccgatggcagccgaaacgaagtaaggaacctgcgcttctatggcggatgacgatgacgaccccac 
rpsLp(TP)-for gttccctgctggtccagtcggtggggtcgtcatccgccatagaagcgcaggttccttact 
rpsLp(TP)-rev gcgctccgtcctggggggagacgcggcccatggcggatgaaccgggtccgcgatcggcgg 
814-for gtggtcaaaagtgttcgcctccgccgatcgcggacccggttcatccgccatgggccgcgt 
814-1-rev ggcaaactcatcgacctcga 
814-2-for ctcgtcggtgatgtcgaggg 
814-rev aggttagtttcacgaacggcacacagaaaccggagaagtaatggccgacgcgaacaaccg 
rpsLp(SG)-for ccaccttgttccgtaacgcccggttgttcgcgtcggccattacttctccggtttctgtgt 
rpsLp(SG)-rev tgcaccacggcttgctccaccacgacttgaggagttcggcaggggcgcgcggccccggcc 
815-for ccccggacgggacggccggcggccggggccgcgcgcccctgccgaactcctcaagtcgtg 
   
168 
 
Table 4.2 (Cont.) 
Construct Primer name Primer sequence 
pYL-RC-SG-6-
gene-d811 
815-rev gtgccggtcagaccagagaacaccgacagacggagacgtaatggacgagcgcgagcactc 
rpsLp(CF)-for aatatattccgccatcggcggagtgctcgcgctcgtccattacgtctccgtctgtcggtg 
rpsLp(CF)-rev tctctctctccccctcatcgccacttgtggagggtcacggcccgccgcgggcgctggagg 
8-for cggcccggggcccgcccgagcctccagcgcccgcggcgggcgtgaccctccacaagtggc 
8-rev ttatagcacgtgatgaaaaggacccaggtggcacttttcggggggctcctcgattcgtt 
9-for cggcacccttccctacgagt 
9-rev ttgaggagtgcctccaggtc 
10-for ggttcggacgaagacgcgtc 
10-rev ttatagcacgtgatgaaaaggacccaggtggcacttttcgcttcgtcatctgggccctgg 
yeast-for cgaaaagtgccacctgggtc 
yeast-rev gtgagtttagtatacatgca 
E.coli-for aaaactgtattataagtaaatgcatgtatactaaactcatgtcatcacgatactgtgat 
E.coli-rev aatattgtgagtttagtatacatgca 
Streptomyces-for acccattcaaaggccggcattttcagcgtgacatcattctgtgggccgtacgctggtact 
Streptomyces-
rev 
ccgcgatactgcgacgagccgtcgacccgaaaggacccaccgcaatccagtgcaaagcta 
pYL-RC-SG-6-
gene-d812 
1-for gtagaaacagacgaagaagctagctttgcactggattgcggtgggtcctttcgggtcgac 
1-1-rev gatggttggcgatgccgttg 
1-1-for gaccttcgagcaggccaacc 
1-rev gacctcccgcagcccgcggcggctcggcgtcaggtggtaggaccggtgcggggcccggcg 
810-for ccggtgcggggcccggtgagcgccgggccccgcaccggtcctaccacctgacgccgagcc 
810-rev gccggagtgcaccgcacacccactcgcagaggagattgcaatgcaccggctgttcttcga 
gapdhp(KR)-for gacggggcggccccggttcctcgaagaacagccggtgcattgcaatctcctctgcgagtg 
gapdhp(KR)-rev gttgaccacgaccgaccccacgcgtccggccccggtgccgcacgggccggtgaaccccgc 
811-for ccacatgaaccaacattcatgcggggttcaccggcccgtgcggcaccggggccggacgcg 
811-rev ggcgtcgaaaaccggcgtacctaacgaggagatcggttcatgaagatcgcgaaatgggtg 
gapdhp(SG)-for cttcgacgtgttcgcggaccacccatttcgcgatcttcatgaaccgatctcctcgttagg 
gapdhp(SG)-rev gctcgaccggtggtccgcacgggagagcgaggaagcgtgactcggcggcgagcgggggac 
813-for ccggcgggtgcgggaccaacgtcccccgctcgccgccgagtcacgcttcctcgctctccc 
813-rev gccgatggcagccgaaacgaagtaaggaacctgcgcttctatggcggatgacgatgacgaccccac 
rpsLp(TP)-for gttccctgctggtccagtcggtggggtcgtcatccgccatagaagcgcaggttccttact 
rpsLp(TP)-rev gcgctccgtcctggggggagacgcggcccatggcggatgaaccgggtccgcgatcggcgg 
814-for gtggtcaaaagtgttcgcctccgccgatcgcggacccggttcatccgccatgggccgcgt 
814-1-rev ggcaaactcatcgacctcga 
814-2-for ctcgtcggtgatgtcgaggg 
814-rev aggttagtttcacgaacggcacacagaaaccggagaagtaatggccgacgcgaacaaccg 
rpsLp(SG)-for ccaccttgttccgtaacgcccggttgttcgcgtcggccattacttctccggtttctgtgt 
rpsLp(SG)-rev tgcaccacggcttgctccaccacgacttgaggagttcggcaggggcgcgcggccccggcc 
815-for ccccggacgggacggccggcggccggggccgcgcgcccctgccgaactcctcaagtcgtg 
815-rev gtgccggtcagaccagagaacaccgacagacggagacgtaatggacgagcgcgagcactc 
rpsLp(CF)-for aatatattccgccatcggcggagtgctcgcgctcgtccattacgtctccgtctgtcggtg 
rpsLp(CF)-rev tctctctctccccctcatcgccacttgtggagggtcacggcccgccgcgggcgctggagg 
8-for cggcccggggcccgcccgagcctccagcgcccgcggcgggcgtgaccctccacaagtggc 
8-rev ttatagcacgtgatgaaaaggacccaggtggcacttttcggggggctcctcgattcgtt 
9-for cggcacccttccctacgagt 
9-rev ttgaggagtgcctccaggtc 
10-for ggttcggacgaagacgcgtc 
10-rev ttatagcacgtgatgaaaaggacccaggtggcacttttcgcttcgtcatctgggccctgg 
yeast-for cgaaaagtgccacctgggtc 
yeast-rev gtgagtttagtatacatgca 
E.coli-for aaaactgtattataagtaaatgcatgtatactaaactcatgtcatcacgatactgtgat 
E.coli-rev aatattgtgagtttagtatacatgca 
Streptomyces-for acccattcaaaggccggcattttcagcgtgacatcattctgtgggccgtacgctggtact 
Streptomyces-
rev 
ccgcgatactgcgacgagccgtcgacccgaaaggacccaccgcaatccagtgcaaagcta 
pYL-RC-SG-6-
gene-d813 
1-for gtagaaacagacgaagaagctagctttgcactggattgcggtgggtcctttcgggtcgac 
1-1-rev gatggttggcgatgccgttg 
1-1-for gaccttcgagcaggccaacc 
1-rev gacctcccgcagcccgcggcggctcggcgtcaggtggtaggaccggtgcggggcccggcg 
810-for ccggtgcggggcccggtgagcgccgggccccgcaccggtcctaccacctgacgccgagcc 
810-rev gccggagtgcaccgcacacccactcgcagaggagattgcaatgcaccggctgttcttcga 
gapdhp(KR)-for gacggggcggccccggttcctcgaagaacagccggtgcattgcaatctcctctgcgagtg 
gapdhp(KR)-rev gttgaccacgaccgaccccacgcgtccggccccggtgccgcacgggccggtgaaccccgc 
811-for ccacatgaaccaacattcatgcggggttcaccggcccgtgcggcaccggggccggacgcg 
811-rev ggcgtcgaaaaccggcgtacctaacgaggagatcggttcatgaagatcgcgaaatgggtg 
gapdhp(SG)-for cttcgacgtgttcgcggaccacccatttcgcgatcttcatgaaccgatctcctcgttagg 
gapdhp(SG)-rev gcccgttcgtcccgccgcaccgacggagaggaagtcatgactcggcggcgagcgggggac 
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Table 4.2 (Cont.) 
Construct Primer name Primer sequence 
pYL-RC-SG-6-
gene-d813 
812-for gctggaccacgcgggcgcgccgacgacgggcgccccggtgtcatgacttcctctccgtcg 
812-rev tgccggttggtaggacaccactcgcgagagaggcgtatccgtgagcggcgacaggacagg 
ermEp-for gggcgcccccgggccgggtccctgtcctgtcgccgctcacggatacgcctctctcgcgag 
ermEp-rev gcgctccgtcctggggggagacgcggcccatggcggatgaggtaccagcccgacccgagc 
814-for gaccaggcgtgccggcgcgtgctcgggtcgggctggtacctcatccgccatgggccgcgt 
814-1-rev ggcaaactcatcgacctcga 
814-2-for ctcgtcggtgatgtcgaggg 
814-rev aggttagtttcacgaacggcacacagaaaccggagaagtaatggccgacgcgaacaaccg 
rpsLp(SG)-for ccaccttgttccgtaacgcccggttgttcgcgtcggccattacttctccggtttctgtgt 
rpsLp(SG)-rev tgcaccacggcttgctccaccacgacttgaggagttcggcaggggcgcgcggccccggcc 
815-for ccccggacgggacggccggcggccggggccgcgcgcccctgccgaactcctcaagtcgtg 
815-rev gtgccggtcagaccagagaacaccgacagacggagacgtaatggacgagcgcgagcactc 
rpsLp(CF)-for aatatattccgccatcggcggagtgctcgcgctcgtccattacgtctccgtctgtcggtg 
rpsLp(CF)-rev tctctctctccccctcatcgccacttgtggagggtcacggcccgccgcgggcgctggagg 
8-for cggcccggggcccgcccgagcctccagcgcccgcggcgggcgtgaccctccacaagtggc 
8-rev ttatagcacgtgatgaaaaggacccaggtggcacttttcggggggctcctcgattcgtt 
9-for cggcacccttccctacgagt 
9-rev ttgaggagtgcctccaggtc 
10-for ggttcggacgaagacgcgtc 
10-rev ttatagcacgtgatgaaaaggacccaggtggcacttttcgcttcgtcatctgggccctgg 
yeast-for cgaaaagtgccacctgggtc 
yeast-rev gtgagtttagtatacatgca 
E.coli-for aaaactgtattataagtaaatgcatgtatactaaactcatgtcatcacgatactgtgat 
E.coli-rev aatattgtgagtttagtatacatgca 
Streptomyces-
for 
acccattcaaaggccggcattttcagcgtgacatcattctgtgggccgtacgctggtact 
Streptomyces-
rev 
ccgcgatactgcgacgagccgtcgacccgaaaggacccaccgcaatccagtgcaaagcta 
pYL-RC-SG-6-
gene-d814 
1-for gtagaaacagacgaagaagctagctttgcactggattgcggtgggtcctttcgggtcgac 
1-1-rev gatggttggcgatgccgttg 
1-1-for gaccttcgagcaggccaacc 
1-rev gacctcccgcagcccgcggcggctcggcgtcaggtggtaggaccggtgcggggcccggcg 
810-for ccggtgcggggcccggtgagcgccgggccccgcaccggtcctaccacctgacgccgagcc 
810-rev gccggagtgcaccgcacacccactcgcagaggagattgcaatgcaccggctgttcttcga 
gapdhp(KR)-for gacggggcggccccggttcctcgaagaacagccggtgcattgcaatctcctctgcgagtg 
gapdhp(KR)-rev gttgaccacgaccgaccccacgcgtccggccccggtgccgcacgggccggtgaaccccgc 
811-for ccacatgaaccaacattcatgcggggttcaccggcccgtgcggcaccggggccggacgcg 
811-rev ggcgtcgaaaaccggcgtacctaacgaggagatcggttcatgaagatcgcgaaatgggtg 
gapdhp(SG)-for cttcgacgtgttcgcggaccacccatttcgcgatcttcatgaaccgatctcctcgttagg 
gapdhp(SG)-rev gcccgttcgtcccgccgcaccgacggagaggaagtcatgactcggcggcgagcgggggac 
812-for gctggaccacgcgggcgcgccgacgacgggcgccccggtgtcatgacttcctctccgtcg 
812-rev tgccggttggtaggacaccactcgcgagagaggcgtatccgtgagcggcgacaggacagg 
ermEp-for gggcgcccccgggccgggtccctgtcctgtcgccgctcacggatacgcctctctcgcgag 
ermEp-rev gctcgaccggtggtccgcacgggagagcgaggaagcgtgaggtaccagcccgacccgagc 
813-for gaccaggcgtgccggcgcgtgctcgggtcgggctggtacctcacgcttcctcgctctccc 
813-rev gccgatggcagccgaaacgaagtaaggaacctgcgcttctatggcggatgacgatgacgaccccac 
rpsLp(TP)-for gttccctgctggtccagtcggtggggtcgtcatccgccatagaagcgcaggttccttact 
rpsLp(TP)-rev tgcaccacggcttgctccaccacgacttgaggagttcggcaccgggtccgcgatcggcgg 
Gap-for gtggtcaaaagtgttcgcctccgccgatcgcggacccggtgccgaactcctcaagtcgtg 
Gap-rev ctggcgacgccgaccggcgccgggccccgcgccggagtgagcaccccctccggagctccg 
815-for ccccggacgggacggccggcggccggggccgcgcgcccctgccgaactcctcaagtcgtg 
815-rev gtgccggtcagaccagagaacaccgacagacggagacgtaatggacgagcgcgagcactc 
rpsLp(CF)-for aatatattccgccatcggcggagtgctcgcgctcgtccattacgtctccgtctgtcggtg 
rpsLp(CF)-rev tctctctctccccctcatcgccacttgtggagggtcacggcccgccgcgggcgctggagg 
8-for cggcccggggcccgcccgagcctccagcgcccgcggcgggcgtgaccctccacaagtggc 
8-rev ttatagcacgtgatgaaaaggacccaggtggcacttttcggggggctcctcgattcgtt 
9-for cggcacccttccctacgagt 
9-rev ttgaggagtgcctccaggtc 
10-for ggttcggacgaagacgcgtc 
10-rev ttatagcacgtgatgaaaaggacccaggtggcacttttcgcttcgtcatctgggccctgg 
yeast-for cgaaaagtgccacctgggtc 
yeast-rev gtgagtttagtatacatgca 
E.coli-for aaaactgtattataagtaaatgcatgtatactaaactcatgtcatcacgatactgtgat 
E.coli-rev aatattgtgagtttagtatacatgca 
Streptomyces-
for 
acccattcaaaggccggcattttcagcgtgacatcattctgtgggccgtacgctggtact 
Streptomyces-
rev 
ccgcgatactgcgacgagccgtcgacccgaaaggacccaccgcaatccagtgcaaagcta 
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Table 4.2 (Cont.) 
Construct Primer name Primer sequence 
pYL-RC-SG-6-
gene-d815 
1-for gtagaaacagacgaagaagctagctttgcactggattgcggtgggtcctttcgggtcgac 
1-1-rev gatggttggcgatgccgttg 
1-1-for gaccttcgagcaggccaacc 
1-rev gacctcccgcagcccgcggcggctcggcgtcaggtggtaggaccggtgcggggcccggcg 
810-for ccggtgcggggcccggtgagcgccgggccccgcaccggtcctaccacctgacgccgagcc 
810-rev gccggagtgcaccgcacacccactcgcagaggagattgcaatgcaccggctgttcttcga 
gapdhp(KR)-for gacggggcggccccggttcctcgaagaacagccggtgcattgcaatctcctctgcgagtg 
gapdhp(KR)-rev gttgaccacgaccgaccccacgcgtccggccccggtgccgcacgggccggtgaaccccgc 
811-for ccacatgaaccaacattcatgcggggttcaccggcccgtgcggcaccggggccggacgcg 
811-rev ggcgtcgaaaaccggcgtacctaacgaggagatcggttcatgaagatcgcgaaatgggtg 
gapdhp(SG)-for cttcgacgtgttcgcggaccacccatttcgcgatcttcatgaaccgatctcctcgttagg 
gapdhp(SG)-rev gcccgttcgtcccgccgcaccgacggagaggaagtcatgactcggcggcgagcgggggac 
812-for gctggaccacgcgggcgcgccgacgacgggcgccccggtgtcatgacttcctctccgtcg 
812-rev tgccggttggtaggacaccactcgcgagagaggcgtatccgtgagcggcgacaggacagg 
ermEp-for gggcgcccccgggccgggtccctgtcctgtcgccgctcacggatacgcctctctcgcgag 
ermEp-rev gctcgaccggtggtccgcacgggagagcgaggaagcgtgaggtaccagcccgacccgagc 
813-for gaccaggcgtgccggcgcgtgctcgggtcgggctggtacctcacgcttcctcgctctccc 
813-rev gccgatggcagccgaaacgaagtaaggaacctgcgcttctatggcggatgacgatgacgaccccac 
rpsLp(TP)-for gttccctgctggtccagtcggtggggtcgtcatccgccatagaagcgcaggttccttact 
rpsLp(TP)-rev gcgctccgtcctggggggagacgcggcccatggcggatgaaccgggtccgcgatcggcgg 
814-for gtggtcaaaagtgttcgcctccgccgatcgcggacccggttcatccgccatgggccgcgt 
814-1-rev ggcaaactcatcgacctcga 
814-2-for ctcgtcggtgatgtcgaggg 
814-rev aggttagtttcacgaacggcacacagaaaccggagaagtaatggccgacgcgaacaaccg 
rpsLp(SG)-for ccaccttgttccgtaacgcccggttgttcgcgtcggccattacttctccggtttctgtgt 
rpsLp(SG)-rev tgcaccacggcttgctccaccacgacttgaggagttcggcaggggcgcgcggccccggcc 
8-for ccccggacgggacggccggcggccggggccgcgcgcccctgccgaactcctcaagtcgtg 
8-rev gtctctctctccccctcatcgccacttgtggagggtcacggcaccccctccggagctccg 
9-for cgtgctggagggggccgtgacggagctccggagggggtgccgtgaccctccacaagtggc 
9-rev ttgaggagtgcctccaggtc 
10-for ggttcggacgaagacgcgtc 
10-rev ttatagcacgtgatgaaaaggacccaggtggcacttttcgcttcgtcatctgggccctgg 
yeast-for cgaaaagtgccacctgggtc 
yeast-rev gtgagtttagtatacatgca 
E.coli-for aaaactgtattataagtaaatgcatgtatactaaactcatgtcatcacgatactgtgat 
E.coli-rev aatattgtgagtttagtatacatgca 
Streptomyces-
for 
acccattcaaaggccggcattttcagcgtgacatcattctgtgggccgtacgctggtact 
Streptomyces-
rev 
ccgcgatactgcgacgagccgtcgacccgaaaggacccaccgcaatccagtgcaaagcta 
  
171 
 
Table 4.3 NMR characterization of compounds c and d in CD3OD. 1H NMR-δ (ppm) 
600 MHz; multiplicities; and 13C NMR-δ (ppm) 145MHz, acquired with gHSQC, 
gHMBC and 13C NMR. m: multiplet; d: doublet ; dd: doublet of doublets. Note: the 
numbers are shown in the structures below. 
Number Compound c Compound d 
 1H (ppm) 13C (ppm) 1H (ppm) 13C (ppm) 
1  167.2 169.3 
2 5.78 (d, 15.0) 122.2 6.03 (d, 14.7) 118.7 
3 6.91 (dd, 15.1, 11.3) 140.5 7.07 (m) 142.1 
4 6.08 (dd, 15.1, 11.1) 128.8 6.42 (m) 134.1 
5 5.65 (dd, 14.9, 9.5) 125.1 5.54 (m) 142.6 
6 2.55 (m) 52.9 2.62 (m) 48.4 
7a 1.23 (m) 43.3 1.89 (m) 39.8 
7b 1.92 (m) 
8 2.43 (m) 41.5 2.29 (m) 40.8 
9a 0.93 (m) 35.2 2.17 (m) 38.8 
9b 1.96 (m) 1.24 (m)
10 1.58 (m) 55.8 1.27 (m) 54.9 
11 1.33 (m) 47.3 1.52 (m) 47.9 
12 2.11 (m) 57.7 2.13 (m) 53.6 
13 1.57 (m) 55.8 2.71 (m) 41.6 
14 3.91 (m) 77.3 5.79 (m) 130.4 
15 5.93 (dd, 15.4, 8.4) 147.5 5.51 (m) 126.1 
16 6.21 (dd, 15.5, 10.8) 131.6 2.84 (m) 41.0 
17 7.33 (dd, 15.6, 10.8) 143.4 7.27 (m) 145.0 
18 7.01 (d, 15.4) 121.7 7.10 (m) 123.7 
19  175.7 174.6 
20  102.5 100.9 
21  176.1 176.3 
22  
23 3.82 (dd, 6.5, 1.7) 61.4 4.03 (m) 61.4 
24  196.6 197.0 
25a 2.07 (m) 26.0 1.82 (m) 27.4 
25b 1.83 (m) 1.19 (m)
26a 1.07 (m) 21.2 1.61 (m) 27.0 
26b 1.48 (m) 1.06 (m)
27a 3.66 (m) 38.6 3.24 (m) 43.1 
27b 2.54 (m) 3.04 (m)
28  
29a 1.62 (m) 25.9 1.60 (m) 27.0 
29b 1.10 (m) 1.19 (m)
30 0.89 (m) 11.6 0.90 (m) 13.1 
31 1.04 (m) 16.8 0.94 (m) 19.9 
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Table 4.4 The primers used for the multiple-gene deletion constructs of S. griseus 
gene cluster SGR 810-815. 
Construct Primer name Primer sequence (5’-3’) 
pYL-RC-SGR814 814-for gtagaaacagacgaagaagctagctttgcactggattgcgtcatccgccatgggccgcgt 
814-1-rev ggcaaactcatcgacctcga 
814-2-for ctcgtcggtgatgtcgaggg 
814-rev tcctgcaattcttagtgcgagtatctgaaaggggatacgcatggccgacgcgaacaaccg 
gapdhp(EL)-for ccaccttgttccgtaacgcccggttgttcgcgtcggccatgcgtatcccctttcagatac 
gapdhp(EL)-rev ttatagcacgtgatgaaaaggacccaggtggcacttttcggctgctccttcggtcggacg 
yeast-for cgaaaagtgccacctgggtc 
yeast-rev gtgagtttagtatacatgca 
E.coli-for aaaactgtattataagtaaatgcatgtatactaaactcatgtcatcacgatactgtgat 
E.coli-rev aatattgtgagtttagtatacatgca 
Streptomyces-
for 
acccattcaaaggccggcattttcagcgtgacatcattctgtgggccgtacgctggtact 
Streptomyces-
rev 
gcgctccgtcctggggggagacgcggcccatggcggatgacgcaatccagtgcaaagcta 
pYL-RC-SGR812-
814 
812-for gtagaaacagacgaagaagctagctttgcactggattgcgtcatgacttcctctccgtcg 
812-rev tgccggttggtaggacaccactcgcgagagaggcgtatccgtgagcggcgacaggacagg 
ermEp-for gggcgcccccgggccgggtccctgtcctgtcgccgctcacggatacgcctctctcgcgag 
ermEp-rev gctcgaccggtggtccgcacgggagagcgaggaagcgtgaggtaccagcccgacccgagc 
813-for gaccaggcgtgccggcgcgtgctcgggtcgggctggtacctcacgcttcctcgctctccc 
813-rev gccgatggcagccgaaacgaagtaaggaacctgcgcttctatggcggatgacgatgacgaccccac 
rpsLp(TP)-for gttccctgctggtccagtcggtggggtcgtcatccgccatagaagcgcaggttccttact 
rpsLp(TP)-rev gcgctccgtcctggggggagacgcggcccatggcggatgaaccgggtccgcgatcggcgg 
814-for gtggtcaaaagtgttcgcctccgccgatcgcggacccggttcatccgccatgggccgcgt 
814-1-rev ggcaaactcatcgacctcga 
814-2-for ctcgtcggtgatgtcgaggg 
814-rev gtgccggtcagaccagagaacaccgacagacggagacgta atggccgacgcgaacaaccg 
rpsLp(CF)-for ccaccttgttccgtaacgcccggttgttcgcgtcggccattacgtctccgtctgtcggtg 
rpsLp(CF)-rev tctctctctccccctcatcgccacttgtggagggtcacggcccgccgcgggcgctggagg 
yeast-for cgaaaagtgccacctgggtc 
yeast-rev gtgagtttagtatacatgca 
E.coli-for aaaactgtattataagtaaatgcatgtatactaaactcatgtcatcacgatactgtgat 
E.coli-rev aatattgtgagtttagtatacatgca 
Streptomyces-
for 
acccattcaaaggccggcattttcagcgtgacatcattctgtgggccgtacgctggtact 
Streptomyces-
rev 
gcccgttcgtcccgccgcaccgacggagaggaagtcatgacgcaatccagtgcaaagcta 
pYL-RC-SGR812-
815 
812-for gtagaaacagacgaagaagctagctttgcactggattgcgtcatgacttcctctccgtcg 
812-rev tgccggttggtaggacaccactcgcgagagaggcgtatccgtgagcggcgacaggacagg 
ermEp-for gggcgcccccgggccgggtccctgtcctgtcgccgctcacggatacgcctctctcgcgag 
ermEp-rev gctcgaccggtggtccgcacgggagagcgaggaagcgtgaggtaccagcccgacccgagc 
813-for gaccaggcgtgccggcgcgtgctcgggtcgggctggtacctcacgcttcctcgctctccc 
813-rev gccgatggcagccgaaacgaagtaaggaacctgcgcttctatggcggatgacgatgacgaccccac 
rpsLp(TP)-for gttccctgctggtccagtcggtggggtcgtcatccgccatagaagcgcaggttccttact 
rpsLp(TP)-rev gcgctccgtcctggggggagacgcggcccatggcggatgaaccgggtccgcgatcggcgg 
814-for gtggtcaaaagtgttcgcctccgccgatcgcggacccggttcatccgccatgggccgcgt 
814-1-rev ggcaaactcatcgacctcga 
814-2-for ctcgtcggtgatgtcgaggg 
814-rev aggttagtttcacgaacggcacacagaaaccggagaagtaatggccgacgcgaacaaccg 
rpsLp(SG)-for ccaccttgttccgtaacgcccggttgttcgcgtcggccattacttctccggtttctgtgt 
rpsLp(SG)-rev tgcaccacggcttgctccaccacgacttgaggagttcggcaggggcgcgcggccccggcc 
815-for ccccggacgggacggccggcggccggggccgcgcgcccctgccgaactcctcaagtcgtg 
815-rev gtgccggtcagaccagagaacaccgacagacggagacgtaatggacgagcgcgagcactc 
rpsLp(CF)-for aatatattccgccatcggcggagtgctcgcgctcgtccattacgtctccgtctgtcggtg 
rpsLp(CF)-rev tctctctctccccctcatcgccacttgtggagggtcacggcccgccgcgggcgctggagg 
yeast-for cgaaaagtgccacctgggtc 
yeast-rev gtgagtttagtatacatgca 
E.coli-for aaaactgtattataagtaaatgcatgtatactaaactcatgtcatcacgatactgtgat 
E.coli-rev aatattgtgagtttagtatacatgca 
Streptomyces-
for 
acccattcaaaggccggcattttcagcgtgacatcattctgtgggccgtacgctggtact 
Streptomyces-
rev 
gcccgttcgtcccgccgcaccgacggagaggaagtcatgacgcaatccagtgcaaagcta 
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Table 4.4 (Cont.) 
Construct Primer name Primer sequence (5’-3’) 
pYL-RC-
SGR810+812-
814 
810-for gtagaaacagacgaagaagctagctttgcactggattgcgctaccacctgacgccgagcc 
810-rev gccggagtgcaccgcacacccactcgcagaggagattgcaatgcaccggctgttcttcga 
gapdhp(KR)-
for 
gacggggcggccccggttcctcgaagaacagccggtgcattgcaatctcctctgcgagtg 
gapdhp(KR)-
rev 
gttgaccacgaccgaccccacgcgtccggccccggtgccgcacgggccggtgaaccccgc 
Gap-for ccacatgaaccaacattcatgcggggttcaccggcccgtgcggcaccggggccggacgcg 
Gap-rev gcccgttcgtcccgccgcaccgacggagaggaagtcatgaacgcgacccgccctccgttc 
812-for gtagaaacagacgaagaagctagctttgcactggattgcgtcatgacttcctctccgtcg 
812-rev tgccggttggtaggacaccactcgcgagagaggcgtatccgtgagcggcgacaggacagg 
ermEp-for gggcgcccccgggccgggtccctgtcctgtcgccgctcacggatacgcctctctcgcgag 
ermEp-rev gctcgaccggtggtccgcacgggagagcgaggaagcgtgaggtaccagcccgacccgagc 
813-for gaccaggcgtgccggcgcgtgctcgggtcgggctggtacctcacgcttcctcgctctccc 
813-rev gccgatggcagccgaaacgaagtaaggaacctgcgcttctatggcggatgacgatgacgaccccac 
rpsLp(TP)-for gttccctgctggtccagtcggtggggtcgtcatccgccatagaagcgcaggttccttact 
rpsLp(TP)-rev gcgctccgtcctggggggagacgcggcccatggcggatgaaccgggtccgcgatcggcgg 
814-for gtggtcaaaagtgttcgcctccgccgatcgcggacccggttcatccgccatgggccgcgt 
814-1-rev ggcaaactcatcgacctcga 
814-2-for ctcgtcggtgatgtcgaggg 
814-rev gtgccggtcagaccagagaacaccgacagacggagacgta atggccgacgcgaacaaccg 
rpsLp(CF)-for ccaccttgttccgtaacgcccggttgttcgcgtcggccattacgtctccgtctgtcggtg 
rpsLp(CF)-rev tctctctctccccctcatcgccacttgtggagggtcacggcccgccgcgggcgctggagg 
yeast-for cgaaaagtgccacctgggtc 
yeast-rev gtgagtttagtatacatgca 
E.coli-for aaaactgtattataagtaaatgcatgtatactaaactcatgtcatcacgatactgtgat 
E.coli-rev aatattgtgagtttagtatacatgca 
Streptomyces-
for 
acccattcaaaggccggcattttcagcgtgacatcattctgtgggccgtacgctggtact 
Streptomyces-
rev 
gacctcccgcagcccgcggcggctcggcgtcaggtggtagcgcaatccagtgcaaagcta 
pYL-RC-
SGR811-814 
811-for gtagaaacagacgaagaagctagctttgcactggattgcgtcagagttcgacgagtacct 
811-rev ggcgtcgaaaaccggcgtacctaacgaggagatcggttcatgaagatcgcgaaatgggtg 
gapdhp(SG)-
for 
cttcgacgtgttcgcggaccacccatttcgcgatcttcatgaaccgatctcctcgttagg 
gapdhp(SG)-
rev 
gcccgttcgtcccgccgcaccgacggagaggaagtcatgactcggcggcgagcgggggac 
812-for gctggaccacgcgggcgcgccgacgacgggcgccccggtgtcatgacttcctctccgtcg 
812-rev tgccggttggtaggacaccactcgcgagagaggcgtatccgtgagcggcgacaggacagg 
ermEp-for gggcgcccccgggccgggtccctgtcctgtcgccgctcacggatacgcctctctcgcgag 
ermEp-rev gctcgaccggtggtccgcacgggagagcgaggaagcgtgaggtaccagcccgacccgagc 
813-for gaccaggcgtgccggcgcgtgctcgggtcgggctggtacctcacgcttcctcgctctccc 
813-rev gccgatggcagccgaaacgaagtaaggaacctgcgcttctatggcggatgacgatgacgaccccac 
rpsLp(TP)-for gttccctgctggtccagtcggtggggtcgtcatccgccatagaagcgcaggttccttact 
rpsLp(TP)-rev gcgctccgtcctggggggagacgcggcccatggcggatgaaccgggtccgcgatcggcgg 
814-for gtggtcaaaagtgttcgcctccgccgatcgcggacccggttcatccgccatgggccgcgt 
814-1-rev ggcaaactcatcgacctcga 
814-2-for ctcgtcggtgatgtcgaggg 
814-rev gtgccggtcagaccagagaacaccgacagacggagacgta atggccgacgcgaacaaccg 
rpsLp(CF)-for ccaccttgttccgtaacgcccggttgttcgcgtcggccattacgtctccgtctgtcggtg 
rpsLp(CF)-rev tctctctctccccctcatcgccacttgtggagggtcacggcccgccgcgggcgctggagg 
yeast-for cgaaaagtgccacctgggtc 
yeast-rev gtgagtttagtatacatgca 
E.coli-for aaaactgtattataagtaaatgcatgtatactaaactcatgtcatcacgatactgtgat 
E.coli-rev aatattgtgagtttagtatacatgca 
Streptomyces-
for 
acccattcaaaggccggcattttcagcgtgacatcattctgtgggccgtacgctggtact 
Streptomyces-
rev 
ccgggcggccaaccggggcaaggtactcgtcgaactctgacgcaatccagtgcaaagcta 
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Table 4.5 NMR characterization of compound e in CD3OH. 1H NMR-δ (ppm) 600 
MHz; multiplicities; and 13C NMR-δ (ppm) 145MHz, acquired with gHSQC, gHMBC 
and 13C NMR. m: multiplet; d: doublet ; dd: doublet of doublets. Note: the numbers 
are shown in the structures below. 
Number Compound e 
 1H (ppm) 13C (ppm) 
1 176.07
2 3.90 45.28
3 5.43 124.41
4 5.53 137.01
5 2.92 44.9
6 1.86 58.39
7a 1.95 35.09
7b 0.93
8 2.77 49.03
9a 2.09 35.09
9b 0.95
10 1.33 46.61
11 1.24 46.43
12 1.68 52.69
13 1.82 63.88
14 3.66 80.81
15 3.17 58.15
16 5.74 136.75
17 5.64 124.76
18 3.91 45.28
19 179.26
20 101.3
21 176.3
22 
23 3.83 61.49
24 197.17
25a 2.02 25.87
25b 1.83
26a 1.47 20.46
26b 1.25
27a 3.40 38.49
27b 2.56
28 
29a 1.62 25.87
29b 1.07
30 0.89 11.49
31 1.01 17.04
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Chapter 5 Discovery and Characterization of Strong 
Promoters from Actinomycetes  
5.1 Introduction 
The secondary metabolites produced by living organisms found in nature are 
known as natural products. The natural products produced by actinomycetes serve as 
excellent starting scaffolds for the development of antibiotics, anticancer agents, 
immunomodulators, anthelminthic agents, and insect control agents (1,2). However, 
natural product discovery from actinomycetes has been on the decline in recent years, 
due to the lack of innovative ways to discover new compounds and the high 
rediscovery rate of the known compounds. Recent advances in whole genome 
sequencing techniques have revised our view of the metabolic capabilities of 
actinomycetes as they encode multiple unknown secondary metabolite pathways with 
the great potential for generating novel natural products. However, most of these 
pathways remain silent under standard laboratory culturing conditions, thus they are 
named cryptic pathways. This makes the discovery and economical production of 
these potential natural products difficult as we are hampered in manipulating most 
organisms, determining suitable conditions to elicit pathway expression, and 
producing sufficient compounds for structure identification.  
.  One possible solution for novel natural product discovery is to target the 
expression of these cryptic pathways. Rationally designed and well-characterized 
controlling elements are invaluable tools for activating cryptic pathways as the fine-
tuning of gene expression could be reached. Promoters are the key regulators of gene 
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expression (3). Secondary metabolite production typically occurs during the early 
stationary phase (4) and is affected by a variety of physiological and environmental 
factors conducted through dozens of pleiotropic regulatory genes and pathway-
specific regulators (5-8). Currently, our understanding of the regulation hierarchy is 
insufficient to accurately predict the functions of all the regulatory elements. Hence, it 
is highly desirable to develop generally applicable approaches that reduce regulation 
complexity and achieve transcriptional fine-tuning for optimal gene expression.  
In Chapter 3 we have developed such plug-and-play platform to decouple 
pathway expression from native sophisticated regulation cascades, thus addressing the 
expression issue of cryptic pathways. In this strategy, we first identify novel pathways 
by bioinformatics and then refactor the target pathways in well-characterized hosts 
with known secondary metabolites. In the scaffold, the promoter modules, which 
serve as the most important part to drive the expression of the target genes are set up 
based on the choice of the expression host.  Promoters can be chosen from the well-
studied ones reported in literature or cloned from the potential promoter regions of 
endogenous housekeeping genes in the target expression host or other organisms 
closely related to the target expression host. Native promoters, both constitutive and 
inducible, have long been used in gene expression studies and strain engineering. 
However, very few native constitutive or inducible promoters have been characterized 
in actinomycetes, including the constitutive ermE promoter (9) and the inducible tipA 
(10) and tcp (11) promoters. Later, a stronger variant called ermE*p was reported 
with a TGG deletion in the -35 region of the ermEp promoter (12). To make this 
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scaffold generally applicable for cryptic pathway activation in actinomycetes, a 
quantitatively characterized library of promoters is required to express target gene 
clusters.  
Since Streptomycetes are prolific sources of bioactive compounds, many of 
which exhibit important medical properties (13,14), we chose to clone and 
characterize a panel of constitutive promoters from Streptomycetes for applications in 
the plug-and-play scaffold. Our strategy is to identify a set of strong promoters under 
the selected conditions based on the RNA-seq data and characterize them at both 
transcriptional level and translational level.  To this end, we selected Streptomyces 
albus, whose genome sequence is available, as the host for initial promoter screening.  
Using RNA-seq, 32 genes stood out with much higher transcription levels than all the 
other genes in our target culturing conditions, indicating that their corresponding 
promoters could be very strong.  These 32 candidate promoters were subsequently 
cloned upstream of the Streptomycete reporter gene, xylE, encoding catechol 2, 3-
dioxygenase. The xylE activity assay (15) coupled with the qPCR reaction further 
confirmed that 10 out of the 32 promoters showed much stronger activities than the 
control promoters in S. albus. 
Therefore, we have successfully cloned and characterized 32 constitutive 
promoters from the S. albus genome under the culture conditions that are routinely 
used in the laboratory for production of value added compounds in Streptomyces. The 
comparison of their strengths at both transcriptional and translational level 
distinguished 10 strong promoters from this library. The availability of these 
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promoters has greatly enabled the use of our recently developed plug-and-play system 
(16,17) for cryptic pathway activation and pathway engineering in Streptomyces. 
5.2  Results and discussion 
5.2.1 Host selection 
Heterologous expression of a target cryptic gene cluster has been commonly used 
in natural product discovery, as it could address the tedious de-replication process. 
Several laboratory and industrial production strains have been developed for 
heterologous production of secondary metabolites. To identify products from cryptic 
gene clusters of actinomycetes via the plug-and-play system we developed, it will be 
important to select a suitable actinomycete host for high-level heterologous 
expression of specific types of secondary metabolites, and to facilitate rapid 
identification and testing of novel products.  Molecular engineering, combinatorial 
biosynthesis, and gene cluster expression studies have identified a number of potential 
actinomycete hosts that are widely used in the laboratory, such as Streptomyces 
coelicolor, Streptomyces lividans, and Streptomyces albus J1074 (18). These hosts 
have already proven to be valuable for heterologous expression of cryptic biosynthetic 
gene clusters for novel natural products and combinatorial biosynthesis to produce 
novel derivatives of pharmacologically active secondary metabolites.  
S. coelicolor and S. lividans are two very closely related laboratory strains that 
have been used extensively in the development of streptomycete genetic tools (4). S. 
albus J1074 is a mutant strain from S. albus G defective in SalI restriction and 
modification (19). S. albus J1074 was first used as a cloning host by the Salas group 
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(20,21) to express the steffimycin biosynthetic genes, and obtained a yield of purified 
compounds of about 10 mg/L (22,23). Later, the genome of S. albus J1074 was 
sequenced at the Broad Institute, and is available at the National Center for 
Biotechnology Information (NCBI) website (http://www.ncbi.nlm.nih.gov/). S. albus 
J1074 has been used for the expression of several other secondary metabolite gene 
clusters and in some cases it can lead to a better yield than S. coelicolor and S. 
lividans. 
For example, the fredericamycin biosynthetic gene cluster was heterologously 
expressed in S. albus J1074 from both high copy number (24) and single copy number 
φC31-integrating vectors (25), yielding 120 and 132 mg/L products, respectively. In 
contrast, no product was detected in S. lividans after the fredericamycin pathway was 
inserted into the φC31 attB site (25). Only after the fdmR1 gene encoding a positive 
regulatory protein belonging to the Streptomyces antibiotic regulatory protein (SARP) 
family (7,26,27) was added to the strain on a multicopy plasmid, a small amount of 
product (0.5 mg/L) could be detected. The yield was further enhanced to 17 mg/L 
when the fdmR1 and fdmC genes were expressed driven by the ermEp* promoter. 
However, this is still only 13% of the yield obtained by expressing the fredericamycin 
gene cluster from its native promoters in S. albus J1074.  
Another comprehensive comparison among different Streptomyces hosts was the 
cloning and expression of the complete biosynthetic gene cluster for isomigrastatin 
from Streptomyces platensis NRRL18993 into pStreptoBac V (28). In this study, the 
isomigrastatin gene cluster was integrated into the φC31 attB site in S. albus, S. 
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lividans, S. coelicolor, and S. avermitilis. The results showed that the parental strain 
produced 58 mg/L target product, whereas the S. albus J1074 recombinant strain 
produced 46 mg/L. S. lividans K4-114 and S. coelicolor M512 produced about two-
fold lower yields, and S. avermitilis SUKA5 produced a ten-fold lower yield.  
Another interesting application of S. albus J1074 was the expression of the 
thiocoraline pathway cloned from a marine Micromonospora strain (29). In this study, 
the thiocoraline pathway was expressed in S. albus after the tioA positive regulatory 
gene encoding an OmpR-family regulator was transcribed from the ermEp* promoter. 
This demonstrated that a non-streptomycete actinomycete secondary metabolite gene 
cluster can be expressed in S. albus J1074. Taken together, we decided to choose S. 
albus J1074 as the heterologous host for our plug-and-play platform. The strong 
constitutive promoters from this strain will be screened and characterized for 
heterologous expression of cryptic secondary metabolite pathways from 
streptomycete and non-streptomycete actinomycetes not amenable to standard 
molecular genetics and fermentation manipulations. 
5.2.2 Screening for strong promoters via RNA-seq 
Seed cultures of the S. albus J1074 were grown for 48 hours and 0.5 mL was used 
to inoculate 25 mL of main cultures in both MYG and R2YE medium. After 24 hours 
and 72 hours of cultivation at 30Ԩ in shaking flasks, 1 mL of culture was pelleted and 
the total RNA was isolated. The quality of the total RNA was determined by 
Bioanalyzer using RNA chips. The RNA integrity number (RIN) numbers of the 
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samples were summarized in Table 5.1 and the Bioanalyzer trace of total RNA of all 
the samples were shown in Figure 5.1.  
The qualified samples were sent on dry ice to Roy J. Carver Biotechnology 
Center (UIUC, Illinois) for removal of ribosomal RNA and whole transcriptome 
shotgun sequencing (RNA-Seq). Briefly, the mRNA fragments were reverse-
transcribed into cDNA and subjected to Illumina sequencing. The processing of RNA-
Seq reads was submitted to High-Performance Biological Computing Center 
(HPCBio) (University of Illinois, Urbana) for analysis. 
The results obtained after analysis (Figure 5.2 and 5.3) showed that for all eight 
samples, one SA-MYG-72-hour sample may be contaminated by genomic DNA as 
the reads mapped evenly between “within a gene” and “not within a gene,” while the 
other 7 total RNA samples are in good quality. The comparison between the 
biological duplicates of each sample showed little variations. Therefore, the single 
SA-MYG-72-hour sample could be used as well. The expression levels of all 5937 
genes were sorted based on the two culture conditions and time points chosen. The 
number of highly expressed genes was counted on different cut-offs (Figure 5.4).  
Finally, we decided to characterize the promoters that drove the expression of the 1% 
highly expressed genes (28 genes) based on all four criteria (two time points under 
two culturing conditions).  
5.2.3 Cloning of the constitutive promoters 
Among all 28 highly expressed genes, some did not have a promoter directly in 
front of the selected gene and some genes even contained overlap regions with the 
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adjacent genes. Therefore, to ensure the success rate of strong promoter identification, 
we extended the selection to 32 promoter regions. The promoter region of the 32 
highly expressed genes were PCR amplified and further spliced with the amplified 
xylE gene, and inserted into a Yeast-E. coli-Streptomyces shuttle vector based on the 
DNA assembler method (Figure 5.5). The assembled constructs were purified from E. 
coli and submitted for sequencing to confirm the sequence of the promoter region 
cloned. As a result, for all the promoter-xylE constructs built, an efficiency of 80-100% 
has been achieved.   
The verified clones were transformed to E. coli WM6026 (30) and these 
transformants were then used as the donors for conjugative transfer of the assembled 
plasmids to S. albus J1074 following the protocol described elsewhere (30). Initially, 
two single colonies from different ex-conjugants were inoculated into 2 mL of MYG 
liquid medium, and 1 mL of this seed culture was transferred to 50 mL fresh MYG 
medium and incubated at 30 °C. Samples were taken every 48 hours and 72 hours.  
In the meantime, three different control constructs were built. Previously, our lab 
identified that the gapdh and rpsL promoters from actinomycetes are highly active 
under normal laboratory culturing conditions (16). The gapdh promoter, named as 
gapdhp, is located upstream of the gapdh operon consisting of Gapdh, 
phosphoglycerate kinase (pgk) and triosephosphate isomerase (tpiA), the enzymes 
catalyzing the 6th, 7th and 5th steps, respectively, in the glycolysis pathway; and the 
rpsL promoter, named as rpsLp, resides upstream of another operon consisting of 30s 
ribosomal proteins S12 and S7, and elongation factor G and Tu.  Among all the 32 
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promoter regions selected, quite a few reside upstream of 30s ribosomal proteins. 
Therefore, the previously characterized rpsLp from S. griseus was chosen as a 
positive control as it is one of the strongest constitutive promoters ever reported. 
Another control promoter was ermE*p, which is the mutated variant of the promoter 
of the erythromycin resistance gene from Saccharopolyspora erythraea, and is 
believed to be one of the strongest constitutive promoters in Streptomycetes (31,32). 
Based on the RNA-seq analysis, the expression of the gene encoding for 
glyceraldehyde-3-phosphate dehydrogenase from S. albus J1074 ranked number 86. 
The promoter region of this gene was cloned to serve as a control as well.  
5.2.4 Trouble-shooting experiments 
The first batch XylE activity assay (15) showed that between the two biological 
duplicates, large variations existed (data not shown). The second batch including two 
single colonies from two different ex-conjugants respectively was repeated and large 
variations still existed. To fix this problem, a trouble-shooting experiment was 
designed as illustrated in Figure 5.6. We chose promoter 1 as the target and took 
samples at 48 hours. As shown in Figure 5.7, the data from both qPCR analysis and 
XylE activity assay confirmed that the variations generated from the same ex-
conjugant was much smaller than that from different ex-conjugants. Therefore, the 
data for all four ex-conjugants of each promoter selected was analyzed again and the 
one showed highest activity was selected to perform a biological duplicate experiment.  
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5.2.5 Characterization of the selected promoters 
The S. albus strains harboring the candidate promoter constructs as well as the 
three controls were subsequently cultured in MYG liquid medium. Two single 
colonies from one ex-conjugant were picked and inoculated. Samples were taken at 
48 hours and 72 hours, respectively. The XylE activity assay (15) revealed their 
activities as shown in Figure 5.8. For the promoter library we constructed, it covered 
promoter strengths varying from 4%-1300% of the strength of ermE*p.  
According to the XylE activity assay, some of these promoters seem to be quite 
weak under the culturing condition. To investigate the possible causes, we located 
these promoters with their downstream genes on the chromosome of S. albus. For all 
the 32 promoters we selected, they actually could be distributed in 19 clustered gene 
groups (Table 5.2).  Therefore, it is possible that several of the adjacent genes may 
be involved in one operon structure and the high expression of these genes may be 
driven by only one promoter in front of the whole operon. According to this 
hypothesis, we could explain the weak activity performed by the #3, #5, #7, #10, #11, 
#13, #17, #32 and #33 promoters, as they may actually just be intergenetic non-coding 
regions instead of constitutive promoters. Among the rest of promoters, 10 promoters 
showed strong activity under this culturing condition. Comparing with the ermE*p, 
these 10 promoters (#1, #2, #8, #12, #14, #21, #22, #25, #28 and #30) showed at least 
2-10 fold enhancement in expression levels.  
To characterize these 10 strong constitutive promoters in detail, a time course 
(24h-48h-72h) analysis was performed and the three controls were also included 
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(Figure 5.9). In general, these strong promoters are highly active at 24 hours, the most 
active one reached nearly 10-fold enhancement in the expression level. The ermE*p is 
a constitutive promoter as its activity does not vary distinguishably during the 72 
hours time course. Using ermE*p as a benchmark, the #2, #8, #14, #25, #30 promoters 
retain a consistent transcription level of the downstream gene.  Therefore, we would 
claim them as strong constitutive promoters under the chosen culturing condition. In 
addition, the previously identified strong constitutive promoters closely related to 
gapdhp seemed to be true in S. albus as well. For example, #35 is the gapdhp homolog 
in S. albus and it showed strong activity in the chosen culturing condition. 
5.2.6 Analysis of the strong promoters characterized 
After we confirmed the strengths of all the 32 selected promoters and the three 
controls at the translation level using the XylE activity assay, we analyzed the 
strengths of all these promoters at their transcription level.  
In order to quantify the gene expression level, quantitative real-time PCR (qPCR) 
was employed to track the gene expression level. The rpoD gene, homologous to the 
hrdB gene (33), the principal sigma factor, was chosen as the internal control for all 
following qPCR experiments and its transcription signal remained comparable in all 
samples. The RpoD (HrdB) protein is a house-keeping protein in Streptomyces strains 
(34). Due to its stable and consistent expression level in Streptomyces strains, we 
chose this gene to serve as the internal control. Primers for genes in the target cluster 
were designed by the Real-Time PCR tools on the website of Integrated DNA 
Technologies (https://www.idtdna.com/scitools/Applications/RealTimePCR/). 
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Samples were run on the ABI Prism 7900 HT Real-Time Quantitative PCR machine 
and the results were analyzed by SDS software. Standard curves were made first for 
the two pairs of primers using genomic DNA of S. albus harboring the #1-promoter-
xylE cassette as the template (Figure 5.10). Real-Time PCR was performed according 
to a protocol described elsewhere (35).  
In order to obtain stable and consistent data, cells were grown for 3 days and 
samples for RNA isolation were collected at different time points: 48 hours and 72 
hours. Total RNA was isolated based on the protocol of Total RNA Isolation Mini Kit 
and cDNA was synthesized afterwards. In parallel, to eliminate genomic DNA 
contamination, cDNA synthesis reaction without reverse transcriptase was carried out 
to serve as the negative control. Primers were designed to amplify a ~300 bp fragment 
for the xylE gene from the cDNA library. As shown in Figure 5.11, all 35 promoters 
(32 selected ones plus three controls) were analyzed at both time points under the 
chosen growth condition. The gene expression levels from different time points were 
compared. Overall, the expression level reached its plateau at around 48 hours. The 10 
strong promoters characterized from the XylE activity assay also showed high 
expression levels in the qPCR experiments, which further confirmed the strengths of 
these promoters. Interestingly, #24, #26, #29 and #33 promoters also showed strong 
activity, while they did not appear in the XylE assay.  
5.3 Conclusions 
Notably, a total of 100 promoters in Escherichia coli were recently characterized 
(36) and similarly, a total of 14 constitutive promoters from S. cerevisiae were cloned 
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and characterized using a green fluorescent protein (GFP) as a reporter (37). However, 
no such promoter library of Streptomyces has been well-established. Our group firstly 
identified 13 strong constitutive promoters for actinomycetes (16) and successfully 
applied it for cryptic pathway activation (17). To further explore the application of 
actinomycetes’ promoters, we have successfully screened 33 promoters from S. albus 
J1074 via RNA-seq analysis. We analyzed the strengths of these 33 promoters, 
indirectly determined through the activity of catecho1 2,3-dioxygenase, the product of 
the xylE reporter gene. Their strengths range from 4%-1300% of the strength of the 
ermE*p. This was further confirmed by qPCR analysis of these genes under the same 
culturing condition. Meanwhile, we found that 11 out of the 33 characterized 
promoters showed strong activities, which are at least 2-fold higher than that of the 
ermE*p. A detailed 24h-48h-72h time course study of the selected 11 promoters 
further revealed that several of them serve as strong constitutive promoters.  
This variety of promoter strengths could be applied for different applications. For 
single gene analysis or protein expression, strong constitutive promoters could be 
used for the overexpression of a gene of interest, whereas the expression of genes 
responsible for toxic substances would benefit from weak promoters. Moreover, the 
promoters could be applied in pathway engineering. For example, they could be used 
in our plug-and-play platform to replace the native promoters and therefore drive the 
expression of the pathway genes. The strong promoters would be especially useful to 
researchers’ work with actinomycetes to overproduce natural products via 
transcription enhancements of the corresponding genes (38). This could benefit the 
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field of novel natural product discovery as a new approach for cryptic pathway 
activation. Fine-tuning gene expression has been demonstrated to be very useful for 
pathway optimization. Thus the promoter library could be employed in fine-tuning 
and balancing specific gene expression due to the complexity of regulatory networks 
(39,40). Promoters in our promoter library with various strength could be used for 
such experiments.  
5.4 Materials and methods  
5.4.1  Strains and reagents 
 S. cerevisiae HZ848 (MATα, ade2-1, Δura3, his3-11, 15, trp1-1, leu2-3, 112 and 
can1-100) was used as the host for DNA assembly and integration. S. albus J1074 
was a gift from Professor Wenjun Zhang (University of California, Berkeley). 
Plasmids pAE4, E. coli strains WM6026 and WM1788 were developed by the 
Metcalf group (University of Illinois, Urbana-Champaign). The pRS426 and pRS416 
plasmid (New England Biolabs, Beverly, MA) were modified by incorporating the 
hisG and partial δ sequence (δ2) that flank the multiple cloning site and serve as the 
vectors for assembly of various pathways. Nalidixic acid was obtained from Sigma-
Aldrich (St. Louis, MO). ISP2, agar, beef extract, yeast extract, malt extract, and other 
reagents required for cell culture were obtained from Difco (Franklin Lakes, NJ).  
All restriction endonucleases, as well as T4 DNA ligase and antarctic phosphatase, 
were purchased from New England Biolabs (Beverly, MA). Q5 DNA polymerase was 
from New England Biolabs (Beverly, MA). FailsafeTM 2x premix buffer G was 
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purchased from EPICENTRE Biotechnologies (Madison, WI). SYBR Green PCR 
master mix was purchased from Applied Biosystems (San Francisco, CA). The 
QIAprep Spin Plasmid Mini-prep Kit, QIAquick PCR Purification Kit, QIAquick Gel 
Extraction Kit and the Total RNA Isolation Mini Kit were purchased from Qiagen 
(Valencia, CA). All primers were synthesized by the Integrated DNA Technologies 
(Coralville, IA). Yeast YPAD medium-containing 1% yeast extract, 2% peptone and 2% 
dextrose supplied with 0.01% adenine hemisulphate was used to grow S. cerevisiae 
YSG50 strain. Synthetic complete drop-out medium lacking uracil (SC-Ura) was used 
to select transformants containing the assembled biochemical pathways of interest. 
MYG medium (4 g/L yeast extract, 10 g/L malt extract and 4 g/L glucose) and R2YE 
medium (41) was used for growing S. albus strains. 
5.4.2 Streptomycete cultivation and RNA extraction 
Wild type S. ablbus culture was grown in both MYG medium (10 g/L malt 
extract, 4 g/L yeast extract, and 4 g/L glucose) and R2YE medium (41) at 30 °C with 
constant shaking (250 rpm) until saturation, and inoculated into fresh MYG and 
R2YW with a ratio of 1:100. Cells of 1 mL culture of each medium were collected at 
24 hours and 72 hours respectively. The total RNA was extracted using the RNeasy 
Mini Kit (QIAGEN, Valencia, CA). RNA preparations were treated with TURBO 
DNA-free™ Kit (Life Technologies, Carlsbad, CA) to remove contaminating DNA. 
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5.4.3 RNA-seq analysis 
For the analysis and quantitation of total RNA samples, Agilent RNA 6000 Nano 
Kit from Agilent Technologies (Santa Clara, CA) was used to determinate the RNA 
integrity number of the samples. Qualified samples with RIN larger than 8 were 
submitted to the Roy J. Carver Biotechnology Center (CBC) (University of Illinois, 
Urbana) and were sequenced on an Illumina HiSeq 2500 with a read length of 100 
bases. The sequencing data was submitted to High-Performance Biological 
Computing Center (HPCBio) (University of Illinois, Urbana) for analysis. The reads 
were mapped to the published S. albus J1074 genome sequence, using the prokaryote 
settings and RPKM (reads per kilobase of exon model per million mapped reads) (42) 
as the method of determining the expression level of the gene regions. 
5.4.4 Promoter cloning 
The promoter region of 33 strong expressed genes under both culturing 
conditions at the two time points chosen were selected and cloned with xylE gene by 
DNA assembly method (43). S. albus was grown in liquid MYG medium (4 g/L yeast 
extract, 10 g/L malt extract and 4 g/L glucose) at 30 °C with constant shaking (250 
rpm) for 2 days.  The genomic DNA was isolated from S. albus using the Wizard 
Genomic DNA isolation kit from Promega (Madison, WI). Pairs of primers were 
designed with the sequences shown in Table 5.3. Promoters of all 33 chosen regions 
were amplified from the genomic DNA of S. albus. Generally, the PCRs were carried 
out in 100 µL reaction mixture consisting of 50 µL FailSafeTM PCR 2xPreMix G from 
Epicentre Biotechnologies (Madison, WI), 2.5 pmol of each primer, 0.5 µL genomic 
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DNA and 2.0 unit Phusion DNA polymerase for 35 cycles on a PTC-200 Thermal 
Cycler (MJ Research, Watertown, MA).  Each cycle consisted of 10 s at 98 °C, 30 s 
at 58 °C and 1 min at 72 °C, with a final extension of 8 min. The S. cerevisaie helper 
fragment was amplified from the commercial vector pRS416, while the E. coli helper 
fragment and the S. albus helper fragment were amplified from the Streptomyces-E. 
coli shuttle vector pAE4. Following electrophoresis, the PCR products were 
individually gel-purified from 1.0% agarose gels using Qiagen Gel Purification kit. 
100 ng of each individual fragments was mixed and precipitated with ethanol.  The 
resulting DNA pellet was air-dried and resuspended in 4 µL Milli-Q double deionized 
water and subsequently electroporated into S. cerevisiae using the protocol reported 
elsewhere (43).   
5.4.5 Yeast transformation 
Yeast transformation was performed by electroporation. YPAD medium (50 mL) 
was inoculated with a 0.5 mL overnight S. cerevisiae YSG50 culture and shaken at 
30 °C and 250 rpm for 4-5 h until OD600 reached 0.8-1.0. Yeast cells were harvested 
by centrifugation at 4 °C and 4000 rpm for 5 min.  The supernatant was discarded 
and the cell pellet was washed with 50 mL ice-cold Milli-Q double-deionized water, 
followed by another wash with cold 1 M sorbitol and finally resuspended in 250 µL 
cold sorbitol. An aliquot of 50 µL of yeast cells together with 4 µL DNA mixture was 
electroporated in a 0.2 cm cuvette at 1.5 kV. The transformed cells were immediately 
mixed with 1 mL room temperature YPAD medium and shaken at 30 °C for 1 h.  
Following that, the cells were harvested by centrifugation, washed with room 
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temperature 1 M sorbitol several times to remove the remaining medium and finally 
resuspended in 1 mL sorbitol. Aliquots of 30-50 mL were spread on SC-Ura plates for 
the selection of the transformants, and the plates were incubated at 30 °C for 2-4 days 
until colonies appeared. Colonies were randomly picked to SC-Ura liquid medium 
and grown for 1 day, after which yeast plasmid was isolated using Zymoprep II Yeast 
plasmid Miniprep kit (Zymo Research, CA), and genomic DNA was prepared using 
Wizard Genomic DNA isolation kit from Promega (Madison, WI). 
5.4.6 Verification of the assembled gene clusters 
Colonies were randomly picked to SC-Ura liquid media and grown for 2 days, 
after which yeast plasmid was isolated using Zymoprep II Yeast plasmid Miniprep kit 
(Zymo Research, CA). Yeast plasmids were transformed to E. coli strain WM1788 
and selected on Luria Broth (LB) agar plates supplemented with 50 µg/ml apramycin.  
Colonies were inoculated into 5 mL of LB media supplemented with 50 µg/mL 
apramycin, and plasmids were isolated from the liquid culture using the plasmid 
miniprep kit from Qiagen. Plasmids isolated from E. coli were then submitted for 
sequencing. 
5.4.7 Heterologous expression in S. albus 
The verified clones were transformed to E. coli WM6026 (30) and selected on LB 
agar plates supplemented with 19 µg/mL 2,6-diaminopimelic acid and 50 µg/mL 
apramycin. These transformants were then used as the donors for conjugative transfer 
of the assembled plasmids to S. lividans 66 following the protocol described 
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elsewhere (30). S. lividans exconjugants were picked and re-streaked on ISP2 plates 
supplemented with 50 µg/mL apramycin and grown for 2 days. For each construct, a 
single colony was inoculated into 2 mL of MYG liquid medium supplemented with 
50 µg/mL apramycin in a 14 mL Falcon tube. 1 mL of the saturated culture was 
inoculated into 50 mL of MYG medium supplemented with 50 µg/mL apramycin in a 
125 mL shake-flask shake-flask (3 mm glass beads were added to improve liquid 
mixing and aeration). Samples were taken for further analysis at different time points: 
24 hours, 48 hours, and 72 hours.  
5.4.8 Promoter characterization via the XylE assay 
Catecho1 2,3-dioxygenase, the product of the xylE gene from the Pseudomonas 
TOL p1asmid, converts colorless catecho1 into 2-hydroxymuconic semialdehyde, 
which is yellow. Aliquots of 10 mL of the cell culture at different time points were 
collected and centrifuged at 4000 rpm for 10 minutes to remove the supernatant. 5 mL 
sample buffer (100 mM phosphate buffer, pH = 7.5; 20 mM NaEDTA, pH = 8.0; 10% 
v/v acetone) were added to resuspend the cell pellets followed by sonication on ice. 
0.1% of Triton X-100 solution was added into the samples and incubated on ice for 15 
minutes. Then the samples were centrifuged for 5 minutes (40,000 g, 4 °C) and the 
cell lysate was transferred to a fresh tube. 900 µL of the assay buffer (10 mM 
phosphate buffer, pH = 7.5; 0.2 mM catechol 2,3-dioxygenase) was added to 100 µL 
of the cell lysate and follow the change in absorbance at 375 nm (A375). The 
concentrations of the total proteins were determined by the Bradford method (44). 
The slope of the linear part of the spectrophotometric output was used to calculate the 
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specific activity as follows: mU catechol dioxygena [nmol min-1] = 30.03 * ΔA375 
/time [min]. 
5.4.9 Promoter characterization via qPCR analysis 
Wild type S. ablbus culture was grown in both MYG medium (10 g/L malt 
extract, 4 g/L yeast extract, and 4 g/L glucose) and R2YE medium (41) at 30 °C with 
constant shaking (250 rpm) until saturation, and inoculated into fresh MYG and 
R2YW with a ratio of 1:100. Cells of 1mL culture of each medium were collected at 
24 hours, 48 hours and 72 hours respectively. The total RNA was extracted using the 
RNeasy Mini Kit (QIAGEN, Valencia, CA). RNA preparations were treated with 
TURBO DNA-free™ Kit (Life Technologies, Carlsbad, CA) to remove 
contaminating DNA. Reverse transcription was carried out using the ProtoScript® 
First Strand cDNA Synthesis Kit (New England Biolabs, Beverly, MA). Real-time 
PCR was performed with SYBR® Green PCR Master Mix on the 7900HT Fast Real-
Time PCR System (Applied Biosystems, Carlsbad, CA). Primers were designed by 
the online tool provided by Integrated DNA Technologies 
(https://www.idtdna.com/scitools/Applications/RealTimePCR/). 10 μL of 2× SYBR 
Green Mix, 1 μL of cDNA, 1 μL of each primer at a concentration of 10 pmol/μL and 
7 μl of ddH2O were mixed gently in each well of the Applied Biosystems® 
MicroAmp® Optical 384-well Reaction Plate. Reactions were performed using the 
following program: 2 min at 50 °C, 10 min at 95 °C for one cycle followed by 15 s at 
95 °C, 30 s at 60 °C and 30 s at 72 °C for 40 cycles with a final cycle of 10 min at 
72 °C. The endogenous gene rpoD, encoding a RNA polymerase sigma factor, was 
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used as the internal control for promoter characterization. The expression levels of the 
XylE gene under different promoters were normalized by the expression of the control. 
Data was analyzed using SDS2.4 software (Applied Biosystems).   
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5.6 Figures and tables 
 
  
  
  
Figure 5.1 Bioanalyzer trace of total RNA samples. (a) S. albus J1074 in MYG 
medium (24 hours) sample 1. (b) S. albus J1074 in MYG medium (24 hours) sample 2. 
(c) S. albus J1074 in MYG medium at 72 hours sample 1. (d) S. albus J1074 in MYG 
medium at 72 hours sample 2. (e) S. albus J1074 in R2YE medium at 24 hours sample 
1. (f) S. albus J1074 in R2YE medium at 24 hours sample 2. (g) S. albus J1074 in 
R2YE medium at 72 hours sample 1. (h) S. albus J1074 in R2YE medium at 72 hours 
sample 2.  
 
  
a b 
c d 
e f 
g h 
200 
 
 
Figure 5.2 Breakdown of total reads per sample. SA1_M24: S.albus sample 1 in 
MYG medium at 24 hours. SA1_M72: S.albus sample 1 in MYG medium at 72 hours. 
SA1_R24: S.albus sample 1 in R2YE medium at 24 hours. SA1_R72: S.albus sample 
1 in R2YE medium at 72 hours. SA2_M24: S.albus sample 2 in MYG medium at 24 
hours. SA2_M72: S.albus sample 2 in MYG medium at 72 hours. SA2_R24: S.albus 
sample 2 in R2YE medium at 24 hours. SA2_R72: S.albus sample 2 in R2YE 
medium at 72 hours. 
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Figure 5.3 RNA-seq data analysis. RPKM: Reads Per Kilobase of transcript per 
Million mapped reads. SA1_M24: S.albus sample 1 in MYG medium at 24 hours. 
SA1_M72: S.albus sample 1 in MYG medium at 72 hours. SA1_R24: S.albus sample 
1 in R2YE medium at 24 hours. SA1_R72: S.albus sample 1 in R2YE medium at 72 
hours. SA2_M24: S.albus sample 2 in MYG medium at 24 hours. SA2_M72: S.albus 
sample 2 in MYG medium at 72 hours. SA2_R24: S.albus sample 2 in R2YE medium 
at 24 hours. SA2_R72: S.albus sample 2 in R2YE medium at 72 hours. 
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Cut off Number of hits Top of top 
5% 195 126 
3% 116 NA 
2% 80 NA 
1.5% 58 NA 
1% 28 NA 
 
Figure 5.4 Selection of top hits. 
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Figure 5.5  Vector map of the promoter-xylE cassettes for promoter 1 (promoter 
region for gene XNR_3584: Cold shock domain-containing protein CspD). The 
promoters were placed in front of the xylE reporter gene and assembled into the 
Yeast-E. coli-Streptomyces shuttle vector.  
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Figure 5.6 Design of the trouble-shooting experiments. Two different ex-conjugants 
were picked for the same promoter construct on two different ISP2 plates, and a 
single colony from each ex-conjugant was picked and inoculated into 2 mL MYG 
liquid medium. 1 mL saturated cell culture of each single colony was transferred into 
50 mL fresh MYG liquid medium. For each time point, a duplicate sample was taken 
to calculate the error from experiment handling. 
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Figure 5.7 Data from trouble-shooting experiments. (a) qPCR analysis results of the 
trouble-shooting experiments. Sample annotation see Figure 5.6. For example: 1-1-
Ea1-48h: the first sample for promoter #1 in batch E at 48 hours. 1-1-Ea1’-48h: 
duplicate of the first sample for promoter #1 in batch E at 48 hours. (b) XylE activity 
assay analysis results of the trouble-shooting experiments. Sample annotation see 
Figure 5.6. For example: 1-1-Ea1-48h: the first sample for promoter #1 in batch E at 
48 hours. 1-1-Ea2-48h: the second sample for promoter #1 in batch E at 48 hours.  
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Figure 5.8 Promoter characterization. Evaluation of the activities of the heterologous 
promoters using xylE as a reporter.  Promoters ermE*p is the commonly used 
promoter reported in literature.  
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Figure 5.9 The selected 10 strong promoter characterization. Evaluation of the 
activities of the heterologous promoters using xylE as a reporter. Promoters ermE*p is 
the commonly used promoter reported in literature.  
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Figure 5.10 The standard curves made for Real-Time-PCR. S. albus genomic DNA 
harboring the promoter-xylE cassette was used as the PCR template, which was 
diluted to 10, 100, 1000, 10000, 100000 and 1000000 times. 
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Figure 5.11 Promoter characterization via qPCR analysis. Characterization of strong 
constitutive promoters by real-time PCR analysis of the transcription of the xylE gene 
under different promoters in S. albus. Samples were taken at different time points.  
The y-axis scale represents the expression value relative to that of RpoD, a commonly 
used housekeeping sigma factor, which was set to 1. 
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Table 5.1 The total RNA samples submitted for RNA-seq analysis. 
 
  
  
Sample ID Label on tube Concentration (ng/uL) Volumn(uL) RIN Note
1 SA1 M24 663.7 50 9.8 pdf 1 sample 1
2 SA2 M24 562.5 50 10 pdf 1 sample 2
3 SA1 M72 229 50 9.8 pdf 1 sample 3
4 SA2 M72 398.6 15 9.1 pdf 1 sample 4
5 SA1 R24 236.5 50 10 pdf 1 sample 5
6 SA2 R24 293 50 10 pdf 1 sample 6
7 SA1 R72 327.5 50 8.2 pdf 2 sample 1
8 SA2 R72 362 50 8.5 pdf 2 sample 2
requirments
all samples in one lane. Single read. Read length: 100nt. 
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Table 5.2 The 21 gene clusters identified for the 32 promoters chosen. The promoter 
number highlighted in red indicated the corresponding promoters showed strong 
activity in selected culture conditions. The gene name in red indicates the 
corresponding gene had a short gap between its neighbors (<70 bp). The gene name in 
blue indicates the corresponding promoter was selected to be cloned and characterized 
in this study. The gene name in pink shade indicates that the gene was in reverse 
direction on the chromosome.  
Ranking  Number Gene    Protein
2254     XNR_3719  transcriptional regulator, Crp/Fnr family 
23  22 XNR_3720  30S ribosomal protein S12
47     XNR_3721  30S ribosomal protein S7
79     XNR_3722  Elongation factor G
4  4 XNR_3723  Elongation factor Tu 1
2404     XNR_3724 
Magnesium or manganese‐dependent protein 
phosphatase
3752     XNR_3725  Transcriptional regulator, GntR family
2312     XNR_3726  Aspartate 1‐decarboxylase
1025     XNR_3727  Hypothetical protein
13  14 XNR_3728  30S ribosomal protein S10
29     XNR_3729  50S ribosomal protein L3
72     XNR_3730  50S ribosomal protein L4
19     XNR_3731  50S ribosomal protein L23
66     XNR_3732  50S ribosomal protein L2
63     XNR_3733  30S ribosomal protein S19
49     XNR_3734  50S ribosomal protein L22
76     XNR_3735  30S ribosomal protein S3
80     XNR_3736  50S ribosomal protein L16
107     XNR_3737  50S ribosomal protein L29
40     XNR_3738  30S ribosomal protein S17
43     XNR_3739  50S ribosomal protein L14
69     XNR_3740  50S ribosomal protein L24
50     XNR_3741  50S ribosomal protein L5
91     XNR_3742  30S ribosomal protein S14 type Z
14  15 XNR_3743  30S ribosomal protein S8
33     XNR_3744  50S ribosomal protein L6
31     XNR_3745  50S ribosomal protein L18
54     XNR_3746  30S ribosomal protein S5
105     XNR_3747  50S ribosomal protein L30
36     XNR_3748  50S ribosomal protein L15
139     XNR_3749  Preprotein translocase secY subunit
115     XNR_3750  Adenylate kinase
807     XNR_3751  Methionine aminopeptidase
11  12 XNR_3752  Translation initiation factor IF‐1 1
5  5 XNR_3753  50S ribosomal protein L36
9  10 XNR_3754  30S ribosomal protein S13
12  13 XNR_3755  30S ribosomal protein S11
119     XNR_3756  DNA‐directed RNA polymerase alpha subunit 
10  11 XNR_3757  50S ribosomal protein L17
212 
 
Table 5.2 (Cont.)  
Ranking  Number Gene    Protein 
1450     XNR_1215  Ribosome maturation factor rimM 
92     XNR_1216  putative RNA‐binding protein (contains KH domain) 
24  23 XNR_1217  30S ribosomal protein S16 
399     XNR_1218  Hypothetical protein 
5218     XNR_1219  Hypothetical protein 
 
Ranking  Number Gene    Protein 
22  21 XNR_4375  30S ribosomal protein S20 
 
Ranking  Number Gene    Protein 
5895     XNR_2187  MutT‐like protein 
45     XNR_2188  Hypothetical protein 
18  19 XNR_2189  secreted protein 
1123     XNR_2190  GntR‐family transcriptional regulator 
1388     XNR_2191  Transposase 
 
Ranking  Number Gene    Protein 
2551     XNR_4882  SAM‐dependent methyltransferase 
25  24 XNR_4883  SSU ribosomal protein S1p 
5100     XNR_4884  Sheath polysaccharide‐degrading enzyme 
 
Ranking  Number Gene    Protein 
4477     XNR_1695 
Oligopeptide ABC transporter, periplasmic oligopeptide‐
binding protein OppA 
124     XNR_1696  Oligopeptide transport ATP‐binding protein OppF 
146     XNR_1697  Oligopeptide transport ATP‐binding protein OppD 
133     XNR_1698  Oligopeptide transport system permease protein OppC 
97     XNR_1699  Dipeptide transport system permease protein DppB 
26  25 XNR_1700 
Peptide transport system secreted peptide‐binding 
protein 
503     XNR_1701  GTP‐binding protein TypA/BipA 
2569     XNR_1702  Hypothetical protein 
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Table 5.2 (Cont.) 
Ranking  Number Gene    Protein 
1228     XNR_4343  Ribonuclease, Rne/Rng family 
39  34 XNR_4344  50S ribosomal protein L21 
24     XNR_4345  50S ribosomal protein L27 
833     XNR_4346  GTPase obg 
 
Ranking  Number Gene    Protein 
288     XNR_3706  Transcription antitermination protein nusG 
17  18 XNR_3707  50S ribosomal protein L11 
21     XNR_3708  50S ribosomal protein L1 
569     XNR_3709  lipoprotein 
8  9 XNR_3710  50S ribosomal protein L10 
3  3 XNR_3711  50S ribosomal protein L7/L12 
169     XNR_3712  DNA‐directed RNA polymerase beta subunit 
 
Ranking  Number Gene    Protein 
5097     XNR_3798  Polysaccharide deacetylase 
2  2 XNR_3799  Heat shock protein 60 family co‐chaperone GroES 
37  32 XNR_3800  Heat shock protein 60 family chaperone GroEL 
2085     XNR_3801  Dehydrogenase 
 
Ranking  Number Gene    Protein 
5438     XNR_3583  Acyl‐CoA synthetase 
1  1 XNR_3584  Cold shock domain‐containing protein CspD 
1343     XNR_3585  Menaquinone via futalosine step 1 
 
Ranking  Number Gene    Protein 
4011     XNR_2392  Hypothetical protein 
7  8 XNR_2393  Heat shock protein 60 family chaperone GroEL 
87     XNR_2394  Cold shock protein 
1488     XNR_2395  Threonine synthase 
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Table 5.2 (Cont.)  
Ranking  Number Gene    Protein 
3770     XNR_2974  DNA‐damage‐inducible protein F 
75     XNR_2975  50S ribosomal protein L9 
38  33 XNR_2976  30S ribosomal protein S18 2 
67     XNR_2977  Single‐stranded DNA‐binding protein 1 
6  7 XNR_2978  30S ribosomal protein S6 
3605     XNR_2979  integral membrane protein 
 
Ranking  Number Gene    Protein 
597     XNR_5228  Hypothetical protein 
65     XNR_5229  Translation initiation factor IF‐3 
15  16 XNR_5230  50S ribosomal protein L35 
16  17 XNR_5231  50S ribosomal protein L20 
2360     XNR_5232  rRNA methyltransferase 
5615     XNR_5233  Hypothetical protein 
 
Ranking  Number Gene    Protein 
4641     XNR_2497  ATP‐dependent RNA helicase 
27  26 XNR_2498  Cold shock protein 
576     XNR_2499  MarR‐family transcriptional regulator 
3029     XNR_2500  regulatory protein 
 
Ranking  Number Gene    Protein 
4678     XNR_3015  secreted protein 
29  27 XNR_3016  Membrane protein 
2988     XNR_3017  von Willebrand factor type A domain‐containing protein 
 
Ranking  Number Gene    Protein 
1496     XNR_1129  peptidase, M16 family 
167     XNR_1130  Polyribonucleotide nucleotidyltransferase 
30  28 XNR_1131  30S ribosomal protein S15 
1753     XNR_1132  BldB protein 
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Table 5.2 (Cont.) 
Ranking  Number   Gene    Protein 
2640       XNR_3586 Cell division FtsK/SpoIIIE 
32  29   XNR_3587 Hypothetical protein 
539       XNR_3588 Hypothetical protein 
 
Ranking  Number Gene    Protein 
4807     XNR_3169  glycosyltransferase 
34  30 XNR_3170  Chaperone protein DnaK 
60     XNR_3171  Protein grpE 
117     XNR_3172  Chaperone protein DnaJ 1 
155     XNR_3173  HspR, transcriptional repressor of DnaK operon 
1769     XNR_3174  LuxR‐family transcriptional regulator 
 
Ranking  Number Gene    Protein 
861     XNR_1473  Peptide chain release factor 1 
35  31 XNR_1474  50S ribosomal protein L31 
2344     XNR_1475 
Cell envelope‐associated transcriptional attenuator LytR‐
CpsA‐Psr, subfamily A1 
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Table 5.3 The primers used for cloning the 32 promoters and the control promoter. 
  Primer Name  Primer Sequence
1  XNR_3584‐For  GTAGAAACAGACGAAGAAGCTAGCTTTGCACTGGATTGCGCTCGTGAGGCTAGCTCCGCC
  XNR_3584‐Rev  GCAGCTGCACATGGCCCGGTCGCATTACACCTTTGTTCATAAGCCCTCCTTGGGCCAAAG
2  XNR_3799‐For  GTAGAAACAGACGAAGAAGCTAGCTTTGCACTGGATTGCGGCCCGGCCATATCCGGCCCG
  XNR_3799‐Rev  GCAGCTGCACATGGCCCGGTCGCATTACACCTTTGTTCATGATCCGACCTCCCCCTTCGG
3  XNR_3711‐For  GTAGAAACAGACGAAGAAGCTAGCTTTGCACTGGATTGCGTTCGGCTCGCGTAATGACCT
  XNR_3711‐Rev  GCAGCTGCACATGGCCCGGTCGCATTACACCTTTGTTCATGATGGCGTCCTTCCACTAAT
4  XNR_3723‐For  GTAGAAACAGACGAAGAAGCTAGCTTTGCACTGGATTGCGCTCTTCGGAGCACACGCTTT
  XNR_3723‐Rev  GCAGCTGCACATGGCCCGGTCGCATTACACCTTTGTTCATTGGGGTCCTCCTGGAGAGTG
5  XNR_3753‐1‐For  GTAGAAACAGACGAAGAAGCTAGCTTTGCACTGGATTGCGATCTTGCCCGCTCGCCGCCC
  XNR_3753‐1‐Rev  GCAGCTGCACATGGCCCGGTCGCATTACACCTTTGTTCATGGTGAGGTTCTCCGGGTCAG
6  XNR_3753‐2‐For  CTGACCCGGAGAACCTCACCCTTCCCCGGGGTGGTGGCCGGCAC
  XNR_3753‐2‐Rev  GGTGAGGTTCTCCGGGTCAGGTGCCGGCCACCACCCCGGGGAAG
7  XNR_2978‐For  GTAGAAACAGACGAAGAAGCTAGCTTTGCACTGGATTGCGTACGGCACCTCCTGCGGAAG
  XNR_2978‐Rev  GCAGCTGCACATGGCCCGGTCGCATTACACCTTTGTTCATGTAGAACCCACCTCCTTTGG
8  XNR_2393‐For  GTAGAAACAGACGAAGAAGCTAGCTTTGCACTGGATTGCGGGCGCCGACCGCACCACACT
  XNR_2393‐Rev  GCAGCTGCACATGGCCCGGTCGCATTACACCTTTGTTCATGTGAAGTGGTCCTCCCAGGA
9  XNR_3710‐For  GTAGAAACAGACGAAGAAGCTAGCTTTGCACTGGATTGCGTCCGCTCCTCCGGGCGGGGT
  XNR_3710‐Rev  GCAGCTGCACATGGCCCGGTCGCATTACACCTTTGTTCATGAGCCTCGGCCTCCTTCCGG
10  XNR_3754‐For  GTAGAAACAGACGAAGAAGCTAGCTTTGCACTGGATTGCGCGCACACCTGCTCTCGCAGA
  XNR_3754‐Rev  GCAGCTGCACATGGCCCGGTCGCATTACACCTTTGTTCATCTAATGGCTCCAGTTGTCTG
11  XNR_3757‐For  GTAGAAACAGACGAAGAAGCTAGCTTTGCACTGGATTGCGGGTTCTGCTCGGCAGGGGTG
  XNR_3757‐Rev  GCAGCTGCACATGGCCCGGTCGCATTACACCTTTGTTCATGGTCTTTCTCCTTGTGATCT
12  XNR_3752‐For  GTAGAAACAGACGAAGAAGCTAGCTTTGCACTGGATTGCGTCCAGAGATGTCCGGCGTGC
  XNR_3752‐Rev  GCAGCTGCACATGGCCCGGTCGCATTACACCTTTGTTCATGCTTCGCCCTTCGAATCGAC
13  XNR_3755‐For  GTAGAAACAGACGAAGAAGCTAGCTTTGCACTGGATTGCG
  XNR_3755‐Rev  GCAGCTGCACATGGCCCGGTCGCATTACACCTTTGTTCAT
14  XNR_3728‐For  GTAGAAACAGACGAAGAAGCTAGCTTTGCACTGGATTGCG
  XNR_3728‐Rev  GCAGCTGCACATGGCCCGGTCGCATTACACCTTTGTTCAT
15  XNR_3743‐For  GTAGAAACAGACGAAGAAGCTAGCTTTGCACTGGATTGCG
  XNR_3743‐Rev  GCAGCTGCACATGGCCCGGTCGCATTACACCTTTGTTCAT
16  XNR_5230‐For  GTAGAAACAGACGAAGAAGCTAGCTTTGCACTGGATTGCG
  XNR_5230‐Rev  GCAGCTGCACATGGCCCGGTCGCATTACACCTTTGTTCAT
17  XNR_5231‐For  GTAGAAACAGACGAAGAAGCTAGCTTTGCACTGGATTGCG
  XNR_5231‐Rev  GCAGCTGCACATGGCCCGGTCGCATTACACCTTTGTTCAT
18  XNR_3707‐For  GTAGAAACAGACGAAGAAGCTAGCTTTGCACTGGATTGCG
  XNR_3707‐Rev  GCAGCTGCACATGGCCCGGTCGCATTACACCTTTGTTCAT
19  XNR_2189‐For  GTAGAAACAGACGAAGAAGCTAGCTTTGCACTGGATTGCG
  XNR_2189‐Rev  GCAGCTGCACATGGCCCGGTCGCATTACACCTTTGTTCAT
20  XNR_3708‐For  GTAGAAACAGACGAAGAAGCTAGCTTTGCACTGGATTGCG
  XNR_3708‐Rev  GCAGCTGCACATGGCCCGGTCGCATTACACCTTTGTTCAT
21  XNR_4375‐For  GTAGAAACAGACGAAGAAGCTAGCTTTGCACTGGATTGCG
  XNR_4375‐Rev  GCAGCTGCACATGGCCCGGTCGCATTACACCTTTGTTCAT
22  XNR_3720‐For  GTAGAAACAGACGAAGAAGCTAGCTTTGCACTGGATTGCG
  XNR_3720‐Rev  GCAGCTGCACATGGCCCGGTCGCATTACACCTTTGTTCAT
23  XNR_1217‐For  GTAGAAACAGACGAAGAAGCTAGCTTTGCACTGGATTGCG
  XNR_1217‐Rev  GCAGCTGCACATGGCCCGGTCGCATTACACCTTTGTTCAT
24  XNR_4883‐For  GTAGAAACAGACGAAGAAGCTAGCTTTGCACTGGATTGCG
  XNR_4883‐Rev  GCAGCTGCACATGGCCCGGTCGCATTACACCTTTGTTCAT
25  XNR_1700‐For  GTAGAAACAGACGAAGAAGCTAGCTTTGCACTGGATTGCG
  XNR_1700‐Rev  GCAGCTGCACATGGCCCGGTCGCATTACACCTTTGTTCAT
26  XNR_2498‐For  GTAGAAACAGACGAAGAAGCTAGCTTTGCACTGGATTGCG
  XNR_2498‐Rev  GCAGCTGCACATGGCCCGGTCGCATTACACCTTTGTTCAT
27  XNR_3016‐For  GTAGAAACAGACGAAGAAGCTAGCTTTGCACTGGATTGCG
  XNR_3016‐Rev  GCAGCTGCACATGGCCCGGTCGCATTACACCTTTGTTCAT
28  XNR_1131‐For  GTAGAAACAGACGAAGAAGCTAGCTTTGCACTGGATTGCG
  XNR_1131‐Rev  GCAGCTGCACATGGCCCGGTCGCATTACACCTTTGTTCAT
29  XNR_3587‐For  GTAGAAACAGACGAAGAAGCTAGCTTTGCACTGGATTGCG
  XNR_3587‐Rev  GCAGCTGCACATGGCCCGGTCGCATTACACCTTTGTTCAT
30  XNR_3170‐For  GTAGAAACAGACGAAGAAGCTAGCTTTGCACTGGATTGCG
  XNR_3170‐Rev  GCAGCTGCACATGGCCCGGTCGCATTACACCTTTGTTCAT
31  XNR_1474‐For  GTAGAAACAGACGAAGAAGCTAGCTTTGCACTGGATTGCG
  XNR_1474‐Rev  GCAGCTGCACATGGCCCGGTCGCATTACACCTTTGTTCAT
32  XNR_3800‐For  GTAGAAACAGACGAAGAAGCTAGCTTTGCACTGGATTGCG
  XNR_3800‐Rev  GCAGCTGCACATGGCCCGGTCGCATTACACCTTTGTTCAT
33  XNR_2976‐For  GTAGAAACAGACGAAGAAGCTAGCTTTGCACTGGATTGCG
  XNR_2976‐Rev  GCAGCTGCACATGGCCCGGTCGCATTACACCTTTGTTCAT
35  XNR_4919‐For  GTAGAAACAGACGAAGAAGCTAGCTTTGCACTGGATTGCGCGCACCCCCTGGTCAACGCG
  XNR_4919‐Rev  GCAGCTGCACATGGCCCGGTCGCATTACACCTTTGTTCATGAGCCGATCTCCTCGTTGGT
 
